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1 Drawbacks in cancer chemotherapy 
Cancers figure among the leading causes of morbidity and mortality 
worldwide and consist in an uncontrolled and fast cellular proliferation 
due to a combination of different mutation. This is coupled to a chaotic 
irregular generation of blood vessels which give nutrients and oxygen to 
tumor tissues, and a degradation of the extracellular matrix (ECM) which 
confines the stromal mass of solid tumor.1Metastasis, the spread of 
cancer from primary tumors to secondary tumors in distant sites, is one 
of the main issue to manage in cancer treatments. For many patients, 
when cancer is detected, metastases have just developed. Although 
cancer therapies are improving, many drugs are not reaching the site of 
metastases, and doubt remains over the efficacy of those that do.2 
Cancer treatment is currently based on a combination of surgery, 
radiotherapy, chemotherapy, and more recently immunotherapy. Each 
treatment modality bears advantages and drawbacks and needs to be 
established depending on tumor location, stage of tumor growth, and 
presence of metastasis. Chemotherapy is one of the principal modes of 
treatment for cancer. The main Achilles‘ heel in a chemotherapeutic 
regimen resides in poor selectivity of the treatment that generates severe 
side effects, contributing to decrease patient compliance and quality of 
life.3Indeed, the vast majority of chemotherapeutics are administered by 
the intravenous route, distribute in the whole body according to their 
physical chemical features – which drive interactions with plasma 
proteins – and reach, besides diseased tissue, also healthy organs. 
Furthermore, several conventional chemotherapeutics, such as taxanes, 
are poorly water-soluble and are formulated in pharmaceutical vehicles 
including synthetic solvents (polysorbate 80 or castor oil) that directly 
                                                     
1A. K. Iyer, A. Singh, S. Ganta, and M. M. Amiji, "Role of integrated cancer nanomedicine in 
overcoming drug resistance," Advanced Drug Delivery Reviews 65, no. 13-14 (2013). 
2A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks, 
and D. G. Anderson, "Treating metastatic cancer with nanotechnology," Nature Reviews Cancer 
12, no. 1 (2012). 
3S. P. Egusquiaguirre, M. Igartua, R. M. Hernandez, and J. L. Pedraz, "Nanoparticle delivery 
systems for cancer therapy: advances in clinical and preclinical research," Clinical & 
Translational Oncology 14, no. 2 (2012). 
│Chapter 1 
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contribute to adverse effects.4 Thus, a fine balance between therapeutic 
and toxic effects needs to be found for each patient adapting standard 
combination protocols time by time.  
The effectiveness of a chemotherapy is also limited by intrinsic or 
acquired drug resistance.5,6 Upon treatment, tumor develops drug 
resistance mechanisms, which can be roughly grouped into five 
categories: i) induction of drug transporters, ii) DNA repair, iii) change 
in drug metabolism, iv) gene amplification or mutation of target proteins, 
v) changes in survival/apoptotic pathways. The overexpression of 
multidrug transporters and the altered apoptosis are the major 
mechanisms of drug resistance. In particular, the up-regulation of 
transmembrane drug efflux pumps under the ATP-binding cassette 
(ABC) superfamily actively pump the drug out of the cancer cell which 
reduces drug intracellular concentration and activity as well. These 
transporters act on a variety of anticancer drugs, such as a glycoprotein 
(P-gp)which is over-expressed in liver cancers and can pump out 
Doxorubicin (DOX) and paclitaxel (PTX).7 
Although the knowledge of molecular, cellular, and physiological 
mechanisms involved in the initiation and progression of cancer has been 
significant refined, the benefit of cancer treatments remains mainly 
confined to an increased survival of patients while ensuring a sufficiently 
good quality of life.8 
  
                                                     
4R. K. Jain and T. Stylianopoulos, "Delivering nanomedicine to solid tumors," 
Nat.Rev.Clin.Oncol. 7, no. 11 (2010). 
5C. Holohan, S. Van Schaeybroeck, D. B. Longley, and P. G. Johnston, "Cancer drug resistance: 
an evolving paradigm," Nature Reviews Cancer 13, no. 10 (2013). 
6Q. Wu, Z. P. Yang, Y. Z. Nie, Y. Q. Shi, and D. M. Fan, "Multi-drug resistance in cancer 
chemotherapeutics: Mechanisms and lab approaches," Cancer Letters 347, no. 2 (2014). 
7H. Y. Yuan, X. Li, J. F. Wu, J. P. Li, X. J. Qu, W. F. Xu, and W. Tang, "Strategies to overcome 
or circumvent P-glycoprotein mediated multidrug resistance," Current Medicinal Chemistry 15, 
no. 5 (2008). 
8Rebecca A. Burrell, Nicholas McGranahan, Jiri Bartek, and Charles Swanton, "The causes and 
consequences of genetic heterogeneity in cancer evolution," Nature 501, no. 7467 (2013). 
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2 Nanocarriers for cancer therapy 
2.1 Generalities 
In the past twenty years, nanotherapeutics have been introduced in the 
clinical practice for treating tumors with the goal to improve therapeutic 
outcome of conventional pharmacological therapies and to alleviate their 
toxicity as well as to overcome multidrug resistance (MDR).9,10,11,12 
Nanomedicine is described as the application of nanotechnology to 
medicine and healthcare, nanotechnology consist of engineering 
materials and systems on the nanometer scale (10-200 nm).Nanoscale 
delivery system scarrying an anticancer drug can in theory offer the 
advantages of drug protection from degradation, efficient control of 
pharmacokinetics and accumulation in tumor tissue, thus limiting drug 
interaction with healthy cells and as a consequence side effects. 
In the attempt to improve the rate of success of a cancer therapy, 
chemotherapeutics should i) be able to reach the desired tumor tissues 
through the penetration of barriers in the body with minimal loss of 
activity in the bloodstream; ii) drugs should have the ability to 
selectively kill tumor cells without affecting normal cells and extend 
their effect over time.  
The delivery of chemotherapeutics through nanocarriers has been 
mainly focused on intravenous route to reach remote sites in the body 
through blood system.13In fact, the unique properties of tumor 
vasculature and microenvironment result in a natural tendency of a 
nanocarrier bearing a drug cargo to accumulate in solid tumors referred 
                                                     
9K. K. Jain, "Advances in the field of nanooncology," BMC.Med. 8 (2010). 
10A. Z. Wang, R. Langer, and O. C. Farokhzad, "Nanoparticle delivery of cancer drugs," 
Annu.Rev.Med. 63 (2012). 
11J. L. Markman, A. Rekechenetskiy, E. Holler, and J. Y. Ljubimova, "Nanomedicine 
therapeutic approaches to overcome cancer drug resistance," Adv.Drug Deliv.Rev. 65, no. 13-14 
(2013). 
12Srinath Palakurthi, Venkata Kashyap Yellepeddi, and Kiran Kumar Vangara, "Recent trends 
in cancer drug resistance reversal strategies using nanoparticles," Expert Opinion on Drug 
Delivery 9, no. 3 (2012). 
13D. M. Webster, P. Sundaram, and M. E. Byrne, "Injectable nanomaterials for drug delivery: 
Carriers, targeting moieties, and therapeutics," Eur.J.Pharm.Biopharm. (2013). 
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as passive targeting.14,15 Architectural defectiveness and high degree of 
vascular density generate abnormal ―leaky‖ tumor vessels, aberrant 
branching and blind loops of twisted shape. Blood vessels in tumor 
present an irregular architecture compared with those in normal tissue. 
Tumor vessels are heterogeneous in their spatial distribution, dilated and 
tortuous, leaving a vascular spaces of various size. In addition, in tumors, 
vassel-wall structure is abnormal with interendothelial junctions, present 
an abnormally thick or thin basement membrane, large numbers of 
fenestrae and transendothelial channels formed by vesicles, and 
maximum pore diameters as large as several hundred nanometers (Fig. 
1). 
                                                     
14Hiroshi Maeda, "Macromolecular therapeutics in cancer treatment: The EPR effect and 
beyond," Journal of Controlled Release 164, no. 2 (2012). 
15Jun Fang, Hideaki Nakamura, and Hiroshi Maeda, "The EPR effect: Unique features of tumor 
blood vessels for drug delivery, factors involved, and limitations and augmentation of the 
effect," Advanced Drug Delivery Reviews 63, no. 3 (2011). 
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Fig. 1. (Top) Main features of a solid tumor relevant for nanodelivery. (Bottom) 
Enhanced Permeability and retention (EPR) effect Hisataka Kobayashi, ―Improving 
conventional EPR effects; what is the appropriate target? ― Theranostics, 4 (2014). The 
accumulation of a drug delivery platform by the EPR effect requires high sustained 
plasma concentrations. Minimizing accumulation in peripheral tissue by transendothelial 
or paracellular transport is important in maintaining high plasma concentrations 
(http://www.uspharmacist.com/content/s/197/c/33020/). 
 
Moreover, normal lymphatic network drains excess fluid from tissue 
in order to maintain tissue interstitial fluid balance. In tumor tissue the 
proliferating cancer cells compress lymphatic vessels, particularly at the 
center of the tumor, causing their collapse. Impaired lymphatic drainage 
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decreases the clearance of locally resident macromolecules. Blood flow 
behavior, such as direction of blood flow, is also irregular or inconsistent 
in these vessels. The pore size of tumor vessels varies from 100 nm to 
almost 1 mm in diameter, depending upon the anatomic location of the 
tumors and the stage of tumor growth.  
EPR effect enables nanocarriers to extravasate through the 
hyperpermeable tumor blood vessels into extravascular spaces and to 
accumulate inside tumor tissues (Fig.2). 
 
Fig. 2. Passive vs active targeting. (Right) NPs tend to passively (by their 
biophysicochemical properties) extravasate through the inflammated vasculature; (Left) 
Once NPs have extravasated in the target tissue, the presence of targeting ligands (e.g. 
proteins) on the NP surface. Morteza Mahmoudi, ― Superparamagnetic iron oxide 
nanoparticles (SPIONs): Development, surface modification and application in 
chemotherapy, ― Advanced Drug Delivery Reviews 63, no 24-46 (2011). 
 
Furthermore, nanocarrier decoration with ligands that specifically 
recognize peculiar elements on the membrane of tumor cells has been 
considered the most favourable option to increase accumulation in 
cancer tissue, an approach known as active targeting (Fig. 2). These two 
basic strategies are expected to simultaneously increase the intracellular 
concentration of drugs and to reduce dose-limiting toxicities finally 
improving patient survival and quality of life. Nevertheless, exploiting 
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EPR effect is complicated by the presence of physiological elimination 
processes, including both renal clearance and mononuclear phagocyte 
system (MPS) uptake. 
Nanocarriers can be designed also with exquisite responsiveness to 
tumor environment (pH, temperature, redox potential) or external stimuli 
(light, magnetic field, ultrasound, temperature), which can in theory 
trigger drug release only at tumor level.16,17,18,19,20,21,22.  
Over recent decades, several nanosized carriers made of different 
materials such as lipids, polymers, metals, inorganic materials have been 
proposed in the biomedical field as therapeutic and diagnostic tools 
(Fig.3). 
 
 
Fig. 3. Examples of nanoplatforms used in drug development Archana Swami, 
―Nanoparticles for targeted and temporally controlled drug delivery‖ Springer (2012) 
 
                                                     
16C. S. Kim, B. Duncan, B. Creran, and V. M. Rotello, "Triggered Nanoparticles as 
Therapeutics," Nano.Today. 8, no. 4 (2013). 
17V. Torchilin, "Multifunctional and stimuli-sensitive pharmaceutical nanocarriers," 
Eur.J.Pharm.Biopharm. 71, no. 3 (2009). 
18S. Mura, J. Nicolas, and P. Couvreur, "Stimuli-responsive nanocarriers for drug delivery," 
Nat.Mater. 12, no. 11 (2013). 
19Weiwei Gao, Juliana M. Chan, and Omid C. Farokhzad, "pH-Responsive Nanoparticles for 
Drug Delivery," Mol.Pharmaceutics 7, no. 6 (2010). 
20J. Z. Du, C. Q. Mao, Y. Y. Yuan, X. Z. Yang, and J. Wang, "Tumor extracellular acidity-
activated nanoparticles as drug delivery systems for enhanced cancer therapy," Biotechnol.Adv. 
32, no. 4 (2013). 
21S. Nowag and R. Haag, "pH-Responsive Micro- and Nanocarrier Systems," 
Angew.Chem.Int.Ed Engl. 53, no. 1 (2014). 
22S. R. Abulateefeh, S. G. Spain, J. W. Aylott, W. C. Chan, M. C. Garnett, and C. Alexander, 
"Thermoresponsive polymer colloids for drug delivery and cancer therapy," Macromol.Biosci. 
11, no. 12 (2011). 
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There are currently six FDA-approved nanomedicine (Table 1): 
brentuximab vedotin and trastuzumab amtansine, Doxil, DaunoXome, 
Marquibo and Abraxane.23 
 
Table 1. FDA-approved nanomedicines. 
 
Brentuximab, Vedotin and Trastuzumab emtansine are antibody-drug 
conjugate (ADCs), conceptually engineered for targeting molecule 
respectively to the CD30 protein and growth factor receptor 2 (HER2). 
This drugs are too toxic to be used alone. Doxil, DaunoXome and 
Marquibo are liposomal nanomedicines. Doxil is a pegylated liposome 
about 100 nm in diameter and encapsulating about 10.000 DOX 
molecules.24Encapsulation minimizes side effects, such as cardiotixicity 
associated with high dose of DOX. DaunoXome and Marqibo are 
liposomal formulation of Daunorubicin and Vincristine, respectivetly.In 
contrast to Doxil the design strategy for DaunoXome and Marqibo is to 
promote uptake by MPS, proving a reservoir from which the free drug 
can enter circulation, similar to slow infusion. DaunoXome is about 50 
                                                     
23C. M. Dawidczyk, C. Kim, J. H. Park, L. M. Russell, K. H. Lee, M. G. Pomper, and P. C. 
Searson, "State-of-the-art in design rules for drug delivery platforms: Lessons learned from 
FDA-approved nanomedicines," Journal of Controlled Release 187 (2014). 
24Y. Barenholz, "Doxil (R) - The first FDA-approved nano-drug: Lessons learned," Journal of 
Controlled Release 160, no. 2 (2012). 
Platform class drug Size 
(nm) 
Issue addressed 
Brentuximab 
Vedotin® 
ADC 
Monomethyl 
auristan E 
10 
Drug is too toxic to 
be used alone 
Trastuzumab 
Emtansine® 
ADC Mertansine 10 
Drug is too toxic to 
be used alone 
Myocet Liposome Doxorubicin 100 Cardiac side effect 
Doxil® Liposome Doxorubicin 100 Cardiac side effect 
DaunoXome® liposome Daunorubicine 50 Cardiac side effect 
Marqibo® liposome Vincristine 100 Cardiac side effect 
Abraxane® 
Protein 
carrier 
Paclitaxel 130 
Overcome very slow 
solubiliy of drug 
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nm in diameter and Marqibo 100 nm.25,26Myocet works analogously to 
those latters. Abraxane or nab-paclitaxel (nanoparticle albumin bound) is 
lyophilized human serum albumin non-specifically bound to paclitaxel. 
Paclitaxel has very low solubility and is administered ina toxic non-ionic 
solvent which gives allergic reaction. The diameter of nab-paclitaxel is 
130 nm and it contains 10.000 Paclitaxel molecules per nanoparticle.27 
2.2 Nanocarriers in cancer: biologically driven design rules 
To take benefit of EPR effect, nanocarriers need to escape from 
filtration through the glomerular capillary wall (filtration-size threshold) 
which depends on molecular weight and allows molecules with a 
diameter larger than 15 nm to remain in the circulation. Opsonin 
adsorption on nanocarrier surface mediates MPS recognition and is 
considered a key factor to control nanocarrier biodistribution in the 
body.28 Due to opsonizations, nanocarriers fast disappearance from blood 
circulation and accumulation in the MPS organs (liver, spleen, bone 
marrow) occurs. Accumulation in the liver can be of benefit for the 
chemotherapeutic treatment of MPS localized tumors (e.g. 
hepatocarcinoma or hepatic metastasis arising from digestive tract or 
gynecological cancers, bronchopulmonary tumors) but undesirable when 
trying to target other body compartments (Fig.4). 
In order to overcome opsonization, a number of strategies have been 
investigated to make a nanocarrier ―stealth‖, that is able to evade MPS 
and long-circulating. Coating with a hydrophilic shell can form a cloud 
on nanocarrier surface which repels opsonins giving decreased levels of 
                                                     
25P. S. Gill, J. Wernz, D. T. Scadden, P. Cohen, G. M. Mukwaya, J. H. vonRoenn, M. Jacobs, S. 
Kempin, I. Silverberg, G. Gonzales, M. U. Rarick, A. M. Myers, F. Shepherd, C. Sawka, M. C. 
Pike, and M. E. Ross, "Randomized phase III trial of liposomal daunorubicin versus 
doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma," Journal of Clinical 
Oncology 14, no. 8 (1996). 
26J. A. Silverman and S. R. Deitcher, "Marqibo (R) (vincristine sulfate liposome injection) 
improves the pharmacokinetics and pharmacodynamics of vincristine," Cancer Chemotherapy 
and Pharmacology 71, no. 3 (2013). 
27E. Miele, G. P. Spinelli, E. Miele, F. Tomao, and S. Tomao, "Albumin-bound formulation of 
paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer," International Journal of 
Nanomedicine 4, no. 1 (2009). 
28M. P. Monopoli, C. Aberg, A. Salvati, and K. A. Dawson, "Biomolecular coronas provide the 
biological identity of nanosized materials," Nat Nanotechnol. 7, no. 12 (2012). 
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uptake by the MPS and longevity in the blood, finally promoting 
nanocarrier accumulation in solid tumors through EPR mechanism.29 
Engineering a nanocarrier with a biomimetic shell of polyethylenglycol 
(PEG) is the most explored strategy to obtain long-circulating NPs30 
although other alternatives polymers are under investigation. Thus, 
nanocarriers with hydrophobic surfaces will preferentially be taken in 
MPS organs while long-circulating nanocarriers fulfilling size 
requirements (less than 100 nm) can accumulate at tumor level. 
By exploiting passive mechanisms, only a limited nanocarrier fraction 
can reach tumor site.31 Recent findings highlight that variation of 
nanocarrier dimension in the scale length > 100 nm can heavily affect 
blood circulation time, whereas the role of geometry in driving in vivo 
biodistribution has not been clarified yet.32,33 Only an amount around 
10% of the injected dose benefits of EPR effect while the remnant is 
accumulated in spleen, liver and bone marrow. Drug cargo can be after 
released systemically or inside tumors and this is found to allow a 
significant decrease of side effects. Current research efforts are focused 
on finding strategies to increase tumor to healthy tissue ratio and to 
improve tumor response. Targeting endothelial cells in defective tumor 
vasculature (i.e. integrin receptor) is one of the most advanced strategies 
under investigation . 
Although extracellular matrix itself seems not an evident obstacle to 
NP passage, tissue neighboring tumor cells are surrounded by 
coagulation-derived matrix gel (fibrin gel or stromal tissues) 
representing a further barrier to drug transport. Nevertheless, penetration 
in the remote area of a solid tumor (hypoxic zones) is strictly related to 
                                                     
29Z. Amoozgar and Y. Yeo, "Recent advances in stealth coating of nanoparticle drug delivery 
systems," Wiley Interdiscip.Rev Nanomed Nanobiotechnol 4, no. 2 (2012). 
30R. Gref, A. Domb, P. Quellec, T. Blunk, R. H. Muller, J. M. Verbavatz, and R. Langer, "The 
controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres," 
Advanced Drug Delivery Reviews 64 (2012). 
31F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, "Factors affecting the clearance and 
biodistribution of polymeric nanoparticles," Mol.Pharm. 5, no. 4 (2008). 
32Larken E. Euliss, Julie A. DuPont, Stephanie Gratton, and Joseph DeSimone, "Imparting size, 
shape, and composition control of materials for nanomedicine," Chem.Soc.Rev. 35, no. 11 
(2006). 
33P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari, "Intravascular Delivery of Particulate 
Systems: Does Geometry Really Matter?," Pharmaceutical Research 26, no. 1 (2009). 
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size for drugs, i.e. small drugs penetrates better than a high molecular 
weight antibody.34 
The presence of a hydrophilic coating allows NP escape from MPS 
recognition but decreases the rate and extent of NP uptake inside cancer 
cells.35A strategy to encourage nanocarrier internalization in solid tumors 
resides in surface decoration with ligands recognizing typical or 
overexpressed receptors in tumor microenvironment, which can promote 
its transport through receptor-mediated endocytosis. Different chemical 
motifs interacting with specific receptors overexpressed in cancer cells 
(folate, CD44, transferrin, EGF and some others) can be exploited to this 
purpose. This approach, known as active targeting, can aid selective 
nanocarrier accumulation inside cancer cells while avoiding healthy 
cells, thus decreasing treatment toxicity. Nevertheless, it has been 
recently demonstrated that targeted NPs can paradoxically lose targeting 
ability in a biological environment due to interaction with different high-
affinity proteins or confine their activity to perivascular regions of a 
tumor (binding site barrier).36 Cell cycling also plays a role in NP uptake 
rate and amount of NPs internalized by cells due to splitting between 
daughter cells when the parent cell divides.37 Thus, proper understanding 
of NP properties at biointerface is a critical issue needing future 
investigational efforts.38 
An added sophistication to selective delivery of drug cargo in cancer 
cells can be brought about by utilizing certain cues inherently 
characteristic of the tumor microenvironment or by applying certain 
stimuli to this region from outside the body. Stimuli-sensitive 
                                                     
34T. Fujimori, K. Harada, T. Yoshimura, Y. Yamano, T. Ogawa, and Y. Ikeda, "Good 
Correlation Between Anti-Platelet Effect and Intraplatelet Content of Orally-Administered E-
5510 in Human Healthy-Volunteers," Thrombosis and Haemostasis 62, no. 1 (1989). 
35K. Kettler, K. Veltman, D. van de Meent, A. van Wezel, and A. J. Hendriks, "Cellular uptake 
of nanoparticles as determined by particle properties, experimental conditions, and cell type," 
Environmental Toxicology and Chemistry 33, no. 3 (2014). 
36H. Lee, H. Fonge, B. Hoang, R. M. Reilly, and C. Allen, "The effects of particle size and 
molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles," 
Mol.Pharm 7, no. 4 (2010). 
37J. A. Kim, C. Aberg, A. Salvati, and K. A. Dawson, "Role of cell cycle on the cellular uptake 
and dilution of nanoparticles in a cell population," Nat Nanotechnol. 7, no. 1 (2012). 
38Eugene Mahon, Anna Salvati, Francesca Baldelli Bombelli, Iseult Lynch, and Kenneth A. 
Dawson, "Designing the nanoparticle-biomolecule interface for targeting and therapeutic 
delivery," Journal of Controlled Release 161, no. 2 (2012). 
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nanocarriers based on tailor-made materials can indeed be designed to 
deliver drug payload sharply and ―on demand‖ by undergoing structural 
modifications under internal or external stimuli of chemical, biochemical 
and physical origin. Internal stimuli typical of solid tumors include 
mainly pH, temperature and reductive conditions. In fact, as compared to 
normal/host tissues, pH value in tumor interstitium is lower with an 
average value of 6.84 due to up-regulated glycolysis producing lactates 
and protons.39 Furthermore, once NPs are internalized through endocytic 
pathways involving lysosomes, pH progressively decreases from early 
endosomes (pH 5-6) to more acidiclate endosomes40 (pH 4-5) which can 
strongly alter nanocarrier stability and release features. pH sensitiveness 
has been widely employed to trigger NP disassembly and drug release.41 
Certain tumor microenvironments are also characterized by mild 
hyperthermia (1-2°C above healthy tissues) and some treatment 
modalities implies rising temperature which, together with pH 
sensitiveness, can be of help for triggering drug release. In addition, 
extracellular space is considered oxidative in comparison with 
intracellular compartment (100-1000 folds), mainly in the hypoxic area 
of tumors, due to different concentration levels of glutathione. Finally, 
an array of tumor-associated enzymes, either extracellular or 
intracellular, can be used as biochemical trigger of drug release to attain 
a fine control on spatial distribution of the delivered cargo. 
  
                                                     
39L. Tian and Y. H. Bae, "Cancer nanomedicines targeting tumor extracellular pH," Colloids 
and Surfaces B-Biointerfaces 99 (2012). 
40S. Mukherjee, R. N. Ghosh, and F. R. Maxfield, "Endocytosis," Physiological Reviews 77, no. 
3 (1997). 
41E. Fleige, M. A. Quadir, and R. Haag, "Stimuli-responsive polymeric nanocarriers for the 
controlled transport of active compounds: Concepts and applications," Advanced Drug Delivery 
Reviews 64, no. 9 (2012). 
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2.3 Polymer Nanoparticles for Cancer Therapy 
2.3.1 Generalities 
Polymer-based nanoparticles (NPs) are at limelight in the burgeoning 
field of nanomedicine due to the advantage to manipulate their properties 
by selecting polymer type and mode of carrier assembly.42In fact, the 
advances in polymer chemistry makes it possible to produce an almost 
infinite number of sophisticated structures which can be engineered in 
light of strictly defined biological rules. Thus, not only those features 
affecting distribution of drug dose in the body and interaction with target 
cells can be controlled, but also spatio-temporal release of the delivered 
drug can be finely tuned. 
Polymer-based NPs are matrix-type submicron-sized particles 
prepared from biodegradable or non-biodegradable materials. In some 
cases they can be nanocapsules (NCs), where an oily or aqueous core is 
surrounded by a polymeric shell. The main advantage of polymeric NPs 
is the fact that their features (size, surface properties, and release rate of 
drug cargo) can be easily tuned by selecting appropriate materials among 
a vast variety of commercially available candidates as well as by 
synthesizing novel tailor-made materials. Depending on the type of base 
material, some NPs are biodegradable/bioeliminable and can be 
administered by the parenteral route while others are not and thus useful 
only for local applications, assuming that no systemic NP absorption 
occurs. When dealing with NP entering the systemic circulation, 
degradability of the polymer is of utmost importance since polymer 
accumulation in the body above a certain molecular weight can occur. 
Drug biopharmaceutical properties (solubility, stability, charge, 
molecular weight, etc.) also guide nanocarrier design and suggest the 
needs of specific release features (triggered, sustained) as well as 
preferential location inside or outside cancer cells.  
In their simplest architecture, passively, actively and physically 
targeted NPs can be formed by: i) nanostructuring (self-assembly) of 
                                                     
42N. Kamaly, Z. Y. Xiao, P. M. Valencia, A. F. Radovic-Moreno, and O. C. Farokhzad, 
"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation," 
Chemical Society Reviews 41, no. 7 (2012). 
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amphiphilic all-in-one copolymers; ii) physical adsorption of a shell-
forming material on preformed polymeric NPs acting as a core template.  
Polymers that are insoluble in water form the core template of NPs, 
which is then coated by one or more than one layer of hydrophilic 
materials/phospholipids to impart tailored properties to the shells 
(biomimetic and targeted shells). Hydrophilic polymers can be used also 
as core template after crosslinking with either low molecular weight 
molecules or an interacting hydrophilic polymer with opposite charge, 
thus providing nanogels. Amid shell-forming hydrophilic polymers 
giving long-circulating NPs, PEG is undoubtedly the most common 
material employed to modify hydrophobic NPs, although several others 
have been proposed.  
A wide array of currently-available materials and their possible 
combinations can be employed to fabricate submicron NPs spanning 
from simple biomimetic systems for passive targeting to more 
sophisticated structures integrating specificity and multifunctionality. 
Biodegradability and effective elimination of the polymer is a key 
prerequisite that should be taken into account when developing 
injectable NPs especially when considering novel materials.  
The main biomaterials employed in injectable biodegradable NPs are 
summarized in Table 2 and span from natural materials (polysaccharide, 
proteins, polyaminoacids) to synthetic polymers (polyesters and 
PEGylated polyesters, poloxamers, acrylic polymers, polyammines). 
Stimuli-responsive polymers, referred to as ―environmentally-sensitive‖, 
―smart‖ or ―intelligent‖ polymers are a huge class of chemically diverse 
structures that respond sharply to small changes in physical or chemical 
conditions with relatively large phase or property changes mainly used in 
the cancer field to trigger drug release at tumor level.  
Each polymer presents peculiar solubility features which, coupled 
with drug physico-chemical profile, specific needing for surface 
engineering and drug release rate, drive toward specific fabrication 
methods to attain core/shell NPs. 
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Table 2. Main synthetic polymers employed to prepare polymeric NPs for 
cancer therapy. 
Polymer type Location 
in NPs 
Key Features 
Polyesters 
(PLGA, PLA, 
PCL) 
core Hydrophobic and soluble in common organic solvents 
Biodegraded in the body 
Encapsulation of hydrophilic/hydrophobic drugs as 
well as macromolecules 
Protection of drug cargo 
Sustained release as a function of polymer properties.43 
 
PEGylated 
polyesters 
(PLGA-PEG, 
PLA-PEG, 
PCL-PEG) 
Core-shell Amphiphilic non-ionic copolymers with different 
segment lengths and architectures forming NPs with a 
biomimetic/stabilizing shell 
Shielding ability depends on molecular weight, 
architecture and surface density  
Biodegraded in the body  
Hydrophilic/hydrophobic ratio and fabrication method 
control the mode of aggregation (micelles, 
polymersomes, NPs) 
Molecular weight affects NP size 
Molecular weight and hydrophobicity of lipophilic 
segments affect drug loading and stability inside NPs 
Surface decoration with targeting ligands 
Low molecular weight copolymers (< 500 Da) can 
revert MDR.44,45 
 
Pluronics Core-shell Amphiphilic non-ionic copolymers with different block 
length. 
Able to form small micelles entrapping hydrophobic 
drugs. Mixed micelles of different Pluronic types can 
be formed. 
Unimers act on P-gp and allow to overcome MDR46,47 
                                                     
43F. Danhier, O. Feron, and V. Preat, "To exploit the tumor microenvironment: Passive and 
active tumor targeting of nanocarriers for anti-cancer drug delivery," Journal of Controlled 
Release 148, no. 2 (2010). 
44H. Sah, L. A. Thoma, H. R. Desu, E. Sah, and G. C. Wood, "Concepts and practices used to 
develop functional PLGA-based nanoparticulate systems," International Journal of 
Nanomedicine 8 (2013). 
45C. Conte, I. D'Angelo, A. Miro, F. Ungaro, and F. Quaglia, "PEGylated Polyester-Based 
Nanoncologicals," Current Topics in Medicinal Chemistry 14, no. 9 (2014). 
46Daria Y. Alakhova and Alexander V. Kabanov, "Pluronics and MDR Reversal: An Update," 
Mol.Pharmaceutics 11, no. 8 (2014). 
47E. V. Batrakova and A. V. Kabanov, "Pluronic block copolymers: evolution of drug delivery 
concept from inert nanocarriers to biological response modifiers," J Control Release 130, no. 2 
(2008). 
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PAA 
PAAm  
PMA 
PDEAEMA 
 
Core Obtained by cross-linking different monomer types to 
form nanogels 
Molecular weight and cross-linker chemistry affect 
their elimination from the body 
Some derivatives are protonating/deprotonating 
polymers with charge shift from either anionic to 
neutral or from neutral to cationic 
Acrylic derivatives with hydrazine, hydrazide and 
acetal linkages swells or collapses for electrostatic 
reasons and can be employed to get pH-sensitive 
sheddable coatings.48 
 
PEI/PLL Shell Decoration of negatively-charged NPs via electrostatic 
interactions 
Need of a further polymer coating to shield positive 
charge of the NP shell 
For PEI, enhanced tumoricidal capacity of tumor 
associated macrophages through Toll-like receptor 
signaling.49,50,51 
 
pNIPAM and 
derivatives 
Core Temperature-controlled self-assembly 
Collapse in the hyperthermic tumour environment  
Release depending on the MW and nature of the 
polymer hydrophobic block 
Encapsulation of both hydrophobic/hydrophilic drugs. 
 
Polymers 
sensitive to 
pH or 
enzymes- 
various 
Core/Shell Contain group(s) susceptible to pH variations ( )or 
enzyme degradation (ester or carbamates for proteases, 
disulfide for reductase) 
Enzyme- or pH-sensitive sheddable coatings can be 
designed. 
  
 
  
                                                     
48T. Thambi, V. G. Deepagan, H. Ko, Y. D. Suh, G. R. Yi, J. Y. Lee, D. S. Lee, and J. H. Park, 
"Biostable and bioreducible polymersomes for intracellular delivery of doxorubicin," Polymer 
Chemistry 5, no. 16 (2014). 
49Y. Kaneda, "Update on non-viral delivery methods for cancer therapy: possibilities of a drug 
delivery system with anticancer activities beyond delivery as a new therapeutic tool," Expert 
Opinion on Drug Delivery 7, no. 9 (2010). 
50Z. Huang, Y. Yang, Y. Jiang, J. Shao, X. Sun, J. Chen, L. Dong, and J. Zhang, "Anti-tumor 
immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by 
cationic polymers," Biomaterials 34, no. 3 (2013). 
51P. Hammond, "Nano approaches to using nucleic acids," ACS Nano. 7, no. 5 (2013). 
Chapter 1│ 
-23- 
2.3.2 Fabricating biocompatible nanoparticles for cancer 
 
When developing NPs for cancer therapy, a rational design should be 
planned taking into account specific needs dictated by i) disease features 
(tissue, stage, vascularization extent, presence of metastases); ii) the 
strategy selected to accumulate the highest dose fraction at tumor level 
(pharmacokinetics) and to deliver the drug (intracellular/tumor 
interstitium, sustained or pulsed release); iii) physical-chemical 
properties of the drug (solubility profile, stability); iv) achievement of a 
product with satisfactory shelf-life (preferably a solid). This is certainly 
the most critical step in NP development where a multidisciplinary 
approach at interface between pharmaceutical technology, biology and 
medicine should be carried out. 
Drugs can be loaded in NPs through encapsulation, covalent linkage 
or post-loading. Encapsulation relies on physical entrapment of a drug in 
NP core or shell based on hydrophobic or electrostatic interactions and 
hydrogen bond formation. Drug loading in the core of NPs can 
contribute to achieve a sustained release rate in the biological 
environment while timing of drug release can be finely tuned by 
allocating different drugs in the core or the shell, that is especially 
important in combination therapies. In the post-loading method, drug is 
added to preformed NPs by equilibrium in solution. Covalent binding of 
a drug to NPs is difficult to attain and requires either covalent attachment 
of the drug to monomers that are then polymerized or self-assembled in 
NPs or post-modification of preformed NPs.  
In general, NPs are prepared by bottom-up approaches, primarily 
using monomers or preformed polymers that are then nanostructured by 
techniques such as emulsification/solvent evaporation, interfacial 
deposition after solvent displacement, dialysis or salting-out.52,53,54 
Layer-by-layer deposition method has been recently introduced as NP 
preparation technique to give multifunctional NPs (matrix or reservoir 
                                                     
52Madaswamy S. Muthu and Barnabas Wilson, "Challenges posed by the scale-up of 
nanomedicines," Nanomedicine 7, no. 3 (2012). 
53S. Saraf, "Process optimization for the production of nanoparticles for drug delivery 
applications," Expert Opinion on Drug Delivery 6, no. 2 (2009). 
54N. Anton, J. P. Benoit, and P. Saulnier, "Design and production of nanoparticles formulated 
from nano-emulsion templates-a review," J.Control Release 128, no. 3 (2008). 
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type).Layer-by-layer technique consists in sequentially depositing 
oppositely charged polymers on a nanotemplate to build a stable 
multilayer NPs. For each depositing step, NPs are incubated with a 
polymeric water solution, then centrifuged to eliminate non-adsorbed 
polymer and redispersed to allow the next absorption step. Charged 
polymers have to sequential adsorb with precision over the previously 
deposited layer and can eventually embed a drug. These advantages, 
combined with the ability to incorporate a broad range of therapeutics 
and materials with diverse functionalities, greatly facilitate the 
development of drug delivery platforms with sophisticated control over 
the spatial and temporal release of constituents. Many Layer-by-layer 
NPs has been recently studied in order to delivery different drugs. For 
example based only on electrostatic interactions, core-shell PLGA NPs 
prepared by stepwise modification through several sequential layering of 
positive and negative polymers such as chitosan/alginate, 
polylysine/alginate and polylysine/HA has been found successful to 
achieve physically stable NPs. 
It is worth noting that properties of NPs are strictly dictated by the 
production method, which is especially critical when specific targeting 
elements have to be exposed on the surface. 
From a therapeutic standpoint, timing of drug release is important not 
only to drive administration scheme (number of administrations, 
frequency) but also useful to optimize therapeutic outcome. For example, 
sustained extracellular release can be expected to amplify cell response 
to some chemotherapeutics and to extend activity to hypoxic zones of 
certain tumors resembling a metronomic therapy(subactive doses for 
longer time frames) whereas responsiveness to external or internal 
stimuli can be useful to trigger drug release at specific subcellular level. 
Nevertheless, timing of drug release can be finely tuned by allocating 
different drugs in the core or the shell, that is of utmost importance in 
drug-nucleic acid combination therapies. In all the cases, drug amount 
released from NPs should be reasonably low in the circulation and 
regulated at tumor level to obtain the optimal therapeutic response. 
The unique nano-scale structure of NPs provides significant increases 
in surface area to volume ratio which results in high propensity to 
aggregation during manufacturing, storage and shipping. This aspect 
remains a very challenging issue during pharmaceutical product 
Chapter 1│ 
-25- 
development. The freeze-drying process is the most diffused method to 
handle and stabilize NPs, avoiding undesirable changes upon storage. 
However, freeze-drying also induce aggregation, which mainly affect 
dispersability in a pharmaceutical vehicle for intravenous administration. 
Sugars such as trehalose, glucose, sucrose, fructose and sorbitol have 
been proposed as cryoprotectants to minimize NPs collapse upon freeze-
drying, although papers focusing on this aspects are very few.55 
 
2.4 PLGA nanoparticles in cancer therapy 
2.4.1 Generalities of PLGA nanoparticles 
Many biocompatible and biodegradable polymers, such as poly-(D,L-
lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), 
poly(caprolactone) (PCL) provide safe and non-toxic NPs for in vivo 
administration. In recent years, PLGA derivatives have shown a great 
potential for engineering drug delivery system. PLGA is one of the most 
successfully used biodegradable polymers in the biomedical field due to 
well-recognized biocompatibility. After hydrolysis in the body, it gives 
as metabolites constituting monomers, lactic acid and glycolic acid, 
which are easily metabolized by the body via the Krebs‘cycle. PLGA is 
approved by the US FDA and EMA in various drug delivery systems 
(Fig. 4). 
  
                                                     
55Pedro Fonte, Sandra Soares, Fl+ívia Sousa, Ana Costa, V. + Seabra, Salette Reis, and Bruno 
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The polymers are commercially available with different molecular 
weights and copolymer compositions. The degradation time depends on 
the copolymer composition.  
PLGA NPs have been widely employed for the loading or encapsulation 
of a variety of anticancer drugs, ranging from hydrophilic drugs such as 
DOX,5-Flurouracil,and cisplatin to hydrophobic drugs such as 
Paclitaxel. A variety of methods have been employed to prepare drug-
loaded PLGA based nanoformulations. A brief summary of these 
methods is provided in Table 3 as reported by Jain et al.56 
  
                                                     
56A. K. Jain, M. Das, N. K. Swarnakar, and S. Jain, "Engineered PLGA nanoparticles: an 
emerging delivery tool in cancer therapeutics," Crit Rev Ther.Drug Carrier Syst. 28, no. 1 
(2011). 
 
 
Fig. 4. Chemical structure of poly(lactic-co-glycolic acid) and the products of its 
hydrolytic degradation. In a PLGA copolymer, m and n refer to the amounts of 
lactide and glycolide monomer units,A.C.Dumitru, F.M. Espinosa, ―In situ 
nanomechanical characterization of the early stages of swelling and degradation 
of a biodegradable polymer‖ Nanoscale, n 7 (2015). 
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Table 3. Fabrication methods of PLGA NPs.  
 
 
 
The most common technique used for the preparation of PLGA NPs 
is the emulsification-solvent evaporation technique. Polymer and drugs 
are dissolved in an organic solvent (dichloromethane)e; the emulsion oil 
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(O) in water (W) is prepared by adding water and surfactant (Pluronic 
F68) to the polymeric solution. NPs are homogenized, centrifugated and 
collected. NPs can also formed by precipitation method also called the 
interfacial deposition method. The polymer and the drug are co-
dissolved in an organic phase (such as acetone) and added dropwise to a 
water solution, after the evaporation of solvent, NPs are collected and 
purified by centrifugation step.  
 
2.4.2 Engineering PLGA nanoparticles for cancer therapy 
 
The limits of intravenous PLGA NPs are well know; hydrophobic 
particles are recognized as foreign by body and the reticulo-endothelial 
system (RES) quickly eliminates these from blood stream and takes them 
up in the liver or the spleen. The possibility to modify the surface of NPs 
has been investigated to produce NPs not recognized by the RES. The 
most common surface modification is the covalent conjugation of PLGA 
with the hydrophilic and non-ionic polymer PEG that increases the blood 
circulation half-life of bare PLGA NPs.57 Stealth functionality imparted 
to NPs is found to be strongly influenced by PEG length and surface 
density on NPs surfaces. The length and density of PEG can influence 
the  mushroom or brush-like conformation of PEG onto NPs: long PEG 
favors mushroom conformation while short PEG favors brush-like 
conformation. Generally, higher surface coverage of PEG increases the 
circulation time of NPs, and PEG with a molecular weight of 5000 Da 
provides the ideal surface coating for stealth functionalization.58 
Surface charge of NPs also plays an important role on their 
interaction with cells and on their uptake. It has been shown that 
positively charged NPs seem to allow higher internalization in cells due 
tothe ionic interaction between positively-charged particles and 
negatively-charged cell membranes. In principle, negative charge of 
                                                     
57F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Preat, "PLGA-based 
nanoparticles: An overview of biomedical applications," Journal of Controlled Release 161, no. 
2 (2012). 
58I. Hamad, O. Al-Hanbali, A. C. Hunter, K. J. Rutt, T. L. Andresen, and S. M. Moghimi, 
"Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the 
Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering," Acs Nano 4, 
no. 11 (2010). 
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PLGA NPs can be shifted to positive charge by surface adsorption of 
surfactants and polymers.  
It has been already discussed that cancer cells, unlike normal cells, 
proliferate rapidly. One mechanism underlying this growth is the 
overexpression of receptors, which allows the uptake of growth factors 
via receptor-mediated endocytosis to proceed more efficiently than in 
normal cells. This mechanism could be used as a ―Trojan horse‖ for site-
specific delivery of anticancer agents, and is executable by decorating 
the surface of NPs with antibodies or ligands that specifically bind to 
these receptors. This modification mainly relies on chemical conjugation 
of PLGA or PEG-PLGA NPs with different targeting moieties such as 
antibodies, aptamers, peptides, or small ligands. Very few is known on 
the possibility to modify NP surface through supramolecular chemistry.   
 
2.5  Active targeting of NPs through CD44 receptor 
CD44 receptor is a transmembrane glycoprotein (85 kDa) playing a 
role in a lot of cellular functions, including cell orientation, adhesion, 
migration, and matrix-cell signaling processes.59 CD44 is overexpressed 
in many solid tumor cells: lung, breast, colorectal, gastric, pancreatic 
cancer. Additionally, CD44 is also considered as a common marker for 
several cancer stem cells and exhibit highly malignant and chemo-
resistant properties.  
The ligand for CD44 receptor is the extracellular matrix Hyaluronan 
or hyaluronic acid (HA) which is a linear negatively-charged 
polysaccharide formed by alternating D-glucuronic acid and N-acetyl-D-
glucosamine (Fig. 4). In addition to CD44 receptor, HA can also interact 
with other receptor including RHAMM (receptor for Hyaluronan-
mediated motility CD168), HARE (HA receptor for endocytosis) and 
Toll-like receptor 2 and 4. 
The binding of HA molecule to multiple CD44 receptors (Fig. 5) 
induce the extracellular clustering of the receptors which regulates 
intracellular organization of cytoskeleton, this mechanism giving the 
activation of diverse kinases. The second signaling pathway finally 
                                                     
59H. S. S. Qhattal and X. L. Liu, "Characterization of CD44-Mediated Cancer Cell Uptake and 
Intracellular Distribution of Hyaluronan-Grafted Liposomes," Molecular Pharmaceutics 8, no. 
4 (2011). 
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induces subsequent changes in cellular behavior. The molecular weight 
of HA is a key factor in CD44-mediated signaling. 
 
For example it has been demonstrated that low molecular weight HA 
fragments but not high native molecular weight HA can activate cell-
signaling pathways and induce expression of tumor necrosis factor.60 
HA is internalized into cells that overexpress CD44 receptor via 
receptor-mediate endocytosis and is compartimentalized in the lysosome 
where it is degraded by lysosomal enzyme called Hyaluronidases 1 
(Hyal1).  
A variety of HA-based nanocarriers have been developed for 
targeting drugs to cancer cells, generally encompassing covalent 
conjugates with chemotherapeutics. For example PLGA based NPs for 
                                                     
60K. Y. Choi, G. Saravanakumar, J. H. Park, and K. Park, "Hyaluronic acid-based nanocarriers 
for intracellular targeting: interfacial interactions with proteins in cancer," Colloids Surf.B 
Biointerfaces. 99:82-94. doi: 10.1016/j.colsurfb.2011.10.029. Epub@2011 Oct@20. (2012). 
 
Fig. 5. (Top) Structure of hyaluronic acid. (Bottom)Schematic illustration of CD44-
mediates signal transduction and cellular uptake Ki Young Choi, ―Hyaluronic acid-
based nanocarrier for intracellular targeting: Interfacial interactions with proteins in 
cancer‖, Colloids and Surfaces B: Biointerfaces. 99, n 82-94 (2012). 
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delivering of DOX in particular DOX-loaded HA-g-PLGA micelle NPs 
exhibited higher cellular uptake and greater cytotoxicity than free DOX 
for HCT-116 cells that over-expressed HA receptor, suggesting that they 
were taken up by the cells via HA receptor-mediated endocytosis.61In 
another studies HA coated docetaxel-loaded vesicles performance in 
vivo and in vitro several advances including the high selectivity to CD44 
overexpressing tumor cells, passive target via EPR effect and the 
extremely low cytotoxicity to the normal cells shown that self-assembled 
HA NPs were taken up in MDA-MB-231 cells by CD44-mediate 
endocytosis via an energy-dependent endocytic pathway and compared 
uptake in two cell line with different CD44 expression to elucidate the 
enhanced uptake mediated HA-CD44 interaction (Fig. 5). 
 
2.6 Combining different treatment modalities through 
tailored NPs 
Combination therapy has been introduced in clinical practice to 
overcome problems associated with single chemotherapeutic cancer 
treatments, that is MDR, significant toxicity and undesirable side effects. 
Generally combination therapy consists in the administration of two or 
more than two therapeutic agents co-delivered simultaneously or a 
combination of different strategies, such as chemotherapy, hormone 
therapy, immunotherapy and radiotherapy.62 In the past few years, the 
rationale for this approach has been centered on targeted drugs acting on 
specific biochemical pathways. In fact it has been hypothesized that one-
dimensional mechanism of action of a single chemotherapeutic, often 
determines the activation of alternative pathways, which determines 
failure of therapy or tumor recurrence.  
Accumulating clinical experience, supported by animal studies, 
suggests that chemotherapy is most effective when given in combination 
to give an additive effect as compared  to the individual pharmacological 
activity of single compound. Moreover co-encapsulation of drugs with 
                                                     
61A. Almalik, S. Karimi, S. Ouasti, R. Donno, C. Wandrey, P. J. Day, and N. Tirelli, 
"Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated 
uptake of HA-coated nanoparticles," Biomaterials 34, no. 21 (2013). 
62P. Parhi, C. Mohanty, and S. K. Sahoo, "Nanotechnology-based combinational drug delivery: 
an emerging approach for cancer therapy," Drug Discovery Today 17, no. 17-18 (2012). 
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different pharmacokinetics properties at the same body site allows to 
give a temporal sequencing of drug release. The fact that the two agents 
or more act on different signaling pathways synergistically is very 
promising to overcome the compensatory mechanisms induced in the 
cancer cells. Furthermore, low dosage of each compound or the access to 
context-specific multi-target mechanisms consent to avoid the use of 
high drug doses which are associated to a toxic effects.63 Furthermore, 
the possibility to administer multiple drugs with different molecular 
targets consent to modulate the genetic barrier which are responsible of 
cell mutations and the cancer adaptation process which often causes the 
failure of therapy. These advantages of drugs in combination are 
expected to be greater than the sum of the effects of drugs individually. 
The best drug combination with maximal antitumor efficacy can be 
calculated by multiple drug effect/combination index isobologram 
analysis, an effective way to demonstrate that drugs are working 
synergistically.64 In addition, co-treatment tumor modulators which are 
involved in MDR(P-glycoprotein inhibitors)is an important strategy. 
Nanotechnology-based strategies to deliver drug combinations offer 
the advantage to improve pharmacokinetics increasing drug fraction 
available at tumor site through EPR effect and to overcome the systemic 
toxicity toward normal tissue (Fig. 6). NPs give also the possibility to 
co-delivery multiple drugs at a predetermined ratio, that maximizes the 
combination efficacy. In fact, the ratio of two or more drugs has been 
found to influence the efficacy of combination therapy.65 The degree of 
synergism and antagonism is strongly affect to the relative concentration 
between the combined drugs in combinatorial NPs.66,67 
                                                     
63J. Lehar, A. S. Krueger, W. Avery, A. M. Heilbut, L. M. Johansen, E. R. Price, R. J. Rickles, 
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64T. C. Chou, "Drug Combination Studies and Their Synergy Quantification Using the Chou-
Talalay Method," Cancer Research 70, no. 2 (2010). 
65C. M. J. Hu and L. F. Zhang, "Nanoparticle-based combination therapy toward overcoming 
drug resistance in cancer," Biochemical Pharmacology 83, no. 8 (2012). 
66V. Pavillard, D. Kherfellah, S. Richard, J. Robert, and D. Montaudon, "Effects of the 
combination of camptothecin and doxorubicin or etoposide on rat glioma cells and 
camptothecin-resistant variants," British Journal of Cancer 85, no. 7 (2001). 
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For example, dual-drugs liposomes with precise molar ratio have 
been prepared to deliver cytarabine and daunorubicin in ratio 5:1 for 
leukemia treatment 68,69 and irinotecan and floxuridine formulation in 
ratio 1:1 for colon-rectal cancer treatment.70 These combinations 
                                                                                                                      
67M. Raitanen, V. Rantanen, J. Kulmala, H. Helenius, R. Grenman, and S. Grenman, "Supra-
additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in 
vitro," International Journal of Cancer 100, no. 2 (2002). 
68W. S. Lim, P. G. Tardi, N. Dos Santos, X. W. Xie, M. N. Fan, B. D. Liboiron, X. P. Huang, T. 
O. Harasym, D. Bermudes, and L. D. Mayer, "Leukemia-selective uptake and cytotoxicity of 
CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow 
xenografts," Leukemia Research 34, no. 9 (2010). 
69E. J. Feldman, J. E. Lancet, J. E. Kolitz, E. K. Ritchie, G. J. Roboz, A. F. List, S. L. Allen, E. 
Asatiani, L. D. Mayer, C. Swenson, and A. C. Louie, "First-In-Man Study of CPX-351: A 
Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the 
Treatment of Relapsed and Refractory Acute Myeloid Leukemia," Journal of Clinical Oncology 
29, no. 8 (2011). 
70G. Batist, K. A. Gelmon, K. N. Chi, W. H. Miller, S. K. L. Chia, L. D. Mayer, C. E. Swenson, 
A. S. Janoff, and A. C. Louie, "Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome 
Injection in Patients with Advanced Solid Tumors," Clinical Cancer Research 15, no. 2 (2009). 
 
 
Fig.6 Schematicrepresentationdepictingvariousadvantagesshownbycombinationdrug 
Delivery for cancer therapy Che-Ming Jack Hu, ―Nanoparticles-based combination therapy 
toward overcoming drug resistance in cancer‖, Biochemical Pharmacology 83, no 1104-
1111 (2012). 
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demonstrate the ability to maintain the synergistic ratio in vivo and are 
more effective than the cocktail administration of the free drugs.  
Another important aspect refers to the possibility of a temporal control 
on sequenced drug release in the attempt to deliver the biochemical 
agents at the appropriate cellular stage. Many chemotherapeutics are 
more potent in specific cell cycle state, and, therefore, improper 
sequencing could lead to unintended cell cycle arrest and diminished 
response to the subsequent drugs.71 
2.6.1 Combining chemotherapy with light-activated therapies 
The rapid delivery of biologically relevant species with precise 
spatiotemporal control is a hot topic in life science.72 Light is the most 
on/off trigger to support these criteria. In fact, the fast response of the 
photochemical reactions and their instantaneous initiation/stopping 
represent a powerful tool for the introduction of given amounts of 
―photocaged‖ chemical entities in biological systems in non-invasive 
way. In addition, the use of photons as external impulse offer the 
advantage of not affecting important physiological parameters, such as 
pH, temperature and ionic strength, which is a critical condition for bio-
applications.  
Amid light-activated therapies, Photodynamic therapy (PDT) is an 
emergent and selective therapy for the management of a variety of solid 
tumors including colon, breast, prostate and ovarian cancer. PDT is 
based on photochemical processes where an exogenous and non-toxic 
photosensitizer (PS), after irradiation with light at specific wavelength 
preferentially corresponding at PS maximum absorption, usually visible 
(VIS) or near-infrared (NIR), is able to generate oxygen-based molecular 
species which produce many effects at cell and tissue level.73,74(Fig. 7). 
                                                     
71M. A. Shah and G. K. Schwartz, "Cell cycle-mediated drug resistance: An emerging concept 
in cancer therapy," Clinical Cancer Research 7, no. 8 (2001). 
72E. Vittorino, M. T. Sciortino, G. Siracusano, and S. Sortino, "Light-Activated Release of 
Nitric Oxide with Fluorescence Reporting in Living Cells," Chemmedchem 6, no. 9 (2011). 
73A. P. Castano, P. Mroz, and M. R. Hamblin, "Photodynamic therapy and anti-tumour 
immunity," Nature Reviews Cancer 6, no. 7 (2006). 
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There are several technical difficulties in the application of PDT in 
cancer, partly shared by most clinically relevant chemotherapeutics. First 
is the difficulty in preparing pharmaceutical formulations that allow 
parenteral administration because most existing PSs are hydrophobic, 
aggregate easily under physiological condition and partly lose their 
photophysical properties.  
Although second generation PSs show lower toxicity, most of them 
exhibit poor solubility in aqueous media, complicating intravenous 
delivery into the bloodstream because the use of vehicles 
(Chremophor®, propylenglycol) can give allergy, hypersensitivity and 
toxicity.75 Several hydrophobic PSs tend to aggregate in physiological 
conditions via the strong attractive interactions between π-systems of the 
                                                     
75H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom, "Cremophor EL: the drawbacks 
and advantages of vehicle selection for drug formulation," European Journal of Cancer 37, no. 
13 (2001). 
 
Fig. 7. The mechanism of action on tumours in photodynamic therapy. The 
photosensitizer (PS) absorbs light and an electron moves to the first short-lived 
excited singlet state. This is followed by intersystem crossing, in which the excited 
electron changes its spin and produces a longer-lived triplet state. The PS triplet 
transfers energy to ground-state triplet oxygen, which produces reactive singlet 
oxygen (1O2). 
1O2 can directly kill tumour cells by the induction of necrosis and/or 
apoptosis, can cause destruction of tumour vasculature and produces an acute 
inflammatory response that attracts leukocytes such as dendritic cells and neutrophils. 
A.P. Castano, ―Photodynamic therapy and anti-tumour immunity”,Nature Reviews 
Cancer6 (2006). 
Generation of reactive 
oxygen species 
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polyaromatic macrocycles and, as a consequence, to produce singlet 
oxygen with very low yields.76 
Aggregation is one of the determining factors which can cause a loss 
of PS efficacy in vivo by decreasing its bioavailability and limiting its 
capacity to absorb light.77 Second is the selective accumulation in 
diseased tissues, which is often not high enough for clinical use. 
Foscan®, a first-generation PS, has failed FDA approval for the 
treatment of head and neck cancer due to poor tumor selectivity resulting 
in serious skin burns arising from photosensitivity. A third aspect is 
related to light-activation of PS that generally occurs at a wavelength 
where radiation is poorly penetrating and unable to reach deep tissues. 
Nanotechnological approaches in PDT (nanoPDT) can offer many 
advantages to deliver a PS and to solve at least part of these issues. 
Development of nanoscale-carrier to deliver a PS agent can result in 
optimized pharmacokinetics, enhancing the treatment ability to target 
and kill cancer cells of diseased tissue/organ while affecting as few 
healthy cells as possible.78,79 Furthermore, nanocarriers offer the 
possibility to deliver therapeutic concentrations of PS in the diseased 
tissue at specific subcellular location and to overcome solubility and 
tendency to aggregation of  PSs.  Nanocarriers also serve as a 
multimodal platform to bind/include a great variety of molecules, such as 
tumor-specific targeting ligands for targeted nanoPDT and/or imaging 
agents integrating in a single platform the unique opportunity for 
concurrent diagnostic and treatment of cancer tumors, the so-called 
theranostic. Recently, several multifunctional theranostic systems have 
been developed for real-time imaging-guided PDT of cancer.80 
                                                     
76L. P. F. Aggarwal and I. E. Borissevitch, "On the dynamics of the TPPS4 aggregation in 
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Strategies to deliver PDT agents and chemotherapeutics have been 
recently revised.81 
2.6.2 Combination of chemotherapy with NO release 
In the past twenty years, nanotechnology has offered a valuable tool 
to target bioactive molecules to solid tumors with the goal to improve 
response to conventional pharmacological therapies, to alleviate 
anticancer drug toxicity as well as to overcome multidrug resistance 
(MDR). In recent studies nitric oxide (NO) has been demonstrated a 
promising anticancer activity.82 NO radical is a able to attack biological 
substrates of different nature like plasma membrane,83 mithocondria,84  
and the cell nucleus.85 Moreover NO represents a multitarget cytotoxic 
agent, which does not suffer MDR problems encountered with target-
specific ―conventional‖ anticancer drugs. Evidence of NO-induced death 
in various cell types, both by apoptosis and necrosis, is discussed in 
relevant reviews.86 Furthermore, the short half-life in blood (<1s), the 
lack of charge, the god lipophilicity and the small size, allow NO to 
easily diffuse in the cellular environment over short distances ( <200 nm) 
confining the region of action without inflicting systemic side effects 
common to several chemotherapeutics. An additional advantage of NO is 
allow toxicity towards healthy cells, especially at concentrations toxic to 
cancer cells. However concentration and dose of NO strictly dictate its 
biologic effects.87 Light represent a powerful and minimally invasive 
                                                     
81C. Conte, S. Maiolino, D. S. Pellosi, A. Miro, F. Ungaro, and F. Quaglia, "Polymeric 
Nanoparticles for Cancer Photodynamic Therapy," Light-Responsive Nanostructured Systems 
for Applications in Nanomedicine 370 (2016). 
82D. Fukumura, S. Kashiwagi, and R. K. Jain, "The role of nitric oxide in tumour progression," 
Nature Reviews Cancer 6, no. 7 (2006).. 
83S. Gupta, C. Mcarthur, C. Grady, and N. B. Ruderman, "Stimulation of Vascular Na+-K+-
Atpase Activity by Nitric-Oxide - A Cgmp-Independent Effect," American Journal of 
Physiology 266, no. 5 (1994). 
84M. Nishikawa, E. F. Sato, K. Utsumi, and M. Inoue, "Oxygen-dependent regulation of energy 
metabolism in ascites tumor cells by nitric oxide," Cancer Research 56, no. 19 (1996). 
85M. N. Routledge, D. A. Wink, L. K. Keefer, and A. Dipple, "Dna-Sequence Changes Induced 
by 2 Nitric-Oxide Donor Drugs in the Supf Assay," Chemical Research in Toxicology 7, no. 5 
(1994). 
86Peter C. Ford, "Polychromophoric metal complexes for generating the bioregulatory agent 
nitric oxide by single- and two-photon excitation," Accounts of Chemical Research 41, no. 2 
(2008). 
87Alexis W. Carpenter and Mark H. Schoenfisch, "Nitric oxide release: Part II. Therapeutic 
applications," 41, no. 10 (2012). 

Chapter 1│ 
-39- 
chemical bond, releasing the ―caged‖ molecule, i.e. NO, in its active 
form. This strategy permits to confine the site of action of NO at the 
irradiated area with an exquisite spatial precision and to control its 
dosage with great accuracy by tuning the light intensity and/or duration 
as needed.  
Furthermore, the simple structure of these NO photoprecursors makes 
them suitable for derivatization via simple synthetic procedures.  
In view of image-guided NO-based phototherapies, the visualization 
of the NO photodonor in a cellular environment through fluorescence 
techniques represents an indispensable requisite. This permits to produce 
a highly localized ―burst‖ of NO precisely at the desired sites. 
Differently to photosensitizers used in PDT, which are intrinsically 
fluorescent, the combination of fluorescent imaging and 
phototherapeutic capacity in the same structure is less common in the 
case of NO photodonors.92 Of course, in the case of NO photocages 
lacking of emissive properties, fluorescent character can be imposed by 
their covalent combination with suitable flurogenic centers. In this case, 
inter-chromophoric interactions (i.e. energy or electron transfer) between 
the fluorophoric unit and the NO photocage need to be intentionally 
avoided with a careful choice of chromophoric groups by taking into 
account the energy of the lowest excited states of the components as well 
as their redox potential. Under these conditions, the fluorophoric center 
and the NO photocage can act in tandem even under condition of co-
absorption of the excitation light.  
While combinations of NO and singlet oxygen photorelease have 
been investigated,93 the effect of combining NO release with 
conventional chemotherapy is practically unexplored. 
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2.6.3 Combination of gene therapy with chemotherapy 
The use of combination therapy involving both gene therapy and 
chemotherapy has resulted in enhanced anti-cancer effects and has 
become an increasingly important strategy in medicine. Gene therapy 
consists in the delivery of genes in the form of plasmid DNA (pDNA), to 
supplement down-regulated or to replace mutated genes, and/or nucleic 
acid fragments in the form of small interfering RNA (siRNA), short 
hairpin RNA (shRNA) or micro RNA (miRNA) able to interfere with the 
expression of any gene of interest.  
The majority of research in this area has been focused on the co-
delivery of a drug and a gene using separate carriers to the same target 
tissue. Often this method has failed encouraging the development of 
nanoplatforms combining the gene and drug in one system thus 
overcoming differences in the physicochemical properties, such as 
hydrophobicity, molecular weight and metabolic stability. As a 
consequence this may results in sub-optimal gene transfection/expression 
efficiencies and drug release in target cells.94,95 Moreover, the use of 
polymeric NPs consent to condense and pack pDNA, to protect 
pDNA/nucleic acid fragments from degradation by serum nuclease in the 
extracellular medium, and to neutralize their negative charge to avoid 
repulsion by anionic plasma membrane.  
Several types of multifunctional NPs have been reported in the 
literature where the potential of this approach has been evaluated.96  
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2.7  Aim of the work and outline of thesis contents  
Based on this background, in an attempt to engineer multifunctional 
NPs for cancer therapy, we develop novel double-coated NPs through a 
layer-by-layer deposition technique. The aim was to test different 
combinations of bioactive species and to deliver NPs selectively to 
cancer cell overexpressing CD44 receptor to potentiate chemotherapeutic 
activity. On a technological standpoint, we designed biodegradable NPs 
with sustained delivery of the entrapped drug and surface-decorated with 
polymer layers by electrostatic interactions able to embed ionic drugs 
and to allow NP targeting. 
Core NPs were made of PLGA and entrapped hydrophobic drug 
preferentially. Then a first polycationic layer made of Polyethyleneimine 
and a second decorating polyanionic layer of low molecular weight HA 
are envisaged.  
Branched Polyethyleneimine  (PEI) is a cationic polymer that 
contains primary, secondary and tertiary amino groups. It was selected as 
a bridging layer for several reasons. First, PEI has been found to induce 
anticancer effects through toll-like receptors (TLRs) and considered a 
potential therapeutic agents for cancer immunotherapy.97 Second, HA-
decorated NPs are expected to lose partly the HA layer due to the 
presence of hyaluronidases and to operate as cationic PEI-covered NPs 
with the advantage of i) increased accumulation in cancer cell via 
electrostatic interaction between the NPs and the plasma membrane;ii) 
inhibition of tumor growth through necrosis; iii) deep penetration into 
remote tumor area because the necrosis caused by NPs reduces cell 
density, thus allowing the anticancer drug to diffuse into deep tissue.98In 
addition, the activity of PEI as transfecting agents can be of help in 
delivering nucleic acids.99 
The research activity has been summarized in five chapters and two 
annexes: 
                                                     
97P. Balakumar and M. Singh, "Anti-tumour necrosis factor-alpha therapy in heart failure: 
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98H. Yim, S. J. Park, Y. H. Bae, and K. Na, "Biodegradable cationic nanoparticles loaded with 
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(2013). 
99A. Ediriwickrema, J. B. Zhou, Y. Deng, and W. M. Saltzman, "Multi-layered nanoparticles for 
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‒ Biodegradable NPs sequentially decorated with 
Polyethyleneimine and Hyaluronan for the targeted delivery of 
docetaxel (DTX) to airway cancer cells (Chapter 2). This part 
reports the development of double coated NPs (dcNPs) 
delivering DTX and compares colloidal and biological 
properties of PEI-coated PLGA NPs to those of HA/PEI-coated 
PLGA NPs. 
‒ Hyaluronan-decorated polymer NPs targeting CD44 receptor 
for the combined photo/chemo-therapy of cancer (Chapter 
3).Here, we try to potentiate DTX activity combining a 
Tetraphenylporphirine (TPPS4) to DTX in dcNPs. 
‒ PLGA NPs for the delivery of a doxorubicin-nitric oxide 
photodonor molecular hybrid to overcome multidrug resistance 
(Chapter 4). To this purpose, a Doxorubicin-NO photodonor 
conjugates (DOX/NO) was entrapped in dc-NPs and its 
photochemical properties studied. This part of work has been 
carried out at the University of Catania under the supervision 
of Prof. Salvatore Sortino. 
‒ Combining chemotherapy and gene therapy through 
nanoparticles decorated with a Polyethyleneimine -hyaluronan 
sequential layer (Chapter 5).We based this strategy on a 
preliminary cellular studies which showed that cytotoxicity of 
5-Fluorouracil (5FU) was increased by a high level of rpL3 
ribosomal protein. 5-FU and a plasmid of L3 protein were 
entrapped in dcNPs and their colloidal and biological 
properties deeply explored. 
 
In the two annexes the development of Pluronic micelles for 
drug delivery is reported. In Annex I the combination Sorafenib-
Verteporfin is formulated as a supplementary example of coupling 
chemotherapy to photodynamic therapy while in the Annex II the 
potential of Pluronic micelles as pulmonary delivery platform is 
explored. 
Part of the work has been carried in collaboration with 
colleagues at Department of Pharmacy and Chemistry (University 
of Napoli Federico II, Italy), Department of Biology (University of 
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Padova, Italy), Department of Drug Science (University of Catania, 
Italy) and Department of Chemistry (University of Maringa, 
Brazil). 
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Abstract 
 
Background; Novel polymeric nanoparticles (NPs) specifically 
designed for delivering chemotherapeutics in the body and aimed at 
improving treatment activity and selectivity, cover a very relevant area in 
the field of nanomedicine. Here, we describe how to build a 
bioresponsive polymer shell of Hyaluronan (HA) and Polyethyleneimine 
(PEI) on biodegradable NPs of poly(lactic-co-glycolic) acid (PLGA) 
through electrostatic interactions and to achieve NPs with unique 
features of CD44 targeting as well as sustained delivery of a docetaxel 
(DTX) drug cargo. 
 Results; A stable HA/PEI shell could be obtained by careful 
selection of layering conditions. NPs with exquisite stability in salt and 
protein-rich media, with size and surface charge matching biological 
requirements for intravenous injection and endowed with sustained DTX 
release could be obtained. Since cationic NPs can be formed by 
degradation/dissociation of the surface HA because of the excess 
hyaluronidasess that are overexpressed in tumour interstitium, 
cytotoxicity, uptake and activity of NPs in CD44(+) (A549) and CD44(-) 
(Calu-3) lung cancer cells were evaluated on both PLGA/PEI/HA and 
PLGA/PEI NPs. There was no statistically significant cytotoxic effect of 
PLGA/PEI/HA and PLGA/PEI NPs in either A549 or Calu-3 cell lines, 
thus suggesting that introduction of PEI in NP shell was not hampered 
by its toxicity. Intracellular trafficking of fluorescently labeled RHO-
PLGA/PEI/HA and RHO-PLGA/PEI NPs demonstrated an increased 
time-dependent uptake only for RHO-PLGA/PEI/HA NPs in A549 cells 
as compared to Calu-3. As expected, RHO-PLGA/PEI NP uptake in 
A549 cells was comparable to that observed in Calu-3 cells. RHO-
PLGA/PEI/HA NPs internalized into A549 cells demonstrated a 
preferential perinuclear localization. Cytotoxicity data suggest that the 
delivery of DTX through PLGA/PEI/HA NPs allowed a much more 
potent antiproliferative activity than free DTX in A549 cells. 
Furthermore, DTX-PLGA/PEI NPs, as hypothetical result of 
hyaluronidases-mediated degradation in tumor interstitium, were still 
able to improve the cytotoxic activity of free DTX. 
Conclusions; Taken together, results lead us to hypothesize that 
biodegradable NPs coated with a PEI/HA shell represent a very 
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promising system to treat CD44 overexpressing lung cancer. In principle, 
this novel nanocarrier can be extended to different single drugs and drug 
combinations taking advantage of the shell and core properties. 
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1 Introduction 
In the past twenty years, nanotherapeutics have been introduced in the 
clinical practice for treating tumors with the goal to improve therapeutic 
outcome of conventional pharmacological therapies, to alleviate their 
toxicity as well as to overcome multidrug resistance [1-8]. By providing 
a protective housing for the drug, nanoscale delivery system can in 
theory offer the advantages of drug protection from degradation, efficient 
control of pharmacokinetics and accumulation in tumor tissue, thus 
limiting drug interaction with healthy cells and as a consequence side 
effects. Polymer-based nanoparticles (NPs) specifically designed for 
cancer treatment cover a very relevant and widely explored area in the 
field of nanotechnology [9-11]. The main advantages of polymer NPs 
reside in the opportunity to readily manipulate their properties by 
selecting polymer type and mode of carrier preparation. As a 
consequence, not only those surface features which affect biological 
behavior (spatial distribution of drug dose in the body) are controlled, 
but also timing of drug release (temporal control of drug availability to 
target) is predetermined. Due to their well-established biocompatibility 
and safety profile, nano-oncologicals made of polyesters such as 
poly(lactic-co-glycolic) acid (PLGA) can be considered one of the most 
interesting materials for this application and are greatly emerging in the 
field [2]. To be used as an effective nanomedicine, PLGA NPs need to 
be surface-engineered according to specific technological and 
therapeutic needs [12]. Core-shell architecture represents an effective 
way to attain multiple functionalities on a nanoscopic length scale. 
Indeed, a core (template) generally carrying a chemotherapeutic agent 
can be surrounded by a shell with different composition and 
configuration that provides a functional and interacting interface with 
biological environment [13]. The shell is also responsible of colloidal 
stability of the system ―in the bottle‖ (shelf life) and in biologically 
relevant media. A wide array of currently-available materials and 
possible combinations can be used to fabricate core-shell NPs spanning 
from tailored amphiphilic polymers, able to form nanoassemblies in 
aqueous media, to nanostructures where electrostatic or hydrophobic 
interactions drive shell deposition on a core template. The latter 
approach is very attractive since no complicate synthetic steps to attain 
polymer functionalization are required. In the construction of layered 
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NPs, an emerging aspect in nanotechnology is represented by the use of 
polymers with specific functions for cancer treatment. Two relevant 
examples are Polyethyleneimine (PEI) and Hyaluronan (HA). PEI is a 
cationic polymer widely employed for transfection due to its capacity to 
complex polyanionic DNA and oligonucleotides (decoy, siRNA, 
miRNA)[14]. Recently, it has been demonstrated that PEI can induce 
anticancer effects via electrostatic interaction with cell membranes 
[15,16]. Furthermore, it has been observed that intratumoral injection of 
different cationic polymers evokes a robust inﬁltration of Th 1 and NK 
cells into the tumor site, reversing the tumor microenvironment from 
immunosuppressive to immunostimulatory and inducing massive tumor 
necrosis [17]. In other studies, PEI triggered APC activation via TLR-
signaling and exerted direct tumoricidal activity in a mouse model of 
ovarian tumors [18]. Cationic NPs are considered intriguing systems to 
promote deep penetration in tumor tissues [19,20]. Nevertheless, cationic 
NPs induce rapid formation of complex aggregates with negatively 
charged serum molecules or membranes of cellular components, which 
are then cleared by the reticuloendothelial system (RES). More 
importantly, many cationic vectors developed so far exhibit substantial 
toxicity [21], which has limited their clinical applicability thus 
demanding strategies to reversibly shield their surface with biomimetic 
coatings. A functional anionic polymer such as hyaluronan (HA) can 
perfectly fit the purpose to cover cationic NPs through electrostatic 
interactions and to form a bioresponsive shell. HA is a negatively-
charged polysaccharide with a relevant role in cancer since its receptors 
(CD44, RHAMN) are overexpressed on the surface of a broad variety of 
cancer cells [22]. Recently, combination of chemotherapeutic drugs with 
HA NPs for selectively targeting CD44-overexpressed cancer cells has 
received increasing attention to improve specificity of the drug and 
alleviate side effects [23]. In fact, receptor-mediated endocytosis of HA-
decorated NPs facilitates drug transport inside the cells and contributes 
to enhance drug cytotoxicity [24]. Nevertheless, HA is involved in ECM 
remodeling of cancer tissues since HA degradation by interstitium 
hyaluronidases is a process at basis of facilitated metastasis formation 
[23]. Although based only on electrostatic interactions, core-shell PLGA 
NPs prepared by stepwise modification through several sequential 
layering of positive and negative polymers such as chitosan/alginate, 
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polylysine/alginate and polylysine/HA [25] has been found successful to 
achieve physically stable NPs for the co-delivery of different drugs with 
nucleic acid fragments [26]. In this paper, we describe how to build a 
bioresponsive shell on biodegradable PLGA NPs through PEI/HA 
electrostatic interactions and achieve NPs with unique features of CD44 
targeting, tumor penetration after HA shedding as well as sustained 
delivery of the hydrophobic anticancer drug docetaxel (DTX). After a 
formulation study aimed at optimizing preparation conditions of NPs, a 
powder for injection was obtained and characterized for release 
properties and stability in media with different ions and protein contents. 
HA-decorated NPs were tested for trafficking and activity in CD44(+) 
and CD44(-) lung cancer cells and potential contribute of HA shedding 
highlighted. 
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2 Materials and methods 
Docetaxel (DTX, MW=807.88) was purchased from LC laboratories 
(USA). Poly(lactic-co-glycolic) acid (PLGA) (D,L-lactic, 50:50 Resomer 
RG 502H, inherent viscosity 0.16 - 0.24 dl/g) was purchased from 
Boehringer Ingelheim (Ingelheim, Germany). Rhodamine B (RHO), 
trehalose, polyethyleneimine (PEI, MW= 25 kDa branched), copper (II) 
sulphate (MW= 63.55), hexadecyltrimethyl-ammonium bromide, 
poloxamer 188 (Pluronic® F68), sodium acetate, sodium chloride, 
sodium hydroxide, glacial acetic acid and trifluoracetic acid (TFA) were 
purchased from Sigma-Aldrich. Acetonitrile and acetone were purchased 
from Carlo Erba Reagenti (Milan, Italy).DMEM and Fetal Bovine Serum 
(FBS) were purchased from GibcoLife Technologies. Hyaluronan (HA, 
MW <10 kDa) was a kind gift of Magaldi Life S.r.l. Ultrapure water was 
used throughout the study. 
 
2.1 Preparation of DTX-PLGA/PEI/HA NPs 
NPs were prepared through a layer-by-layer deposition method. In a 
first step, DTX-PLGA NPs were prepared by nanoprecipitation. PLGA 
502H (5 mg) and DTX (5,10,15 and 20 % w/w ) were co-dissolved in 
acetone(1 mL) and added drop-wise to 2 mL of an aqueous phase 
containing Pluronic F68 (0.1% w/v) under magnetic stirring. The organic 
solvent was then evaporated under vacuum using a rotary evaporator for 
15 min, Thereafter, NP dispersion was splitted in 4 Eppendorf® tubes 
and centrifuged at 5000 x g for 15 min (Mikro 20 Zentrifugen). In the 
second step, NP pellet in each Eppendorf® tube was disperded in 1 mL 
of ultrapure water (final PLGA NP concentration was 1.5 mg/mL) and in 
each sample 125 µL of a PEI solution in water (0.5, 1.0 and 1.5 mg/mL) 
were added under stirring for 15 min. Thereafter, the sample was 
centrifuged again (2.800 x g for 10 min) to eliminate un adsorbed PEI 
and redispersed in 1 mL of ultrapure water (DTX-PLGA/PEI). In the 
third step,100 µL of a HA solution (1 mg/mL) were added to PLGA/PEI 
NPs under stirring for 15 min (DTX-PLGA/PEI/HA). Final NPs were 
freeze-dried for 24 h with trehalose as cryoprotectant (30 mg in each 
vial) and kept at 4 °C. Recovery yield of production process was 
evaluated on an aliquot of DTX-PLGA/PEI/HA NPs (without 
cryoprotectant) by weighting the solid residue after freeze-drying. 
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Results are expressed as the ratio of the actual NPs weight to the 
theoretical polymer weight×100. Fluorescent NPs were prepared 
analogously by incorporating a 20% w/w of PLGA-RHO to PLGA NP 
core. 
 
2.2  Characterization of DTX-PLGA/PEI/HA nanoparticles 
2.2.1  Size, surface charge and morphology 
Hydrodynamic diameter, polydispersity index (PI) and Zeta potential 
of NPs after each preparation step were determined on a ZetasizerNano 
Z (Malvern Instruments Ltd., UK). Results are reported as mean of three 
separate measurements of three different batches (n=9) ± SD.  
Particle morphology was analyzed by scanning electron microscopy 
(SEM) (Leica S440, Germany) after gold sputtering. 
2.2.2 DTX entrapment efficiency 
DTX loading inside DTX-PLGA/PEI/HA NPs was assessed by 
placing 0.5 mg of freeze-dried NPs or 30.5 mg of NPs freeze-dried with 
trehalose in 500 μL of DCM under stirring and dried. Thereafter, 500 μL 
of water and 500 μL of acetonitrile were added under stirring and the 
sample was finally filtered through a 0.45 μm filter (RC, Chemtek, 
Italy). DTX was analyzed by HPLC on a Shimadzu apparatus equipped 
with a LC-10ADvp pump, a SIL-10ADvp autoinjector, a SPD-10Avp 
UV–Vis detector and a C-R6 integrator. The analysis was performed on 
a Supelco 5 μm, C18 column (250×4.6 mm, Å). The mobile phase was 
a55:45 (v/v) mixture of water with TFA 0,1 % and acetonitrile pumped 
at a flow rate of 1 mL/min. The UV detector was set at 227 nm. A 
calibration curve for DTX in ethanol was constructed in the 
concentration range 0.980–196 μg/mL. The limits of quantification 
(LOQ) and detection (LOD) were 1.29 and 0.39 μg/mL, respectively. 
2.2.3 PEI amount in NPs 
PEI was quantified by a colorimetric method developed by us [33].To 
evaluate the amount of PEI in DTX-PLGA/PEI/HA NPs, 0.5 mg of 
freeze-dried NPs (with and without 30 mg of cryoprotectant) were 
treated with 1mL of NaOH 1 M and stirred overnight. The sample (0.5 
mL) was diluted with 0.5 mL of 1 M acetic acid. The resulting solution 
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(0.5 mL)was added to 1 mL of acetate buffer 0.1 M at pH 5.4, and 
complexed with 0.25 mL of a copper (II) sulphate water solution 
(0.1%w/v).The absorbance value of each solution was recorded at 
281nm (Shimadzu, UV 1800). A calibration curve was constructed in the 
same condition in the PEI concentration range 15–380 μg/mL. 
2.2.4  HA amount in NPs 
To evaluate the extent of HA adsorption onto DTX-PLGA/PEI/HA 
NPs, 0.5 mg of NPs were centrifuged at 13000 x g for 15 min, the 
supernatant was withdrawn and freeze-dried. The solid residue was then 
dissolved in 1mL of 0.2 M acetate buffer (0.2 M sodium acetate and 0.15 
M sodium chloride) at pH 6. Thereafter,2mL of 
cetyltrimethylammonium bromide reagent (2 g sodium hydroxide, 1 g 
hexadecyltrimethylammonium bromide in 100 mL water) was added and 
the sample was analyzed at 350nm. A calibration curve was constructed 
in same condition in HA concentration range 10–200 μg/mL. 
2.2.5  Stability in different media 
30.5 mg of freeze-dried DTX-PLGA/PEI and DTX-PLGA/PEI/HA 
NPs powder (corresponding to 0.5 mg of NPs) were dispersed in glucose 
5%, NaCl 0.9%, DMEM without and with FBS 10% (1 mL). Size, 
polydispersity index and zeta potential of the samples were evaluated. 
2.2.6  In vitro release studies 
In vitro release of DTX from NPs was assessed in 10 mM phosphate 
buffer containing NaCl (137 mM) and KCl (2.7 mM) at pH 7.4 (PBS) by 
a dialysis method. Around 100 mg of DTX-PLGA/PEI and DTX-
PLGA/PEI/HA freeze-dried powder (corresponding to 2 mg of NPs) was 
dispersed in 0.5 mL of DMEM with 10% FBS and placed in a dialysis 
bag (MWCO=3500 Da,Spectra/Por®). The sample was plunged in PBS 
and kept at 37 °C up to 72 h. At selected time intervals, 1 mL of release 
medium was withdrawn and replaced with an equal volume of fresh 
medium. DTX quantitative analysis was performed as described above. 
Release profile of free DTX dissolved in EtOH (10 μL, 2 μg/μL) and 
added to 0.5 mL of medium was assessed for comparison. Results are 
expressed as % release over time ± SD of three experiments. 
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2.3 Cell cultures and treatments 
The A549 and Calu-3cell lines were cultured in Dulbecco‘s Modified 
Eagle‘s Medium (DMEM) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) (Invitrogen, Life Technologies, Italy), 1.5 mM L-
glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin under 
humidified atmosphere of 5% CO2 at 37°C. Treatments of cells were 
performed replacing the culture medium with those containing 
increasing concentrations of DTX (0.1 ng-2 μg), unloaded and DTX-
loaded PLGA/PEI and PLGA/PEI/HA NPs (0.1 mg–2 NPs, 0.1 ng-2 μg 
DTX). DMSO 0.1% (v/v) was used as vehicle for DTX. 
2.3.1 MTT assay 
A549 and Calu-3 cells were seeded onto 96-well plates (2 × 104 
cells/well) and incubated with NPs for 24 h and 72 h. Then, cell viability 
was evaluated as mitochondrial activity using the MTT [34]. The 
absorbance measured at 540 nm using a microplate reader 
(LabsystemsMultiskan, MS).  
2.3.2 LDH assay 
LDH leakage into the media, an indicator of cell injury, was detected 
using using the cytotoxicity assay, CytoTox 96® (Promega, USA), 
according to the manufacturer‘s instructions, as described [35].Samples 
from clarified medium of treated and untreated A549 and Calu-3 cells 
were taken after 24 h and 72 h of incubation and the LDH activity was 
measured. 
2.3.3 Confocal microscopy 
A549 cells and Calu-3 cells were plated on coverslips at a density of 
2 × 104 cells per well in 12-well plates as previously reported (Russo et 
al., 2006). Images of fluorescence-labeled cells were captured with a 
Zeiss LSM 510 meta confocal microscope equipped with an oil 
immersion plan Apochromat 100× objective 1.4 NA.The laser line was 
set at 553 nm for RHO and 405 nm for DAPI. Images were acquired 
simultaneously in red and blue channels, and as z- stack. A gallery of 
optical slices was collected and xz, yz composites were processed using 
ImageJ Software to reconstruct the x-axis projection using stack images. 
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The scale bars on all the images correspond to 10 µm. The uptake of NPs 
was evaluated by measuring the incorporation of the fluorescent probe 
RHO in A549 and Calu-3 cells. Briefly, cells (2 × 104 cells per well in 
12-well plates) were collected and analysed by fluorimetry. The 
fluorescence was measured with a Cary Eclipse fluorescence 
spectrophotometer (Varian). Excitation and emission wavelengths were 
553 and 627 nm, respectively.  
 
3 Results and discussion 
To improve DTX activity and selectivity to cancer cells, we tried to 
engineer biodegradable PLGA NPs with a PEI/HA shell endowed with 
ability to interact with CD44 receptor thus improving NP accumulation 
in cancer cells. An anionic non end-capped PLGA nanoparticle template 
entrapping the model anticancer drug DTX was covered with a 
polycationic layer of PEI (25 kDa, branched) followed by a finishing 
layer of low molecular weight HA (<10 kDa). We first developed a 
robust layering procedure to obtain NPs and characterized the system in 
biologically-relevant media. Next, we assessed cytotoxicity, uptake and 
activity of NPs in CD44(+) and CD44(-) lung cancer cells also 
considering a possible HA shedding and generation of PEI-coated NPs.  
  
3.1 Layering procedure 
Preparation of DTX-loaded PLGA/PEI/HA NPs is a multistep 
process comprising i) the preparation of a PLGA core template; ii) the 
absorption of a positive PEI layer; iii) the absorption of a negative 
bioresponsive layer of HA (Fig. 1A).  
DTX-PLGA NPs were prepared by nanoprecipitation of a PLGA 
acetone solution in a Pluronic F68 water solution. The size of unloaded 
PLGA NPs was only slightly affected by PLGA concentration while the 
surface was always negative (Fig. 2A). Thus, a PLGA concentration of 5 
mg/mL was selected for all further experiments. After a washing step to 
eliminate surface-adsorbed Pluronic F68, around 60% of NPs with the 
original size/zeta potential could be recovered. Then, a first positive 
layer of PEI was adsorbed through electrostatic interactions by 
incubating NPs with a PEI water solution. 
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Fig. 1. Structure and properties of the NPs at different preparation steps. A) Schematic 
representation of the double coating process. B) Size, polydispersity (PI) and zeta potential of 
NPs during coating and after dispersion of final freeze-dried PLGA/PEI/HA NPs (without and 
with trehalose) in water. Results are the mean of three measurements obtained on three 
different NP batches ± SD. C) SEM micrographs of PLGA/PEI/HA NPs.  
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   The process of polymer film growth onto NP surface can be severely 
altered by several experimental factors and mainly by salt concentration 
of the medium [27]. PEI layering was thereby carried out both in water 
and PBS 0.01 M at pH 7.4. However, only water allowed the prompt re-
dispersion of PLGA/PEI NP pellet without aggregation. Thus, all the 
preparation steps were carried out in water. The addition of 125 µL of a 
PEI water solution at increasing concentration (0.5, 1.0 and 1.5 mg/mL) 
caused an inversion of zeta potential from negative to positive values 
(Fig. 2B). Optimal conditions for layering were found at 1 mg/mL since 
only a slight increase of size and polydispersity index (PI) was observed 
(Fig. 1B). PLGA/PEI NPs were further collected to eliminate un-
adsorbed PEI and dispersed in water again. In the following step, 
PLGA/PEI NPs were finished with a HA layer giving PLGA/PEI/HA 
NPs, which displayed a slightly increased size and negative zeta 
potential. 
Quantitative adsorption of HA on NP surface was confirmed by 
evaluating the amount of HA in the solution after collecting NPs (no free 
HA was detected in the medium). In developing translational NPs for 
intravenous route, it is of key importance to produce a lyophilized NP 
powder with a suitable shelf-life and with effective dispersion in the 
diluting vehicles usually employed for administration. While 
PLGA/PEI/HA NPs freeze-dried as such underwent extensive 
aggregation and could not be dispersed in water (Fig. 1B), the addition 
of a cryoprotectant such as trehalose gave a powder that, after dispersion 
in water, restored the original NP size, PI and zeta potential. 
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3.2 Properties of DTX-loaded NPs 
Overall properties of DTX-loaded PLGA/PEI/HA NPs are reported in 
Table 1. DTX entrapment in the PLGA core did not alter size, PI and 
zeta potential also after the freeze-drying step. Around 50% of the initial 
PEI amount was retained on NP surface whereas the absorption of HA 
was complete. The yield of the production process was found to be 
around 20% (Table 1), which is in line with values reported for layered 
NPs.  
 
Table 1. Properties of DTX-loaded PLGA/PEI/HANPs. SD were calculated on 
five different batches. 
 DTX-PLGA/PEI/HA 
DTX-PLGA/PEI/HA 
freeze-dried powder 
Trehalose/NP 
weight ratio 
- 60 
Yield (%± SD) 21.2 ± 0.8 a - 
Mean DH (nm ± SD) 173 ± 10 
b 203 ± 10 c 
Polydispersity index 0.13 b 0.17 c 
Zeta Potential (mV) -23.2 b -22.3 c 
DTX actual loading 
(mg per 100 mg) 
0.95 ± 0.5 0.013 ± 0.001 
PEI actual loading 
(mg per 100 mg) 
7.94 ± 2.1 0.132 ± 0.010 
HA actual loading 
(mg per 100 mg) 
12.2 ± 0.8 0.20 ± 0.03 
a calculated as ratio between total component weight and NP weight 
b as prepared NPsbefore freeze-drying 
c after dispersion of freeze-dried powder in water 
 
It is worth of note that final NPs can be loaded with amount of DTX 
in the PLGA core up to 15% without altering its size and zeta potential 
(Table 2). SEM analysis confirmed the spherical morphology and size of 
the final formulation (Fig. 1C). A drawback with a layering procedure 
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carried out in water could be the occurrence of weaker interactions 
between negative and positive polymer chains and, as a consequence, the 
formation of a loose and less stable coating. On these bases, we tested 
the stability of DTX-PLGA/PEI and DTX-PLGA/PEI/HA NPs in 
different media by measuring size and zeta potential (Fig. 3A). Both 
types of NPs were stable in NaCl 0.9% or glucose 5% solution giving 
size and zeta potential values comparable to those found in water. To 
mimic more closely NP behavior in cell culture experiments, stability 
was also assessed in DMEM without or with FBS (FBS- and FBS+, 
respectively). 
 
Table 2. Entrapment efficiency of DTX at different loading into PLGA 
nanoparticles. 
DTXtherorical 
loading 
(% w/w) 
Hydrodynamic 
diameter 
(nm ± SD) 
Zeta 
potential 
(mV) 
Actual 
loading 
(mg/100 
mg) a 
Entrapment 
efficacy 
(% w/w) b 
5 123 ± 10 -22 1.3 ± 0.5 26.5 
10 124 ± 2.5 -21 2.7 ±1 27.2 
15 127.5 ±3 -38 4 ±2.4 26.6 
a Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of 
NPs; 
b Ratio between actual and theoretical loading×100. 
 
The results suggested that DTX-PLGA/PEI greatly increase their size 
presumably due to extensive protein adsorption while size increase of 
DTX-PLGA/PEI/HA was limited. Size growth in the presence of 
proteins did not give macroscopic NP aggregation over time. Release 
profile of DTX from different NP type was evaluated by dialysis using 
DMEM FBS+ as dispersing medium and PBS at pH 7.4 and 37°C as 
external medium (sink conditions were realized). DTX release from 
DTX-PLGA/PEI and DTX-PLGA/PEI/HA NPs was monitored for 72 h 
and compared with that of free DTX (Fig. 3B). The transport of free 
DTX toward the external medium was found to be incomplete in this 
experimental set-up due to strong DTX-protein interaction inside the 
dyalisis bag hampering DTX transport in the external medium. This 
behavior is in agreement with previous data collected on DTX 
solubilized in human plasma [28]. However, a slower sustained release 
│Chapter 2 
-62- 
of DTX from DTX-PLGA/PEI and DTX-PLGA/PEI/HA NPs as 
compared with free DTX was found. the release rate observed for coated 
NPs was similar thus suggesting that for an unionized drug such as DTX, 
A  
 
B 
 
 Fig. 3. Properties of DTX-PLGA/PEI and DTX-PLGA/PEI/HA NPs freeze-dried with trehalose. 
A) Size and zeta potential in different media. B) Release profile of DTX from NPs dispersed in 
DMEM FBS+. External dialysis medium was a PBS solution at pH 7.4. Free DTX is reported as 
control. Results are the mean of three experiments ± SD. 
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the presence of the polyelectrolyte layer does not represent a further 
barrier to drug transport from the PLGA core. 
 
3.3 Cytotoxicity of unloaded NPs 
The cytotoxicity of PLGA/PEI/HA and PLGA/PEI NPs was 
evaluated since in biological environments NP shedding due to HA 
degradation can occur. Indeed, several cancers produce elevated levels of 
hyaluronidasess (hyals). A higher expression level of Hyal was also 
found in metastatic tumors as compared to non-metastatic [23]. In 
principle, cationic NPs can beformed by dissociation of the surface HA 
because of the excess hyals in tumor interstitium. The cytotoxicity was 
assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and lactate dehydrogenase (LDH) release assays. The 
experiments were performed in A549 and Calu-3 cells selected as 
CD44(+) and CD44(-) cell line, respectively[29]. Cells were incubated 
with a wide range of NP concentrations (from 0.1 mg to 2 mg) and tested 
upon 24 and 72 h of treatments. Data obtained from MTT and LDH 
assays after 72 h of treatments with PLGA/PEI/HA and PLGA/PEI NPs 
are shown in Fig. 4. 
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Results from MTT assay in Fig. 6A show that 24 h after the treatment, 
A549 and Calu-3 cells retained about 90% viability when treated with 
various concentrations of PLGA/PEI/HA NPs as compared with control 
(untreated cells set to 100%). At 24 h, the cytotoxicity curve for 
PLGA/PEI NPs followed almost similar pattern (Fig. 6B).The observed 
results were confirmed by the values of cell mortality from LDH assay. 
A549 and Calu-3 cells were incubated with the same concentrations of 
PLGA/PEI/HA and PLGA/PEI NPs. 24 h and 72 h later, cell membrane 
damage was assessed. Fig. 6 shows the dose-response histograms after 
24h of treatment with PLGA/PEI/HA (Fig. 6C) and PLGA/PEI (Fig. 
6D).  
 
 
Fig. 6. A549 and Calu-3 cells were exposed to increasing concentrations (0.1-2 mg) 
of PLGA/PEI/HA and PLGA/PEI NPs for 24 h. After incubation, cell viability and 
released of LDH % were evaluated using the MTT (A, B) and LDH (C, D) assay. The 
cell viability and LDH release from untreated control were set to 100% and 0%, 
respectively. Results are presented as percentage (mean ± SEM) (n = 3) of the control 
cells. 
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As shown, the results obtained from the LDH assay were in line with 
those obtained with the MTT assay. All these results clearly showed that 
there was no statistically significant cytotoxic effect of PLGA/PEI/HA 
and PLGA/PEINPs in either A549 or Calu-3 cell lines. 
 
3.4 Uptake of NPs 
The natural turnover of free HA is predominantly based on its CD44 
receptor-mediated internalization in cells[30]. Starting from this 
knowledge, we became interested to study the intracellular uptake of 
PLGA/PEI/HA and PLGA/PEI NPs in A549 (CD44(+)) and Calu-3 
(CD44(-)) cells. To this aim, fluorescently labeled RHO-PLGA/PEI/HA 
and RHO-PLGA/PEI NPs were prepared from a core NP containing 
RHO-PLGA covalent derivative ( Fig. 7). Properties of fluorescent 
RHO-NPs were comparable to those of untagged NPs ( Table 3). 
 
Table 3. Properties of fluorescent NPs. 
NP formulation Hydrodynamic 
diameter 
(nm) 
PI Zeta potential 
(mV) 
RHO-PLGA 138 ± 0.11 0.081 -24.7 
RHO-PLGA/PEI 157 ± 0.19 0.083 +32.0 
RHO-PLGA/PEI/HA 184.3 ± 2.6 0.100 -22.7 
 
 
 
Fig. 7. Structure of fluorescent PLGA-RHO polymer. Synthesis is reported in 
Maiolino S et al., Nanoscale. 2015 Mar 19;7(13):5643-53. 
│Chapter 2 
-68- 
Next, A549 and Calu-3 cells were incubated with RHO-
PLGA/PEI/HA and RHO-PLGA/PEI for 4 h and 24 h. The fluorescence 
intensity of the internalized RHO-NPs was measured by fluorimetry. As 
shown in Fig. 8 A, in A549 cells the treatment with RHO-PLGA/PEI/HA 
NPs was associated to an increasing time-dependent cellular uptake 
(30% and 80% after 4 h and 24 h, respectively). The observation that the 
lack of CD44 receptor did not provoke any significant uptake of 
RHO-PLGA/PEI/HA NPs in Calu-3 cells confirmed that the 
uptake of HA-decorated NPs was CD44 receptor-dependent. These 
results suggest that the endocytosis mechanism of PLGA/PEI/HA 
NPs internalization depends on the presence of HA onto the 
surface. As expected, RHO-PLGA/PEI NP uptake in A549 cells 
was comparable to that observed in Calu-3 cells (Fig. 8B). This 
finding highlighted the importance of CD44 receptor in the NPs 
cellular internalization process. However, it is important to note 
that RHO-PLGA/PEI NPs were still able to penetrate into cancer 
cells, giving about 10% and 35% NP uptake after 4 h and 24 h of 
treatment, respectively (Fig. 8B). This finding is very intriguing in 
the light of recent data demonstrating that in tumor 
microenvironment HA-coated NPs could be converted to uncoated 
NPs as results of hyaluronidases-mediated degradation (Yim et al., 
2013).In perspective, loss of HA coating can allow in situ 
generation of cationic NPs, which are still able to effectively enter 
inside cancer cells. Next, to investigate the subcellular distribution 
of internalized NPs, we carried out confocal laser scanner 
microscopy (CLSM) analysis into A549 cells.  
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Fig. 8. Fluorescent RHO-PLGA/PEI and RHO-PLGA/PEI/HA NPs were used to detect 
the intracellular NPs levels. A549 and Calu-3 cells were incubated with 0.5 mg/ml of 
RHO-PLGA/PEI/HA (A) and RHO-PLGA/PEI (B) for 4 h and 24 h. All measurements 
were normalized to the fluorescence of RHO labeled NPs in cell medium set as 100%. 
Results are presented as percentage (mean ± SEM) (n = 3) of the control cells. 
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After incubation with RHO-PLGA/PEI/HA NPs (Fig. 9A) and RHO-
PLGA/PEI NPs (Fig. 9E), the cells were stained with DAPI (Fig. 9B and 
9F) and observed under the microscope. A large majority of the RHO-
PLGA/PEI/HANPs-associated fluorescence appeared to be distributed in 
the vicinity, and surrounding, of the cells nuclei, confirming the 
internalization of NPs (Fig. 9C). The x-axis projections are shown in Fig. 
9D. Analysis of z-sections taken through the cell nucleus showed the 
absence of any signal in the nucleus ( Fig. 10). It may be noticed that the 
perinuclear accumulation of NPs after internalization in cells provides 
sustained drug delivery in the proximity of the nucleus. This feature 
might be interesting for the development of tumor suppressor gene-
loaded NPs as apoptosis-induction adjuvant, aimed at improving the 
outcome of common anticancer therapies as 5-FU and L-OHP [31]. The 
localization of internalized RHO-PLGA/PEI NPs is shown in Fig. 9G 
and H. The quantification of fluorescence demonstrated the efficacy of 
HA to mediate RHO-PLGA/PEI/HANP internalization (about 80%) as 
compared to non-targeted RHO-PLGA/PEI NPs (about 30%). In addition 
to internalization mechanisms, the intracellular trafficking of NPs within 
the cell are critical elements to study when a new drug carrier is 
proposed. Among these issues, the degradation pathway of the 
NPs represents an important aspect of intracellular NP 
dynamics. Lysosomes are a common terminal degradative compartment 
of certain endocytotic pathways. Thus, understanding whether NPs are 
delivered to the lysosomes following their internalization is a key point 
[32].  
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Fig. 9. A549 cells were incubated with RHO-PLGA/PEI/HA NPs (A) and RHO-PLGA/PEI NPs 
(E) for 24 h. Confocal microscope images 100X: A549 cell nuclei stained with DAPI (B, 
F).Merge of the same field for composite images (C, G), scale bar = 10 μm. Pictures were 
processed using ImageJ Software to reconstruct the x-axis projection using stack images (D, H). 
Quantification of intensity fluorescence is shown. Bars represent mean values ± SEM of 
experiments done in triplicate. *p < 0.005 
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To determine whether the internalized RHO-PLGA/PEI/HA NPs 
were addressed to the lysosomal compartments, A549 cells were 
incubated with fluorescent RHO-PLGA/PEI/HANPs for 24 h (Fig. 10A) 
and then stained with LysoTracker Green (Fig.10B) and DAPI (Fig. 
10C). As shown in Fig. 10D, a partial colocalization of RHO-
PLGA/PEI/HA NPs with lysosome, as evident from the appearance of 
orange to yellow fluorescence, was observed.The x-axis projection is 
also shown (Fig. 10E). 
 
 
  
 
Fig. 10. A549 cells were incubated with RHO-PLGA/PEI/HA NPs for 24 h. Confocal 
microscope images 100X: RHO-PLGA/PEI/HA NPs (A), lysosomes of A549 cells 
stained with LysoTracker Green (B), A549 cell nuclei stained with DAPI (C),Merge of 
the same field for composite images (D), scale bar = 10 μm. Pictures were processed 
using ImageJ Software to reconstruct the x-axis projection using stack images (E). 
Composite image demonstrated colocalization of RHO-PLGA/PEI/HA NPs with 
lysosomes 
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3.5 Cytotoxicity of DTX-loaded NPs 
Once the biological behavior of NPs was characterized, we tested 
their ability to improve the activity of DTX. In vitro cytotoxicity of 
DTX-PLGA/PEI/HA and DTX-PLGA/PEI NPs was evaluated in A549 
cells after 24 h and 72 h exposure by using MTT and LDH assays and 
compared to that of free DTX. Extrapolation from the dose-response 
curve demonstrated that the dose causing 50% cell death (IC50) in cells 
treated with free DTX was 0.1 µg/mL at 72 h while DTX loaded on 
PLGA/PEI/HA NPs gave the same effect at 0.05 µg/ml (Fig. 12A). 
These data suggest that the delivery of DTX through PLGA/PEI/HA NPs 
allowed a much more potent antiproliferative activity than free DTX. 
The observed results were confirmed by the values from LDH assay 
(Fig. 12C). Results from MTT and LDH assays of DTX-PLGA/PEINPs 
at 72 h (Fig. 12B and D) showed that the cytotoxicity induced by DTX-
PLGA/PEINPs was increased of about 15% as compared with free DTX. 
This finding indicated that DTX-PLGA/PEI NPs, as hypothetical result 
of hyaluronidases-mediated degradation in tumor, are still able to 
improve the cytotoxic activity of free DTX contributing in this way to 
further increase the therapeutical potential of original DTX-
PLGA/PEI/HA NPs. Data from MTT and LDH assays at 24 h are shown 
in Fig. 11.Taken together, results lead us to hypothesize that once the 
DTX-PLGA/PEI/HA NPs reach the CD44-overexpressed tumor site, 
they could be uptaken through CD44 receptor, be driven to lysosomes 
where drug release in a critical compartment more efficiently as 
compared with the free form is achieved.  
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Fig. 12. A549 cells were exposed to increasing concentrations (0.001-0.5 μg) of free 
DTX, DTX- PLGA/PEI/HA NPs (A, C) or DTX-PLGA-PEI NPs (B, D) for 72 h. After 
incubation, cell viability and released of LDH % were evaluated using the MTT (A, B) 
and LDH (C, D) assay. The cell viability and LDH release from untreated cells were set 
to 100% and 0%, respectively. Results are presented as percentage (mean ± SEM) (n = 
3) of the control cells 
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4 Conclusion 
This study has demonstrated that it is possible to build CD44-targeted 
NPs with sustained drug delivery by electrostatic assembly of proper 
polymer building blocks. Bioresponsive NPs with excellent stability in 
complex media and demonstrating unprecedented uptake and activity in 
CD44-overepressing lung cancer cells as compared with free drug were 
obtained. Cationic NPs generated after possible HA shedding in tumor 
interstium were still more cytotoxic than free drug, further highlighting 
the therapeutic potential of the whole nanocarrier. Taken together, results 
lead us to hypothesize that biodegradable NPs developed here represent 
a very promising system to treat CD44 overexpressing lung cancer. In 
principle, this system can be extended to different single drugs and drug 
combinations taking advantage of the shell and core properties. 
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Abstract 
 
In the attempt to develop novel concepts in the design of targeted 
nanoparticles for combination therapy of cancer, here we proposeCD44-
targeted hyaluronan-decorated double-coated nanoparticles(dcNPs) 
delivering the lipophilic chemotherapeutic Docetaxel (DTX) and the 
photosensitizerTetrasodium-Meso-tetra(4-sufonatophenyl)porphyrine 
(TPPS4).dcNPs were fabricated through electrostatic interactions 
between a negative DTX-loaded nano scaffold of poly(lactide-co-
glycolide), a polycationic Polyethyleneimine  (PEI) cationic shell 
entangling negatively-charged TPPS4andfinallydecorated with 
hyaluronan (HA) to promote internalization through CD44 receptor-
mediated endocytosis. DTX/TPPS4-dcNPs, prepared through layer-by-
layer deposition, showed a hydrodynamic diameter around 170 nm, 
negative zeta potential and efficient loading of both DTX and TPPS4. 
DTX/TPPS4-dcNPs were freeze-dried with trehalose giving a powder 
that could be easily redispersed in different media. Excellent stability of 
dcNPs in specific salt- and protein-containing media was found. 
Spectroscopic behavior of DTX/TPPS4-dcNPs demonstrated a face-to-
face arrangement of the TPPS4units in non-photoresponsive H-type 
aggregates accounting for a massive aggregation of the porphyrin 
embedded in the shell. Experiments in MDA-MB231 cells 
overexpressing CD44 receptor demonstrated a 9.4-fold increase of 
intracellular level of TPPS4delivered from dcNPs as compared to 
freeTPPS4.Light-induced death was increased tremendously in cells that 
had been treated with the combination of TPPS4 and DTX delivered 
through dons as compared with free drugs, presumably due to efficient 
uptake and co-localization inside cells. In perspective, the strategy 
proposed here to target synergistic drug combinations through HA-
decorated  NPs seems very attractive to improve specificity and efficacy 
of a cancer treatment. 
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1 Introduction 
Combination chemotherapy has long been adopted as the standard of 
care against many cancer types. It is generally recognized that through 
the proper drug combination, the treatment can promote synergistic 
actions, improve target selectivity, and prevent the development of 
cancer drug resistance.1-3This approach has been found promising when 
Photodynamic Therapy (PDT) has been combined to conventional 
chemotherapy in the management of several cancer types.4-7 In PDT a 
photosensitizer (PS), after irradiation at specific wavelength, causes 
mainly the formation of the cytotoxic species singlet oxygen (1O2) which 
reacts with tissue components, leading to cell death through the initiation 
of apoptosis and necrosis.8Indeed acting by different mechanisms, 
cytotoxic drugs can act in concert with PS for tumor killing, achieving 
potentiated therapeutic outcome through an anticancer synergistic effect.  
Entrapment of multiple therapeutic agents in a nanocarrier offers an 
unprecedented opportunity to devise a better scheme for precise and 
controlled delivery of multiple therapeutic agents in the same area of the 
body and at predefined extra/intracellular level.9-14 As compared to other 
nanocarriers, polymer-based nanoparticles (NPs) offer a great prospect in 
this area since they can be designed to target a solid tumor, to 
incorporate drugs with different solubility and to deliver them at finely 
tuned rates.15By exploiting the presence of dysfunctional endothelium of 
tumor capillary wall and the absence of effective lymphatic drainage in 
solid tumors, biomimetic and long –circulating NPs can extravasate from 
the blood circulation and reach solid tumor interstitium.16,17 This 
mechanism referred as Enhanced Permeability and Retention (EPR) 
effect is the main determinant in passive targeting while surface 
modification with structural motifs able to specifically recognize 
peculiar elements of tumors have been explored to further ameliorate 
drug specificity and effective drug accumulation in tumors/cancer 
cells.18-20 Furthermore, timing of drug release (temporal control of drug 
availability at target site) can be finely tuned. From a therapeutic 
standpoint, timing of drug release is of key importance to drive 
administration scheme (number of administrations, frequency) as well as 
to optimize cell response. In particular, sustained release of some 
chemotherapeutic from NPs is gaining overwhelming interest since it is 
expected to amplify cell response and extend activity to hypoxic zones of 
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certain tumors but also to improve drug activity resembling a 
metronomic therapy (subactive doses for longer time frames).21 
Despite of the great potential, there have been very few attempts to 
developing tumor-targeted nanosystems for the co-delivery of PS and 
anticancer drugs.22-26A challenging task in the design of polymeric NPs 
for combination therapy resides in the design of systems carrying drugs 
with a different solubility. Core-shell architecture represents an effective 
way to serve this purpose and to attain multiple functionalities on a 
nanoscopic length scale. In one of the possible configurations, a 
polymeric hydrophobic core (template),generally carrying a lipophilic 
chemotherapeutic agent, is surrounded by one or more than on a 
polymeric hydrophilic layers that entraps an interacting drug and 
provides a functional interface with biological environment. As core-
forming polymers, poly(lactide-co-glycolide)s are excellent candidates to 
form NPs with sustained delivery features. By varying polymer 
molecular weight and crystallinity, facile control on both encapsulation 
efficiency and biodegradation rate, and in turn on drug delivery rate, are 
attained.27Amid shell-forming hydrophilic polymers, hyaluronan (HA) is 
emerging for its activity as biological response modifiers in 
cancer.28,29HA is widely employed in cancer to direct a drug or a NP to 
tumor tissues due to its ability to recognize HA receptors (CD44, 
RHAMN) which are overexpressed in different cancer cell lines.28,30 
Receptor-mediated endocytosis facilitates drug transport inside the cells 
and contributes to improve cytotoxicity.31 It has been recently 
demonstrated that targeting a receptor such as CD44, which can undergo 
recycling between cell surface and endosomes/lysosomes and mediate 
transcytosis, can also promote tumor penetration of NPs.32 
Here, we develop CD44-targeted double-coated NPs(dcNPs) for the 
combined conventional and photodynamic therapy of cancer delivering 
the lipophilic taxane Docetaxel (DTX) and the negatively-charged PS 
Tetrasodium-Meso-tetra(4-sufonatophenyl)porphyrine (TPPS4). dons 
based on a DTX-PLGA core template and decorated with HA via 
electrostatic interactions with PEI as positively-charged TPPS4-
containing bridging polymer were produced and fully characterized for 
colloidal properties, photochemical behavior and phototoxicity in cancer 
cell lines overexpressing the CD44 receptor.  
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2 Material and Methods 
Docetaxel (DTX, MW=807.88) was purchased from LC laboratories 
(USA). Poly (D,L-lactide-co-glycolide) (PLGA) (50:50 Resomer RG 
502H inherent viscosity 0.16-0.24 dl/g) was purchased from 
BoehringerIngelheim (Ingelheim, Germany). Tetrasodium-Meso-tetra(4-
sufonatophenyl)porphyrine(TPPS4, MW=1239.1) was purchased from 
Frontier Scentific. Trehalose, Polyethyleneimine (PEI, MW= 10-25 kDa 
branched), Poloxamer 188 (Pluronic® F68) and Trifluoracetic acid 
(TFA) were purchased from Sigma-Aldrich. Acetonitrile and acetone 
were purchased from Carlo ErbaReagenti (Milan, Italy). DMEM and 
Fetal Bovine Serum (FBS) were purchased from Gibco life technologies. 
Hyaluronan (HA, MW <10 kDa) was a kind gift of Magaldi Life S.r.l. 
Ultrapure water was used throughout the study.N-(4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diazas-indacene-3-pentanoyl)sphingosine 
(BODIPY® FL C5-ceramide) and LysoTracker® Green DND-26were 
from Molecular Probes (Life Technologies, Milan, Italy). The 
CellTiter96®Aqueous One Solution Cell proliferation Assay (MTS) was 
from Promega Co (Madison, USA). 
 
2.1 Preparation of double-coated nanoparticles (dcNPs) 
dcNPs loaded with DTX,TPPS4or DTX/TPPS4 (DTX-dcNPs, TPPS4-
dcNPs,DTX/TPPS4-dcNPs) were prepared by a layer-by-layer deposition 
method. Briefly, DTX-loaded PLGA NPs were prepared by solvent 
diffusion of an organic phase (10 mg of PLGA and 0.5 mg of DTX in 2 
mL of acetone) in an aqueous phase (4 mL of water with Pluronic F68 
0,1%). After solvent evaporation and washing, NPs were coated first 
with 125 µL of a PEI water solution (1mg/mL), centrifuged and then 
addedwith25µL of a TPPS4water solution (0.2 mg/mL). Thereafter, 100 
µL of a HA water  solution(1 mg/mL) were added. The interval between 
each addition was kept constant at 15 min. dons were freeze-dried for 24 
h with trehalose(60 mg) as cryoprotectant and kept at 4 °C. Recovery 
yield of production process was evaluated on an aliquot of DTX/TPPS4-
dcNPs(without cryoprotectant) by weighting the solid residue after 
freeze-drying. Results are expressed as the ratio of the actual NP weight 
to the theoretical polymer weight×100.  
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2.2 Characterization of dcNPs 
2.2.1 Size, surface charge and morphology 
Hydrodynamic diameter,polydispersity index (PI) and zeta potential 
of NPs after each preparation step were determined on a ZetasizerNano 
Z(Malvern Instruments Ltd., UK). Results are reported as mean of three 
separate measurements of three different batches (n=9)±SD. Particle 
morphology was analyzed by scanning electron microscopy (SEM) 
(Leica S440, Germany) after gold sputtering. 
2.2.2 DTX and TPPS4 actual loading  
DTX loading inside DTX/TPPS4-dcNPs was assessed by placing 0.5 
mg of freeze-dried NPs (without cryoprotectant) in 500 μL of DCM and 
overnight stirring until a film was formed at bottom of the vial. 
Thereafter, 500 μL of water and 500 μL of acetonitrile were added and 
the sample was filtered through a 0.45 μm filter (RC, Chemtek, Italy). 
DTX was analyzed by HPLC on a Shimadzu apparatus equipped with a 
LC-10ADvp pump, a SIL-10ADvp autoinjector, a SPD-10Avp UV–Vis 
detector and a C-R6 integrator. The analysis was performed on a Supelco 
5 μm, C18 column (250×4.6 mm, Å). The mobile phase was a 40:60 
(v/v) mixture of water with TFA 0.1 % and acetonitrile pumped at a flow 
rate of 1 mL/min. The UV detector was set at 227 nm. A calibration 
curve for DTX in ethanol was constructed in the concentration range 
0.980–19.6 μg/mL. The limits of quantification (LOQ) and detection 
(LOD) were 1.29 and 0.39 μg/mL, respectively.TPPS4 loading inside 
DTX/TPPS4-loaded dcNPs was evaluated in the supernatant by UV after 
NP centrifugation at  13000 xg for 15 min. A calibration curve was 
constructed at 413 nm (Shimadzu, UV 1800)in the TPPS4 concentration 
range 0.05-5 μg/mL. 
2.2.3 PEI and HA dosage 
PEI amount in DTX/TPPS4-dcNPswas quantified by a colorimetric 
method developed previously.33Freeze-dried NPs (0.5 mg, without 
cryoprotectant)were treated with 0.5 mL of 1 M NaOH and stirred 
overnight. The sample (0.5 mL) was diluted with 0.5 mL of 1 M acetic 
acid. The resulting solution (0.5 mL) was added to 1 mL of 0.1 M acetate 
buffer at pH 4.5, and complexed with 0.25 mL of a copper (II) sulphate 
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water solution. The absorbance value of each solution was recorded at 
281 nm. A calibration curve was constructed in the same condition in the 
PEI concentration range 15–380 μg/mL. To evaluate the extent of HA 
adsorption onto NPs, DTX/TPPS4-dcNPs(0.5 mg) were centrifuged at 
13000 xg for 15 min and the supernatant was freeze-dried. The solid 
residue was then dissolved in 1mL of acetate buffer (0.2 M) at pH 6. 
Thereafter, 2mL of cetyltrimethylammonium bromide reagent was added 
and the sample was analyzed at 350 nm. A calibration curve was 
constructed in same condition in HA concentration range 10–200 μg/mL. 
2.2.4 DTX and TPPS4 release 
In vitro release of DTX and TPPS4 was performed on 30.5 mg of 
freeze-dried powder (corresponding to 0,5 mg of NPs)dispersed in 1 mL 
DMEM FBS+ 10% at 37°C. At predetermined time interval, the sample 
was centrifuged 13000 x g (15 min). TPPS4 release as assessed in the 
supernatant by spectrophotometry at wavelength of 422 nm. A TPPS4 
calibration curve in the range 0.2-4 g/mL was constructed in the release 
medium. DTX release was assessed by HPLC as reported in 2.2.2 after 
treating 1 mL of medium with acetonitrile (1 mL) to precipitate proteins 
and final centrifugation at 13000 x g (15 min).Results are expressed as % 
release overtime ± SD of three experiments. 
 
2.3 Spectroscopic and photochemical experiments 
2.3.1 Absorption and emission 
UV/Vis absorption and fluorescence spectra were recorded with a 
thermostated HP-8452 diode array spectrophotometer and Fluorolog-2 
(Model, F-111) spectrofluorimeter respectively. All measurements were 
performed in a thermostated quartz cell (1 cm path length, 3 mL 
capacity). Fluorescence spectra were corrected for the different fraction 
of the absorbed photons by the different samples at the excitation 
wavelength.  
2.3.2 Laser flash photolysis 
All samples were excited with the second harmonic of Nd–YAG 
Continuum Surelite II–10 laser (532 nm, 6 ns FWHM), using quartz cells 
with a path length of 1.0 cm. The excited solutions were analyzed with a 
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Luzchem Research mLFP–111 apparatus with an orthogonal pump/probe 
configuration. The probe source was a ceramic xenon lamp coupled to 
quartz fiber-optic cables. The laser pulse and the mLFP–111 system 
were synchronized by a Tektronix TDS 3032 digitizer, operating in pre-
trigger mode. The signals from a compact Hamamatsu photomultiplier 
were initially captured by the digitizer and then transferred to a personal 
computer, controlled by Luzchem Research software operating in the 
National Instruments LabView 5.1 environment. The solutions were 
deoxygenated by bubbling with a vigorous and constant flux of pure 
nitrogen (previously saturated with solvent). In all of these experiments, 
the solutions were renewed after each laser shot (in a flow cell of 1 cm 
optical path), to prevent probable photodegradation processes. The 
sample temperature was 295 ± 2 K. The energy of the laser pulse, 
measured at each shot with a SPHD25 Scientechpyroelectric meter, was 
ca. 10 mJ/pulse. 
 
2.4 Cell studies 
2.4.1 Cells 
Human breast cancer cell lines MDA-MB231 and MCF-7 were 
purchased from American Type Tissue Culture Collection (ATCC, 
Rockville, Maryland). The cells were grown in DMEM with GlutamaxTM 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 1 
mM sodium pyruvate, 100 U/mL streptomycin and 100 µg/mL penicillin 
G (Life Technologies, Milan, Italy), and maintained at 37 °C in a 
humidified atmosphere containing 5% CO2. 
2.4.2 Uptake studies 
Flow cytometry experiments were carried out to investigate the 
expression level of CD44 receptor and its involvement in the 
internalization of fluorescent dcNPs labeled with rhodamine B (RHO-
dcNPs) in MDA-MB231 and MCF-7 and to measure the uptake of 
TPPS4 and TPPS4-dcNPs in MDA-MB231 cells. RHO-dcNPs were used 
in place of TPPS4-dcNPs to avoid any misleading result generated by 
TPPS4 release in the cell external medium. Rho-dcNPs were prepared as 
described in 2.1 by incorporating a 20% w/w of PLGA covalently linked 
to rhodamine B in the PLGA core.  
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The preparation of PLGA-RHO conjugate was performed under inert 
nitrogen or argon atmosphere and dry conditions according to scheme 1.  
c-PLGA502H-N3.The terminal hydroxyl group of PLGA502H was 
changed into azide by two-step azidation with mesyl chloride activation. 
After 24 hours reaction mixture was concentrated and precipitated in 
diethyl ether methanol solution 1/1 v/v obtaining a sponge like solid. 
Thereafter, nucleophilic substitution with sodium azide was carried out 
in DMF and water solution (20/1 v/v) as described above, but 
temperature was set at 38°C. Reaction mixture was dried, redissolved in 
CHCl3 and precipitated as described above.The conversion degree is 
higher than 95% as evaluated by 1H-NMR analysis. 
Rhodamine-alkyne. Rhodamine B was reacted with 3-Butynol in 
presence of DCC and DMAP to give alkyne ester. After 48 h reaction 
mixture was filtered from dicyclohexylurea, concentrated and purified by 
silica gel chromatography with CHCl3/Methanol 9/1 v/v as eluent.  
PLGA-RHO. Thereafter, the Huysgen cycloaddition between 
Rhodamine-alkyne and c-PLGA502H-N3 was carried out at 30% 
Rhodamine-alkyne molar excess. After 48 h, reaction mixture was 
concentrated, purified by Cu(I) catalyst by neutral alumina column and 
precipitated in diethyl ether methanol solution 1/1 v/v according to 
developed protocol.1H-NMR analysis was used to confirm product 
chemical structure and conversion degree which is higher than 95%.  
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The level of CD44 expression in MDA-MB231 and MCF-7 cells was 
measured by staining the cells with a FITC-conjugated anti-CD44 
antibody (Abcam, Cambridge, UK). To study the role of CD44 in the 
uptake of RHO-dcNPs, 4 x 104 cells were grown in 24-well plates for 24 
h and incubated for 2 h with 50 µg/mL of NPs diluted in medium added 
with 3% FBS. Some samples were pre-incubated for 1 h with 10 mg/mL 
free HA (Sigma-Aldrich, St. Louis, USA) before NP addition in order to 
saturate CD44 receptors (competition experiments). At the end of the 
incubation time, the cells were washed twice with VerseneTM, detached 
from the plates with trypsin, that was neutralized by the addition of FBS. 
Cells were centrifuged and resuspendedin VerseneTMbefore measuring 
RHO fluorescence using a BD FACSCantoTM II flow cytometer (Becton 
Dickinson, San Jose, USA). The blue laser at 488 nm was used for 
excitation and wavelengths longer than 560 nm were selected for the 
detection of RHOfluorescence. For each sample 105events were acquired 
and analyzed with the FACSDiva software. For TPPS4 and TPPS4-dcNPs 
uptake, cells were seeded and handled as described above and incubated 
for 24 h with increasing concentrations of PS in medium added with 3% 
FBS. For the detection of TPPS4 fluorescence wavelengths longer than 
670 nm were selected. 
2.4.3 Intracellular localization of NPs 
The intracellular localization of TPPS4, free and in NPs (TPPS4-
dcNPs) was determined by confocal microscopy. MDA-MB231 cells (6 
x 104), seeded in special tissue culture dishes for fluorescence 
 
 
Scheme 1. Huysgen cycloaddition between Rhodamine-alkyne Rhodamine-alkyne 
and c-PLGA502H-N3. 
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microscopy (µ-Dish 35mm, high, Ibidi GmbH, Planneg, Germany), were 
allowed to growth for 24 h and then incubated for 24 h with 1 µg/mL PS 
diluted in medium added with 3% FBS. Fifteen min before the end of the 
incubation with the PS, the cells were stained with BODIPY® FL C5-
Ceramide (15 µM) or LysoTracker® Green DND-26 (75 nM) used as 
markers for Golgi apparatus and lysosomes, respectively. Cells were 
then washed twice with PBS with Ca2+ and Mg2+andimmediately 
analyzed with a Leica SP5 confocal laser-scanning microscope (Leica 
Microsystems Srl, Milan, Italy); the images were elaborated with the 
ImageJ software. 
2.4.4 Cytotoxicity assay 
Viability of MDA-MB231 cells incubated with free TPPS4, free 
DTX, TPPS4-dcNPs, DTX-dcNPs, DTX/TPPS4-dcNPs and empty dcNPs 
in the absence of light was measured with the MTS assay. Cells (5 x 103) 
were seeded in 96-well plates (24 h of growth) and then incubated with 
the various formulations diluted in medium added with 3% FBS. Cell 
viability was measured at the end of incubation time (24, 48, 72 h) as 
well as after additional 24 h in which the cells were kept in drug-free 
medium (24 + 24 h). For MTS assay the culture medium was replaced 
with 100 µL of serum-free medium and 20 µL of CellTiter 96® Reagent 
and the wells were incubated for 1 h at 37 ◦C. The absorbance at 492 nm 
was measured with a Multiskan Go (Thermo Fischer Scientific, 
Waltham, USA) plate reader and the viability of treated cells was 
expressed as percentage of the absorbance of control cells that was taken 
as 100% viability. 
2.4.5 In vitro photo-toxicity 
MDA-MB231 cells (5 x 103) were grown for 24 h and incubated for 
further 24 h with free TPPS4, combination of free TPPS4and free DTX, 
TPPS4-dcNPs, DTX/TPPS4-dcNPs and empty dcNPs in the dark. After 
incubation with the drugs, the cells were washed twice with PBS with 
Ca2+ andMg2+, and irradiated in PBS with 8 J cm-2of blue light (390-460 
nm, fluence rate 11 mWcm-2) from a UV 236 lamp (WaldmannEclairage 
SA, Germany). Immediately after irradiation the cells were brought back 
to the incubator after replacement of PBS with fresh medium. Cell 
viability was measured with the MTS test after additional 24 h. 
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2.4.6 Cell cycle analysis 
MDA-MB231 cells (1 × 106) were seeded in 100 mm culture dishes 
and incubated with free DTX or DTX NPs for 24 h. Treated and control 
cells were harvested, fixed in 70% cold ethanol and stored at 4 °C 
overnight. Before analysis, cells were washed in distilled water, 
centrifuged and resuspended in 1 mL PBS containing 50 μg/mL 
propidium iodide (Sigma-Aldrich) and 100 μg/mL RNAse, for DNA 
staining. Samples were incubated for 1 h at 37 °C and then analyzed by 
flow cytometry. Data from 2 × 104 cells/sample were acquired with the 
FACSDiva software and analyzed with the ModFit LT 3.0 software (BD 
Biosciences) to determine alterations in cell cycle distribution. 
2.4.7 Statistical analysis 
The Primer software for biostatistics (McGraw-Hill, Columbus, USA) 
was used for statistical analysis of the data. The data are expressed as 
means  standard deviations (SD) of at least 3 independent experiments. 
The difference between groups were evaluated with the Student‘s t-test 
and considered significant for p < 0.05. 
  
 Chapter 3│ 
 
-99- 
3 Results 
 
3.1 Preparation and characterization of double-coated 
nanoparticles (dcNPs) 
dcNPs made of a negatively-charged PLGA core loaded with the 
lipophilic drug DTX, a positively-charged bridging layer of PEI 
embedding the water-solubleTPPS4and a negatively-charged HA coating 
were produced through electrostatically-driven layer-by-layer assembly 
(Fig 1A). Layering was followed through size and zeta potential 
measurements. DTXPLGA NPs have a negative charge and adsorb 
firstly the positively charged PEI and then the negatively charged 
TPPS4through electrostatic interactions. Amount of PEI added strongly 
affects dispersibility of NPs after the washing step (data not shown). 
During layering, the size of NPs progressively increases up to around 50 
nm and zeta potential is reversed after each polymer layer deposition 
step (Fig. 1B). TPPS4 adsorption onto PEI layer covering DTX-PLGA 
core does not alter size and zeta potential of NPs up to a TPPS4amount of 
5 µg (Fig. 1C). At this concentration, TPPS4is quantitatively adsorbed 
onto NPs as demonstrated by the fact that the supernatant does not give 
any appreciable ABS at maximum wavelength of TPPS4adsorption. Final 
dcNPs show a hydrodynamic diameter below 180 nm and a net negative 
zeta potential. Actual loading of DTX and TPPS4in the final formulation 
was 0.95 ± 0.5 and 0.97 ± 0.2 mg per100 mg of dcNPs, respectively. 
Amount of PEI and HA adsorbed onto final formulation was 7.94 ± 2.1 
and12.2 ± 0.8mgper100 mg of dcNPs, respectively. DTX/TPPS4-dcNPs 
can be freeze-dried with trehalose to produce a powder that can be easily 
redispersed in water giving the original NP properties (Table 1). SEM 
analysis confirms the morphology of the final dcNPs (Fig. 1D). 
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Effect of medium on DTX/TPPS4-dcNPs colloidal properties were 
assessed (Table 2). Size of dcNPs in 5% glucose and 0.9% NaCl, 
commonly employed to disperse NPs before injection, does not greatly 
change. A slight size growth is observed in DMEM FBS- which 
becomes more marked in DMEM FBS+. In the case of PBS a significant 
three-fold increase of dcNP size occurred. In all the cases, no 
macroscopic aggregation of DTX/TPPS4-dcNPs is observed. 
Nevertheless, zeta potential is decreased in the media tested and remains 
unaltered independently of the salt composition and presence of proteins. 
 
Table 2. Properties of DTX/TPPS4-dcNPs in different media. 
 Size 
nm 
PI Zeta potential 
mV 
Water 203 ± 10 0.15 -22 
5% Glucose 221 ± 9 0.18 -11.3 
0.9% NaCl 257 ± 27 0.2 -12.1 
PBS 615 ± 58 0.25 -12.3 
DMEM FBS- 244 ± 28 0.26 -9.5 
DMEM FBS+ 328 ± 10 0.27 -10.0 
 
 
Release profile of DTX and TPPS4 from DTX/TPPS4-dcNPs was 
assessed in DMEM FBS+ at 37 °C and evaluated up to 72 h to simulate 
conditions occurring in cell studies. dcNPs display slow DTX release 
while60% of TPPS4is immediately released probably due to its high 
solubility in the medium (Fig. 1E). DTX release is much slower than that 
of TPPS4 as expected from their different lipophilicity. 
 
3.2 Spectroscopic and photochemical experiments 
Fig. 2 shows the absorption and fluorescence emission spectra of 
DTX/TPPS4-dcNPs and, for comparison, those of free TPPS4in water 
and in DMEM FBS+. In water solution, the free TPPS4 shows a sharp 
Soret band with a maximum centered at 413 nm (a, left) and a double 
band fluorescence emission with maxima at 640 and 700 nm (a, right), 
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respectively. These spectral features are typical for the monomeric form 
of TPPS4.
34 In the presence of DMEM medium the Soret absorption is 
always narrow but undergoes a slight hypochromism and significant red-
shift (b, left). Besides, a red-shift was also observed in the fluorescence 
emission but the fluorescence quantum yield was only slightly affected 
by DMEM (b, right). This spectroscopic scenario excellently reflects that 
reported for the same porphyrin in the presence of micellar systems34and 
is consistent with the presence of TPPS4 mainly as a monomer in DMEM 
FBS+.  
The spectroscopic properties of TPPS4 are profoundly affected when 
it is loaded within the dcNPs in the presence of DTX. In particular, a 
broadening of the Soret band accompanied by a dramatic hypocromic 
effects and blue-shift of ca. 6 nm was observed (c, left).Besides, the 
fluorescence was significantly suppressed and the emission bands were 
both red-shifted of ca. 16 nm (c, right). This spectroscopic behavior is 
typical for a face-to-face arrangement of the TPPS4 units in non-
photoresponsive H-type aggregates34,35and thus accounts for a massive 
aggregation of the porphyrin in the dcNPs. However, the low but not 
negligible fluorescence emission observed, suggests a slight deviation 
from the strict parallel arrangement of the dipole moments of TPPS4 
 
Fig. 2. Absorption (left) and fluorescence emission (right) spectra of TPPS4 and 
DTX/TPPS4-dcNPs in water (a,c) and in DMEM FBS+ (b,d). λex= 530 nm are 
shown. 
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units.36The whole DTX/TPPS4-dcNPs are quite stable in the presence of 
DMEM FBS+. In fact, the absorption spectrum (d, left) shows the Soret 
band shifted in two components with maxima at ca. 408 and 420 nm, 
respectively. While the former component is related to the H-types 
aggregates of TPPS4 in the dcNPs, the latter indicates that a small 
fraction of TPPS4 (ca. 20 %) undergoes displacement and is released in 
its monomeric form in DMEM medium. Accordingly the fluorescence 
spectrum (d, right) shows a slight revival with the emission maxima 
corresponding well to those observed for the free TPPS4 in the same 
medium (see spectrum b, right). This scenario was well confirmed by the 
behavior of the lowest triplet state of TPPS4. This excited state is the key 
transient intermediate for the photosensitization of 1O2 and its effective 
generation is thus crucial for the photodynamic action.37,38 
Laser flash photolysis with nanosecond time-resolution is a powerful 
tool for obtaining spectroscopic and kinetic features of excited triplets of 
porphyrins since these transient species exhibit very intense absorptions 
in the visible region and possess lifetimes falling in the microsecond 
time scale.39 Figure 3 shows that the transient spectra observed 0.1 µs 
after laser excitation of TPPS4 free and DTX/TPPS4-dcNPs dispersed in 
water and in DMEM FBS+, respectively. Excitation of aqueous solutions 
of free TPPS4 results in the formation of a transient absorption with a 
maximum at ca. 440 nm and a bleaching due to the Soret ground-state 
absorption (Figure 3, spectrum a). This species decays mono-
exponentially with a lifetime of ca. 20 µs (Figure 4A), and can be safely 
attributed to the lowest excited triplet state of the TPPS4.  
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The triplet state of TPPS4 was also effectively populated in the 
presence of DMEM FBS+ (Fig. 3, spectrum b) but its lifetime was much 
longer being ca. 1.5 ms (Fig. 4B). In contrast no significant transient 
signal was observed for DTX/TPPS4-dcNPs in water (Fig.3, spectrum c) 
according to the assembling of the porphyrin in the form of non-
photoresponsive H-type aggregates within dcNPs. In the presence of 
DMEM FBS+, DTX/TPPS4-dcNPs exhibited a weak revival of the triplet 
signal. The appearance of this signal can be due to the displacement of 
the TPPS4 from the NPs and its release in DMEM medium under as 
photoactive monomeric form. The triplet decay observed in these 
conditions (Fig. 4C) was in fact virtually the same to that observed for 
the free TPPS4 under the very same experimental conditions (Fig. 4B) 
  
 
Fig.3. Transient absorption spectra observed 0.1 µs after 532 nm laser 
excitation (E532 ~ 10 mJ/ pulse) of N2-saturated solutions of TPPS4 in water (a) 
and DMEM FBS+ (b) and DTX/TPPS4-dcNPs in water (c) and DMEM FBS+ 
(d). 
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Fig. 4. Normalized decay traces monitored at 440 nm and the related first-order 
fittings, observed upon 532 nm laser excitation (E532 ~ 10 mJ/ pulse) of N2-
saturated ofTPPS4in water (A) and DMEM FBS+ (B) and DTX/TPPS-dcNPs in 
DMEM FBS+ (C). 
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3.3 CD44-mediated cell uptake of dcNPs 
The involvement ofCD44 receptor in the uptake of HA-coated NPs 
was studied measuring the uptake of RHO-dcNPs in MDA-MB-231 and 
MCF-7 cells exhibiting high and low CD44 expression, respectively. As 
shown in Fig. 5 A, RHO-dcNPs were taken up by both cells lines but as 
expected, the uptake was significantly higher in MDA-MB-231 with 
respect to MCF-7cells. The active role of CD44 in mediating the uptake 
of dcNPs was further confirmed with the competition experiments in 
which the cells were pre-incubated with an excess of free HA in order to 
saturate the receptors.  
 
The reduction of NP uptake caused by free HA was significant in 
both cell lines but it was more important in MDA-MB-231 than MCF-7 
cells (37% vs 23%) showing a clear dependence on the expression levels 
of CD44. Given the more important role of CD44 in MDA-MB-231, 
with respect to 
 
 
Fig.5. Uptake of RHO-dcNPs and TPPS4-dcNPs. A) Uptake of RHO-dcNPs (50 
µg/mL) in MDA-MB-231 (high CD44 expression) and MCF-7 (low CD44 
expression) cells after 2 h incubation at 37 °C in medium with or without 10 mg/mL 
free HA.* p<0.001, with respect to the sample not incubated with free HA (Student‘s 
t test). B) Concentration-dependent uptake of free TPPS4 and TPPS4-dcNPs in MDA-
MB-231 cells after 24 h incubation at 37 °C. * p<0.001, with respect to TPPS4 free 
(Student‘s t test). 
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     MCF-7 cells, the first were selected for our uptake and cytotoxicity 
studies on TPPS4 and DTX delivered by dcNPs. 
The uptake of TPPS4, delivered to the cells in the free form or 
incorporated in TPPS4-dcNPs was measured by flow cytometry after 24 
h of cell incubation (Fig. 5 B).Delivery through dcNPs significantly 
increased the uptake of the PS at all tested concentrations and, at the 
highest concentration of 1 µg/mL, the uptake of TPPS4-dcNPs was about 
9.4-folds that of free TPPS4.Confocal microscopy analysis revealed that 
while free TPPS4 was localized both in lysosomes and Golgi apparatus, 
TPPS4-dcNPs localized exclusively in lysosomes (Fig. 
6).
 
3.4 Cytotoxicity of dcNPs 
The cytotoxicity of DTX toward MDA-MB-231 cells was determined 
for the free and DTX-dcNP formulation by incubating the cells up to 72 
h. The cell viability was reduced at low drug concentrations but reached 
a plateau at approx. 0.1 µg/mL DTX(Fig. 7).  
 
 
Fig. 6. Confocal microscopy images showing the intracellular localization of 
TPPS4-dcNPs (A) and free TPPS4 (B, C) in MDA-MB-231 cells incubated for 24 
h. A and C: merged images of TPPS4and LysoTracker green; B: merged images of 
TPPS4andBODIPY® FL C5-ceramide.  
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The residual cell viability in the plateau region decreased prolonging 
the time of treatment for both formulations. DTX delivered by dcNPs 
was significantly more cytotoxic at very low concentrations (e.g. 0.01 
µg/mL) while, increasing the dose, free DTX resulted more effective in 
inducing cell death. DTX induced cell death by causing an arrest in the 
phase G2M of the cell cycle as already shown for taxanes (Fig. 8). 
However, our cell cycle analyses carried out after 24 h of treatment with 
DTX showed that DTX-dons were significantly more efficient in 
 
 
Fig. 7. Cell viability of MDA-MB-231 cells exposed to increasing 
concentrations of free DTX or DTX-dcNPs for 24 (A), 48 (B), 72 h (C). * 
p<0.001, with respect to control(Student‘s t test). ° p<0.05, °° p<0.01, 
°°°p<0.001, with respect to DTX-dcNPs (Student‘s t test). 
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inducing the block in G2M, especially at doses as low as 0.01 µg/mL. At 
this concentration, free DTX did not cause appreciable alterations of cell 
distribution in the various phases of the cycle while DTX-dcNPs 
increased the percentage of cells in S and G2M phases. This result is 
.. 
 
Fig. 8: Analysis of cell cycle of MDA-MB-231 cells exposed to free DTX or 
DTX-dcNPs for 24 h. Control cellsA); cells exposed to free DTX at 0.01 
µg/mLB) or 0.1 µg/mL D); cells exposed to DTX-dcNPs at 0.01 µg/mLC) 
or 0.1 µg/mL E). Percentages of cells the various phases are shown in F). 
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consistent with higher loss of cell viability measured at low 
concentrations of DTX-dcNPs with respect to free DXT.  
The toxicity of free TPPS4andTPPS4-dcNPswas measured in the 
absence of light after 24 h or 24 + 24 h of cell incubation for 
concentrations up to 1 µg/mL. Both PS formulations were scarcely 
cytotoxic toward MDA-MB-231 cells, with no more than 20% of cell 
mortality at 1 µg/mL TPPS4(Fig. 9 A, B). Prolonging the incubation up 
to 72 h did not increase cytotoxicity (data not shown). MDA-MB-231 
cells treated for 24 h with DTX/TPPS4-dcNPs showed a decrease of 
viability similar to that induced by DTX-dcNPs (p>0.05, Bonferroni test) 
(Fig. 7 A), indicating that in the dark cytotoxicity is mainly due to DTX. 
The combination of the two drugs in their free form caused a decrease of 
cell viability similar to that of DTX/TPPS4-dcNPs at concentrations 
higher than 0.25 µg/mL while at lower concentrations the combination of 
the free drugs was significantly less cytotoxic than DTX/TPPS4-dcNPs 
(Fig. 9 A, B). 
 
 
 
 
Fig. 9. Viability of MDA-MB-231 cells exposed in the dark to drugs free or 
loaded in dcNPs for 24 h (A) or 24 + 24 h (B). *p<0.05, **p<0.01, ***p<0.001, 
with respect to control (Student‘s t test). In C) the cells were irradiated with 8 
J/cm2of blue light after 24 h of exposure to the drugs and viability was measured 
24 h post-irradiation. *p<0.01, **p<0.001, with respect to control (Student‘s t 
test). 
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No effects on cell viability was observed incubating the cells with 
empty dcNPs up to 72 h (Fig. 10) with NP concentrations up to 100 
µg/mL. 
 
Cytotoxicity was also measured in cells incubated for 24 h with the 
various TPPS4formulations and then exposed to 8 J cm
-2of blue light. As 
shown in fig. 9 C, TPPS4 delivered through dcNPs was significantly 
more phototoxic than the free form, with an IC50 of 0.17 and 0.33 µg/mL 
PS, respectively. As expected, light-induced death was increased in cells 
that had been treated with the combination of TPPS4 and DTX in dcNPs 
(IC50 0.008 µg/mL PS). Interestingly, the decrease of cell viability after 
irradiation induced by DTX/TPPS4-dcNPs was significantly higher than 
that induced by the combination of the free drugs (IC50 0.16 µg/mL PS). 
 
 
4 Discussion 
The main goal of this work was to develop biodegradable core-shell 
dcNPs for combined delivery of photo- and chemo-therapeutic sin cancer 
cells overexpressing CD44 receptor. To this end, we exploited the strong 
electrostatic interactions between different and ad-hoc chosen, functional 
blocks. A biodegradable PLGA nanoscaffold, carrying the hydrophobic 
 
 
Fig. 10. Cell viability of MDA-MB-231 cells exposed up to 72 h to increasing 
concentrations of empty dcNPs. 
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chemotherapeutic DTX, was surrounded by a HA/PEI shell, entangling 
the hydrophilic PDT agentTPPS4 to give the complete nanoassembly. 
The rationale behind this logical design is summarized in the following: 
(1) HA is expected to be exposed at the dcNPs periphery, ensuring the 
active targeting to cancer cells; (2) the hydrophobic DTX and the 
hydrophilic TPPS4 are located in different compartments of the dcNPs 
(i.e., the core and the shell); such a large separation distance rules out 
any intermolecular communication between the photoexcited PDT agent 
and DTX(i.e.photoinduced electron transfer); (3) the cationic PEI is 
expected to encourage the massive aggregation of the PDT agent at the 
dcNPs shell; as a consequence, TPPS4is expected to be non-fluorescent 
and unable to photosensitize 1O2 until it is released from the dcNPs in its 
monomeric form. From a formulation standpoint, the amount of 
TPPS4loaded on PEI-coated NPs had an impact on size, which suggests 
that upon TPPS4adsorption some rearrangement of PEI chains due to 
altered negative to positive charge ratio could occur. Freeze-drying of 
dcNPs was feasible by using trehalose as cryoprotectant. After 
dispersion of the powder in water, spherical, non-aggregated 
DTX/TPPS4-dcNPs with unaltered hydrodynamic diameter and zeta 
potential were obtained. Size below 200 nm and negative surface 
perfectly fit the biological requirements for injectable NPs.40 As 
generally found for polyelectrolyte systems, the size of DTX/TPPS4-
dcNPs was very dependent on the presence of salts and proteins. As a 
general trend, dcNPs were prone to size and zeta potential (less negative) 
increase in the presence of salts. For polyelectrolyte NPs where HA is 
adsorbed onto chitosan cross-linked NPs, a tendency to NP shrunk is 
observed due to an increased osmotic pressure of the medium which 
decreases NP swelling.31Indeed, we observed an opposite trend for 
DTX/TPPS4-dcNPs which could be contributed by formation of weaker 
electrostatic interactions between PEI and HA and formation of a looser 
PEI/HA network. The different arrangement of PEI/HA chains can 
explain also the burst release of monomeric TPPS4(around 20%). 
Finally, a further increase of dcNP size in DMEM FBS+ could be 
attributed by protein adsorption onto NP structure possibly due to higher 
extent of exposition of positively-charged PEI to the medium. It is 
expected that PEI positive amino groups are prone to protein interaction 
as demonstrated for PEI or different types of NPs.41,42 Concerning 
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release kinetics, TPPS4release in DMEM FBS+ was incomplete in the 
time-frame of cell experiment while DTX release was slower due to both 
its low water solubility and longer distance to cover in order to reach the 
medium. Targeting ability of HA-coated NPs is strongly related to the 
morphology of the surface HA and in turn its mode of exposition to 
CD44 receptor.43,44. We have evidence that dcNPs bind CD44 receptor 
and are internalized by the cells with an efficiency that depends on the 
level of CD44 expression (Fig. 5 A); as a matter of fact the uptake of 
Rho-dcNPs was significantly higher in MDA-MB-231 cells that exhibit a 
high CD44 expression than MCF-7 cells. The active role of CD44 was 
confirmed by the higher inhibition of dcNP uptake in MDA-MB-231 
with respect to MCF-7 cells when an excess of free HA was added to the 
cell medium before incubation with NPs. Both TPPS4 and DTX 
entrapped in dcNPs could benefit of the CD44-mediated internalization 
of their carrier by increasing selective uptake and cytotoxicity in CD44 
over-expressing cancer cells. TPPS4is an efficient hydrophilic 
photosensitizer of 1O2 in solutions.
45Nevertheless it remains a poor 
photosensiting agent in vitro and in vivo due to its inability to enter and 
to be retained inside the cells46,47 at adequate concentrations able to 
produce efficient cell photoinactivation. Its incorporation into dcNPs 
greatly enhances its uptake in MDA-MB-231 cells and consequently 
increases the efficiency of light-induced cell mortality. TPPS4 loaded in 
dons at 1µg/mL was clearly detected in the lysosomes of the cells while 
intracellular fluorescence of free TPPS4was much less intense and was 
localized both in lysosomes and Golgi apparatus. It is worth mentioning 
that previous studies on cellular localization of free TPPS4 were carried 
out at a concentration of 75 µg/mL for gaining a fluorescence signal 
sufficient to detect a precise lysosomal localization of the porphyrin in 
the cells.48 In line with our observations, Varchi et al.49reported 
undetectable fluorescence in HepG2 cells incubated with free TPPS4 (20 
µg/mL) while TPPS4 delivered to cells in poly(methylmethacrylate) NPs 
showed a high intracellular fluorescence. Consistent with these 
observations our flow cytometry measurements showed higher uptake of 
TPPS4 in dcNPs with respect to the free form; at 1 µg/mL the uptake in 
NPs was increased by approximately 10-fold. The increased uptake led 
to increased phototoxicity to MDA-MB-231 cells which well correlated 
with the increased cellular fluorescence signals. Both the remarkable 
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fluorescence of TPPS4observed in cells as well as the extent of cell 
photoinactivation, cannot be ascribed to an internalization of the dcNPs 
without disassembling of the PDT agent. In fact, spectroscopic and 
photochemical results obtained in both aqueous solution and DMEM 
FBS+ showed negligible red fluorescence and barely detectable signal of 
the excited triplet state precursor of the 1O2 as a result of the massive 
aggregation of the PDT agent in the dcNPs, mainly as H-type aggregates, 
which are well known to be photochemically unactive.35 As a 
consequence, we believe that TPPS4is most likely released as 
photoactive monomer, characterized by good fluorescence and excellent 
photodynamic properties, after cellular internalization. The enhancement 
of DTX toxicity after incorporation into dcNPs was evident at the lowest 
tested concentration of 10 ng/mL. Percentages of death in MDA-MB-
231 cells exposed to DTX for 24 h were about 13 and 20%, respectively, 
for free and DTX-dcNP. The higher cytotoxicity is very likely the 
consequence of a faster and more efficient block in the S and G2/M 
phases of the cell cycle. In fact after 24 h of exposure, free DTX did not 
cause significant perturbations of the cell cycle while DXT-dcNPs 
caused an increase of the percentage of cells in S phase (55% vs 27% of 
the control) as well as G2/M phases (38% vs 18% of the control). 
Slightly different are the effects described by Huang et al.50 on the same 
cell line with 10 ng/mL DXT and this is very likely explained by the fact 
that cell cycle perturbations were analyzed after 48 h of treatment; in any 
case, in agreement with our observations, the arrest in G2/M phases was 
more evident with DTX-dcNPs rather than with free DTX. At 
concentrations higher than 10 ng/mL DXT-dcNPs caused an arrest of the 
cells in the G2/M phases stronger than that of free DTX but this effect 
did not translate into increased cell death also after prolonged treatment 
(48 and 72 h). The dark cytotoxicity of DTX-dcNPs toward MDA-
MB231 cells was not affected significantly by the incorporation of 
TPPS4. On the contrary following light activation of DTX/TPPS4-dcNPs, 
cell death was increased tremendously and reached 100% at drug 
concentrations less than 0.2 µg/mL. Extremely important is the 
observation that the combination of the two drugs in their free form, 
especially at concentrations below 0.2 µg/mL, was much less powerful 
in inducing cell death than the combination delivered through dcNPs. 
Whether the enhancement of cytotoxicity is the result of a synergistic 
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interaction of the two treatments will be determined with properly 
planned experiments and analyses of the data. In any case the results 
reported here strongly indicate that dcNPs are a very useful tool to 
potentiate the cytotoxic effects of the combination TPPS4 plus light and 
DTX. Very likely NPs favor the perfect timing and location of delivery 
of the two drugs to cell targets, namely microtubules. DTX is a well-
known microtubule-stabilizing agent that interferes with mitosis and cell 
division and cause death of breast cancer cells through mitotic 
catastrophe.51 Also light activated TPPS4 exerts its cytotoxic effects by 
perturbing the assembling of the mitotic spindle and arresting the cells in 
mitosis.52 It can therefore be hypothesized that the high efficiency of 
DTX/TPPS4-dcNPs in inducing cell death is related to a concerted action 
of the co-delivered drugs on reorganization of microtubules that leads to 
arrest in mitosis followed by death for excessive damage to mitotic 
apparatus.  
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5 Conclusions 
We have proposed a novel type of targeted dcNPs nanoparticles for 
the combined chemotherapy and photodynamic therapy of cancers 
overexpressing CD44 receptor. These dcNPs are achieved by taking 
advantage of electrostatic interactions between different building blocks, 
contain HA as a targeting moiety, co-encapsulate the chemotherapeutic 
DTX and the PDT agent TPPS4 in the core and the shell, respectively. 
dcNPs have the PDT agent completely aggregated and photochemically 
unactive at their surface and release it as active monomer after cell 
internalization. This feature is of relevance in view of further in vivo 
studies. Indeed, the dcNPs are expected to be non-fluorescent and non-
photoactive while in the circulatory system. Targeting mechanisms 
localize the dcNPs in tumor tissue, where the PDT component is 
disassembled from the dcNPS surface and becomes highly fluorescent 
and phototoxic. The concerted release of the chemotherapeutic results in 
a tremendous improvement of single drug activity. This strategy turns to 
be very attractive to selectively co-localize different drugs in the same 
cell compartment and to find out possible synergic effects. 
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Abstract 
 
Chemotherapy results in severe side effects due to drug accumulation 
at non-target sites and the necessity of high drug doses to eradicate 
tumor. Furthermore, multidrug resistance (MDR) is believed to 
compromise treatment and to be the reason for tumor recurrence despite 
intensive chemotherapy. In view of its multifaceted role in cancer 
biology, nitric oxide (NO) delivery with a very precise control of site, 
time and dosage, presents high potential and opens fascinating prospects 
for innovative/combined treatment modalities. 
In this work, we intend to develop a novel strategy based on the light-
regulated release of NO from tailored NO photodonors (NOPD) to 
overcome the above drawbacks, amplifying doxorubicin(DOX) 
anticancer efficacy in both resistant and non-resistant cancer cells. 
A covalent DOX-NOPD molecular hybrid was entrapped in 
biodegradable polymer nanoparticles (NPs) made of poly(lactic-co-
glycolic) acid. NPs were below 200 nm and had a negative zeta 
potential. Fluorescence of DOX-NOPD was preserved inside NPs which 
displayed, under light, a faster NO photorelease as compared to a 
methanol solution. It is anticipated that NO photorelease from NPs can  
amplify DOX anticancer efficacy allowing not only to maximize the 
overall therapeutic efficacy but also to reduce the massive dosage of 
DOX with consequent reduction of its cardiotoxicity. 
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1. Introduction 
Combination chemotherapy is becoming increasingly relevant to 
attain long-term prognosis and better quality of life in cancer patients. 
The basic concept in this strategy is to attack tumor on different sides by 
acting on a single oncogenic pathway through different mechanisms or 
across parallel pathways without intensification of side effects 
[1].Hence, there is a critical need of novel therapeutic strategies that can 
enhance response to chemotherapeutics and reverse resistance.  
In recent years, nitric oxide (NO) has stimulated an explosion of 
interest not only due to its pivotal role in the maintenance and 
bioregulation of vital functions, but also for its promising anticancer 
activity.[2] NO radical is able to attack biological substrates of different 
nature like the plasma membrane [3],the mitochondria [4]and the cell 
nucleus [5],representing a multitarget cytotoxic agent, which does not 
suffer MDR problems[6] encountered with target-specific 
―conventional‖ anticancer drugs. Evidence of NO-induced death in 
various cell types, both by apoptosis and necrosis, is discussed in 
relevant reviews [7,8]. Further, the short half-life in blood (< 1s), the 
lack of charge, the good lipophilicity and the small size, allow NO to 
easily diffuse in the cellular environment over short distances (< 200 
µm) [9]confining the region of action without inflicting systemic side 
effects common to several chemotherapeutics. An additional, peculiar 
advantage of NO is a low toxicity towards healthy cells, especially at 
concentrations toxic to cancer cells [2]. Furthermore, NO delivery to 
hypoxic regions, which are typical for solid tumors, increases 
significantly the local blood flow and enhances the susceptibility to 
chemotherapy and radiotherapy [10]. However, concentration, location 
and dose of NO strictly dictate its biologic effects[7]. Many classes of 
NO donors have been developed in recent years. However, they suffer 
important limitations since they are cleared rapidly in the body, release 
NO with limited control and need to be tailored to reach the specific 
target.  
Light represents a powerful and minimally invasive trigger for the 
release of NO in biological systems with a superb spatiotemporal 
accuracy by using suitable NO photodonors (NOPD)[11]. These 
compounds allow to confine the site of action of NO at the illuminated 
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area with high spatial precision and to control its dosage with great 
accuracy by tuning the light intensity and/or duration. These unique 
features make the NOPD, especially those activated with Visible (Vis) 
and Near Infrared (NIR) light, a therapeutic arsenal much more 
appealing than that based on NO donors activated by thermal, enzymatic 
or pH stimuli [12]. In addition, light triggering is biofriendly, provides 
fast reaction rates and offers the great benefit of not affecting 
physiological parameters such as temperature, pH and ionic strength, 
fundamental requisite for biomedical applications.  
Doxorubicin (DOX) is one of the most widely employed 
chemotherapeutics in fighting a vast variety of cancers. Despite its large 
use, DOX suffers two main limitations for an effective cancer therapy: i) 
cardiotoxicity, which can occur at both acute and chronic dose-related 
forms, ii) development of resistance through different mechanisms, the 
main of which is the overexpression of ABC transporters. Under the 
action of these transporters, DOX is extruded from the cancer cells, its 
cellular accumulation is decreased and consequently its cytotoxicity 
impaired. Interestingly,NO is also able to inhibit both Pgp and MRPs 
pumps by nitration processes [8]. The consequent decrease of their 
activity leads to an increase of DOX accumulation in the cancer cells 
with a resulting increase in its cell toxicity. Also in this case, NO 
concentration released remains a key issue to be addressed and therefore 
the use of NO precursors with controllable NO release is highly 
desirable. 
Inspired by the above background, we propose a novel strategy to 
amplify the DOX anticancer efficacy in both resistant and non-resistant 
cancer cells based on the appropriate combination of NOPD with DOX. 
To this purpose a DOX-NOPD hybrid was entrapped inside 
biodegradable NPs of poly(lactic-co-glycolic) acid and its photochemical 
properties studied. 
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2. Material and methods 
Poly(lactic-co-glycolic) acid (PLGA) (50:50 Resomer RG 502H 
inherent viscosity 0.16-0.24 dl/g) was purchased from 
BoehringerIngelheim (Ingelheim, Germany). Threalose, hyaluronidases 
400-1000 units, Polyethyleneimine (PEI, MW= 10-25 kDa branched) 
and Poloxamer 188 (Pluronic® F68) were purchased from Sigma-
Aldrich. Acetonitrile, ethanol and acetone were purchased from Carlo 
ErbaReagenti (Milan, Italy). DMEM and Fetal Bovine Serum (FBS) 
were purchased from Gibco life technologies. Hyaluronan (HA, MW 
<10 kDa) was a kind gift of Magaldi Life S.r.l. Ultrapure water was used 
throughout the study. 
 
2.1 Preparation of nanoparticles (NPs) 
DOX-NPs and DOX-NO NPs were prepared by a layer-by-layer 
deposition method as previously shown [13].Briefly PLGA NPs were 
prepared by solvent diffusion of an organic phase (10 mg of PLGA in 
acetone) in an aqueous phase (4 mL of water with Pluronic F68 0.1%). 
After solvent evaporation NPs were splitting in 4 eppendorf tube and 
washing, each eppendorf (0.5 mg NPs/mL) was coated first with a PEI 
and then with HA water solution (1mg/mL). The interval between each 
addition was kept constant at 15 min and, after each polymeric 
deposition, NPs are centrifugated and redisperded in water. NPs were 
freeze-dried for 24 h with threalose (60 mg) as cryoprotectant and kept at 
4 °C. 
 
2.2 NP characterization 
Hydrodynamic diameter, polydispersity index (PI) and zeta potential 
of NPs after each preparation step were determined on a ZetasizerNano 
Z (Malvern Instruments Ltd., UK). Results are reported as mean of three 
separate measurements of three different batches (n=9)±SD.  
For actual loading, NPs were centrifuged at 13000 rpm for 5 min and 
the amount of DOX and DOX-NOPD in water phase was analyzed by 
UV. Release profile of DOX from NPs (2mg) was evaluated by dialysis 
using DMEM FBS+ as dispersing medium and PBS ( 0.01 M) at pH 7.4 
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and 37°C as external medium (sink conditions were realized). DOX 
release was monitored for 72 h and compared with free DOX. 
 
2.3 Photochemical properties 
Photobleaching experiments were carried out by irradiating the 
samples with a 405 nm CW laser 200 mW cm-2. Absorption and 
emission spectra were recorded with a HP 2452 diode array 
spectrophotometer and a Fluorolog Mod 111 spectrofluorimeter 
equipped with a double monocromator.NO release was measured with a 
World Precision Instrument, ISO-NO 1000 meter, equipped with a data-
acquisition system and based on direct amperometric detection of NO 
with short-response time.  
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3. Results and discussion 
A conjugate between DOX and a NO photodonor (DOX-NOPD) was 
synthesized by the group of Prof. Fruttero at the University of Torino. 
The chemical structure is reported in Fig. 1. 
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Fig. 1. Chemical structure of DOX-NOPD. 
 
DOX-NOPD was entrapped inside PLGA core by nanoprecipitation. 
DOX alone was also entrapped and employed as control formulation. All 
NPs present a hydrodynamic diameter below 200 nm and entrapped 
around 50% of drug initially added. (Table 1).  
 
Table.1 Properties of NPs loaded with DOX or DOX-NOPD.  
 
NPs 
Mean DH 
(nm ± SD) 
PI Zeta 
potential 
(mV) 
Actual 
loading 
DOX NPs 170 ± 10 0.13 -23.2 1.9 ± 0.2 
DOX-NOPD 
NPs 
200 ± 10 0.17 -22.6 1.7 ± 0.1 
 
The release of DOX from DOX-loaded NPs dispersed in DMEM with 
FBS 10% was slower as compared with free DOX that was released in 
72h(Fig.2). 
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UV spectra of DOX-NOPD encapsulated in the NPs show a band 
with a maximum at 390 nm corresponding to the NO photoreleasing 
chromophore and around 500 nm corresponding to DOX absorption 
(Fig.3).The spectroscopic behavior observed under laser excitation at 
405 nm was compared to that of free DOX-NOPD dissolved in 
methanol. (meOH)UV spectra of DOX-NOPD in the NPs collected after 
5, 10, 15 and 20 min of irradiation show a bleaching of the 400 nm 
absorption band, according to the release of NO(Fig.3). The behavior 
was investigated also whit DOX-NOPD in meOH (Fig. 3) and kinetic of 
NO release reported as difference of absorbance at 390 nm after each 
single time interval (5, 10 and 15 min) and time 0 (A-A0) (Fig. 4). This 
release is clearly faster when DOX-NOPD is loaded into NPs as 
compared to DOX-NOPD in meOH (Fig. 3). 
 
Fig. 2. Release of DOX from NPs compared to free DOX. 
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This behavior is the result of the presence of a large number of 
abstractable H-atoms present in the core of the polymer, which better 
favor the formation of the phenol derivative after NO photorelease 
through a radical mediated decomposition pathway. In order to verify if 
the photorelease of NO affected the integrity of the DOX component, 
fluorescence emission spectra were simultaneously recorded after each 
irradiation step.  
The results reported in Fig. 5show that no significant change occurs 
upon light irradiation of the sample, according with the preservation of 
the DOX chromogenic unit in the molecular hybrid.  
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Fig. 3.Uv spectra of  DOX-NOPD upon irradiation at 405 nm up to 20 min. 
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Fig. 5. Emission spectra  of  DOX-NOPD NPs upon irradiation at 405 nm up to 20 
min. 
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We also performed time-resolved fluorescence experiments with the 
goal to gain insight into the dynamic behavior of the excited state of the 
DOX component. Normalized decay of DOX in NPs is bi-exponential 
with a lifetime of0.5 ns (64%) for DOX-NOPD loaded NPs as compared 
to DOX NPs showing a life time of 25 ps (59%) . The decay of DOX and 
DOX/-NO inside NPs was slower as compared to the corresponding free 
drugs respectively DOX/-NO and DOX (Fig. 6). 
 
An ultrasensitive electrode which detects NO evolution 
amperometrically was used to evaluate NO release. The results 
illustrated in Fig. 7shows that the release process trictly depends on the 
external light input. In fact it promptly stops as the light turns off and 
restart again as the light is turned on.  
 
 
 
Fig. 6. Normalized decay traces observed upon 532 nm laser excitation (E532 ~ 10 mJ/ pulse) 
of DOX-NOPD NPs , DOX NPs, DOX-NO, DOX in meOH. 
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Fig. 7. Amperometric detection of NO release from DOX-NOPD NPs and DOX NPs under 
light irradiation. 
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4. Conclusions 
 
DOX-NOPD can be encapsulated with high efficiency in PLGA NPs, 
according to our logical design. VIS light excitation of the loaded NPs 
leads to photoregulated release of NO from the nitroaniline moiety 
which converts to a phenyl derivate without inducing any 
photodecomposition of DOX, which well-retains its typical fluorescence 
in the red region. Preliminary cell results show that DOX-NOPD hybrid 
is much more accumulated in human M14 melanoma cells which express 
several ABC transporter and induced significant cytotoxicity compared 
to native DOX. Based on this preliminary data DOX-NOPD NPs can be 
tested onto different cancer cell lines in order to ameliorate DOX 
pharmacological profile. 
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Abstract 
The possibility to develop nanoparticles (NPs) combining different 
drugs which act on different biological pathways offers an 
unprecedented opportunity for finding novel treatment strategies for 
cancer. In this paper we designed double coated NPs based on a core of 
poly(lactic-co-glycolic) acid (PLGA) and a polymer shell of sequential 
layers of Polyethyleneimine (PEI) and Hyaluronan (HA) for the co-
delivery of a conventional drug 5-Fluorouracil (5FU) and a plasmid 
encoding for the fusion proteinrpL3-GFP (pL3) in CD44+ HCT 116 p53-
/-colon cancer cells to find out if a combined effect could occur. 
NPs showed a negative zeta potential and a hydrodynamic diameter 
below 200 nm, with a satisfactory actual loading of both 5FU and pL3. 
PEI adsorbed plasmid tightly onto NP surface as confirmed by gel 
retardation assay. Release profile of 5FU from NPs evaluated by 
dialysis using DMEM FBS+ as dispersing medium and PBS at pH 7.4 
and 37°C as external medium showed a sustained release as compared 
with the free drug. Cytotoxicity of 5FU-loaded NPsHCT 116 p53 -/-colon 
cancer cells was higher as compared to free 5FU. Transfection studies 
in A549 lung cancer and HCT 116 p53 -/-colon cancer cells demonstrated 
that plasmid-loaded NPs are capable of a persistent GFP expression up 
to 96 h as compared to conventional lipofectamine. Results on the 
combination of5FU and pL3in HCT 116 p53 -/-cells indicate again a 
potentiated cytotoxic effect of the combination as compared to single 
plasmid and 5FU. 
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1. Introduction 
In cancer, the combination of various drugs acting on different 
biological targets has paved the way to a novel view of old 
chemotherapeutics in the attempt to enhance their therapeutic effect, 
thus decreasing the dose and side effects, and to limit multidrug 
resistance (MDR). The knowledge of molecular pathways involved in 
the cytotoxic effect of conventional chemotherapeutic drugs offers an 
infinite number of possibility to amplify a certain biological effect by 
modifying the expression of a single gene [1].  
In cancer cell proliferation the rate of ribosome production plays a 
key role since an abundance of ribosomes is needed to sustain cell 
growth and proliferation suggesting that cancer cells are more sensitive 
to nucleolar stress than normal cells. Thus, chemotherapeutic agents 
that selectively target ribosome biogenesis could be less toxic to 
normal and differentiated cells. Many common anticancer drugs as 
5FU[2] and Actinomycin D [3] interfere with rRNA synthesis and/or 
processing thereby inhibiting ribosome biogenesis. The resulting 
nucleolar stress activates signaling pathways including ribosomal 
protein-MDM2-p53 pathway to mediate cell cycle arrest, apoptosis, 
differentiation and/or senescence [4]. Although these pathways are 
well studied, most cancer cells contain mutant p53 or no p53 at all and 
p53-independent pathways mediating the nucleolar stress response are 
emerging. In fact, accumulating data revealed the existence of p53-
independent but still ribosomal protein-dependent mechanisms that 
links nucleolar stress to cell cycle arrest. Recently, we demonstrated 
that ribosome-free rpL3 plays a crucial role in cell response to 
nucleolar stress induced by anticancer drugs known to interfere with 
RNA metabolism as 5FU, Actinomycin D and Oxaliplatin in colon and 
lung cancer cells devoid of p53 [5]. In particular, we demonstrated that 
upon drug-induced nucleolar stress free rpL3 is able to induce cell 
cycle arrest and apoptosis, and to inhibit cell proliferation and 
migration by controlling p21 expression both at post-transcriptional 
and post-translational levels independently from p53 [6]. It is 
noteworthy that the depletion of pL3 abolishes the cytotoxic effects of 
5FU in colon cancer cells lacking functional p53 indicating that the 
loss of pL3 makes drug cytotoxic effects ineffective; consistently, pL3 
│Chapter 5 
-148- 
overexpression associates to a strong increase of drug cytotoxicity. 
Taking together these results show that the efficacy of 5FU 
chemotherapy depends on pL3 status. Along this line, the knowledge 
of pL3 status in p53 null cancers may have a significant value in terms 
of the efficacy of chemotherapy based on 5FU. Hence, the 
development of treatments aimed at upregulating pL3 may be 
beneficial for the treatment of these cancers. 
In recent years, non-viral carriers for plasmid DNA delivery have 
been introduced because viral carriers, although showing good 
transfection properties, induce immune response and possible 
recombination with wild-type virus [7]. The main class of cationic 
polymers for gene delivery include poly-L-lysine (PLL) and 
polyethyleneimmine (PEI) which are effective agents for transfection 
of short sequences of DNA, RNA and plasmids, but characterized by 
severe cytotoxicity due to ionic interaction with negatively-charged 
cell membranes resulting in collapse of membrane potential [8]. 
Cationic polymers with low molecular weight or linear structure show 
lower toxicity as compared to their high molecular weight counterpart 
but also a reduction of DNA condensation ability and reduced 
transfection.  
Biodegradable polymers such as poly(lactic-co-glycolic) acid 
(PLGA) have been tested as gene nanovectors [9]. PLGA is a 
biodegradable polymer with a long history of safe use in 
pharmaceutical formulations and suitable for sustained delivery of 
small and large molecules [10]. Plasmid DNA can be either entrapped 
inside or adsorbed onto the surface of PLGA NPs. The encapsulation 
of plasmid DNA in PLGA is rather problematic since low 
encapsulation efficacy of DNA generally occurs [11]. Several attempts 
have been reported to enhance the loading of PLGA, comprising DNA 
condensation whit poly-L-lysine or PEI [12]. 
Over recent decades, nanotechnology has been found an interesting 
tool to combine different drugs with complementary mechanisms in 
one delivery system allowing their localization at the pharmacological 
target [13]. Some examples of NPs based on a PLGA core template 
including as cationic polymers PLL or PEI have been investigated for 
combined gene therapy and chemotherapy with the aim to overcome 
MDR. For example, co-delivery of camptothecin (CPT) and a plasmid 
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encoding TNF-related apoptosis genes loaded in multilayer NPs has 
shown a synergic effect in MDA-MB231 breast cancer cells [14]. Also 
the group of Paula Hammond attempted co-delivery of doxorubicin 
(DOX) and a siRNA for multidrug resistance protein (MRP1) to breast 
cancer cells through multilayer NPs based on PLGA and decorated 
with PLL layers [15] 
We have also engineered double-coated NPs based on PLGA and 
decorated with a layer of Hyaluronic acid to deliver selectively drug 
cargo to cancer cells overexpressing CD44 receptor [16]. The ability of 
this system to co-deliver DTX in combination with photosensiting 
agents has been highlighted [17].  
On this basis, we tried to investigate the possible combined 
cytotoxic effect of these NPs delivering 5FU and a plasmid of the 
proapoptoticL3 protein (pL3) in HCT 116Cp53 -/-cells, a colon cancer 
cell line devoid of p53.  
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2 Material and methods 
Poly(D,L-lactic-co-glycolic) acid (PLGA) (50:50 Resomer RG 
502H inherent viscosity 0.16-0.24 dl/g) was purchased from 
Boehringer Ingelheim (Ingelheim, Germany). Threalose, 
Hyaluronidases 400-1000 units, 5-Fluorouracil (5FU), glucuronic acid, 
Carbazole reagent, Polyethyleneimine (PEI, MW= 10-25 kDa 
branched), Poloxamer 188 (Pluronic® F68), heparin, formic and 
solforic acid were purchased from Sigma-Aldrich. Acetonitrile, ethanol 
and acetone were purchased from Carlo ErbaReagenti (Milan, Italy). 
DMEM and Fetal Bovine Serum (FBS) were purchased from Gibco 
life technologies. Hyaluronan (HA, MW <10 kDa) was a kind gift of 
Magaldi Life S.r.l. Ultrapure water was used throughout the study. 
 
2.1 Plasmid Construction 
The cDNA of pL3 was obtained by RT–PCR from HCT 116 p53 -/- 
cells using the primers 5′-ATGTCTCACAGAAAGTTC-3′ (forward) 
and 5′-TTAAGCTCCTTCTTCCTT-3′ (reverse) and subsequently 
inserted downstream from the reporter gene GFP ( green fluorescence 
protein) in the pEGFP-C1 expression vector (Clontech, Palo Alto, CA, 
USA) using the EcoRI and XbaI cloning sites. The plasmid pEGFP-C1 
and the fusion plasmid pL3 were purified using QIAGEN Plasmid 
Mega Kit (QiagenGmbH, Hilden, Germany). The pGFP- plasmid was 
sequenced to verify the accuracy of the construct. 
 
2.2 Preparation and characterization of nanoparticles 
NPs loaded with 5FU, pL3 or 5FU/pL3(5FU-NPs,  pL3-NPs, 5FU/ 
pL3-NPs, respectively) were prepared by a layer-by-layer deposition 
method as previously shown [16]. Briefly 5FU-loaded PLGA NPs 
were prepared by solvent diffusion of an organic phase (2 mL) in an 
aqueous phase (4 mL of water with Pluronic F68 0.1%). Organic phase 
was prepared by dissolving 10 mg of PLGA in acetone and adding 
different amount of 5FU in ethanol in a acetone/ethanol ratio 5:1 v/v). 
After solvent removal at reduced pressure and room temperature, NP 
dispersion was splitted in 4 eppendorf tubes, centrifuged (8.000 rpm) 
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and redispersed in water (1 mL). Thereafter, 125 µL of a PEI solution 
(2.5 mg/mL) was added and the NPs centrifuged again (6.000 rpm)for 
washing. Each eppendorf (0.5 mg NPs/mL) was coated first with a PEI 
and then with HA water solution (1mg/mL). The interval between each 
addition was kept constant at 15 min and, after each polymeric 
deposition, NPs are centrifuged and redispersed in water. For NPs 
loaded with pL3, 25 µL of a pL3 water solution at different 
concentrations were added in each eppendorf tube before HA 
absorption. Thereafter, 100 µL of a HA water solution (2 mg/mL) were 
added. NPs were freeze-dried for 24 h with threalose (60 mg) as 
cryoprotectant and kept at 4 °C.  
2.2.1 Size, surface charge and morphology of NPs 
Hydrodynamic diameter, polydispersity index (PI) and zeta 
potential of NPs after each preparation step were determined on a 
ZetasizerNano Z (Malvern Instruments Ltd., UK). Results are reported 
as mean of three separate measurements on three different batches 
(n=9)±SD. 
2.2.2 5FU and pL3 actual loading 
5FU loading inside NPs was assessed by placing 0.5 mg of freeze-
dried NPs (without cryoprotectant) in 500 μL of DCM and 500 μL of 
water. Thereafter, sample was mixed vigorously and centrifuged at 
5000 rpm for 5 min. The amount of 5FU in the water phase was 
analyzed by HPLC on a Shimadzu apparatus equipped with a LC-
10ADvp pump, a SIL-10ADvp autoinjector, a SPD-10Avp UV–Vis 
detector and a C-R6 integrator. The analysis was performed on a 
Synergy Hydro, C18 column (25x 4.6 mm). The mobile phase was a 
100% (v/v) mixture of water with formic acid (99:1) pumped at a flow 
rate of 1 mL/min. The UV detector was set at 285 nm. A calibration 
curve of 5FU in water was constructed in the concentration range 1–
100 μg/mL.  
pL3 loading inside NPs was evaluated by a DNA KIT 
ASSAYPICOGREEN (life technologies) at Ex-Em 480-520 nm. After 
NP centrifugation at 13000 rpm for 5 min the pellet was treaty with 
DCM and water (1:1 ratio) then water phase was freeze dried and 
redisperded in 100μL of TE buffer 1X(10 mM Tris-HCl,1mM EDTA 
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pH 7.5) with heparin (5 mg/mL), in order to separate plasmid from 
complex with PEI. A calibration curve was constructed in a 
concentration range 0.026-1.3 μg/mL. 
2.2.3 5FU and pL3 release 
Release of 5FU from 5FU/ pL3-NPs(2mg) was evaluated by 
dialysis using DMEM FBS+ as dispersing medium and PBS at pH 7.4 
and 37°C as external medium (sink conditions were realized). 5FU 
release was monitored for 72 h and compared with free 5FU.  
In vitro release ofpL3 was performed on 30 mg of freeze-dried 
powder (corresponding to 0.5 mg of NPs) dispersed in 1 mL DMEM 
FBS+ 10% at 37°C.At predetermined time interval, the sample was 
centrifuged at 13000 rpm for 5 min. pL3 released was assessed 
indirectly in the pellet as reported above. A pL3 calibration curve in 
the range 0.02-1 µg/mL was constructed. 
2.2.4 Stability of 5FU/ pL3-NPs 
The stability of pL3 association to NPs was analyzed by the gel 
retardation assay. NPs (10 µL, 0.5 mg/mL) with theoretical amount of 
10% of 5FU and 2.6 or 5.2 µg/mL of pL3, respectively, were mixed 
with a TE buffer and then loaded on a 0.8% agarose gel. After running 
the gel at 100 V for 30 min, staining with ethidium bromide in TBE 
buffer was carried out. NPs were compared to cationic NPs (without 
the external PEI layer) and free plasmid.  
2.2.5 Enzymatic degradation of hyaluronic acid shell 
Unloaded NPs (2 mg) were added to0.5mL of a hyaluronidases 1 
FROM BOVINE testes (Sigma) solution in acetate buffer (0.1M) at 
pH6 (0.5 mg). The sample was placed into a dialysis bag (3500 kDa)at 
37°C. External phase was the same buffer acetate at pH 6. At 
predetermined intervals 1 mL of external phase was collected and 
replaced with 1 mL of fresh medium. The quantity of glucuronic acid 
released was determined according to a reported method. 200 µL of 
sample was treated with concentrated sulfuric acid (3 mL)[18]. 
Carbazole reagent (0.1%, 100 µL) was added to the sample and mixed. 
The sample was then incubated at 60° in a water bath for 1 h and 
cooled at room temperature in another water bath. The absorbance of 
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the pink- to red-colored samples was read on a spectrophotometer at 
530 nm against a water blank. 
 
2.3 Cell cultures and treatments 
The HCT 116-/- p53 cell line was cultured in Dulbecco‘s Modified 
Eagle‘s Medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (Invitrogen, Life Technologies, Italy), 1.5 
mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin 
under humidified atmosphere of 5% CO2 at 37 
◦C. Treatments of cells 
were performed replacing the culture medium with those containing 
increasing concentrations of 5FU-NPs or free 5FU (0.05-100 μM). 
Subsequently, treatments of cells were performed replacing the culture 
medium with those containing increasing concentrations of free 5FU 
(0.05-100 μM), 5FU-NPs, pL3-NPs or 5FU/ pL3-NPs (0.06-3,6-10 
μM). 
2.3.1 Transfection 
For DNA transfection, HCT 116 -/- p53 cells were seeded sub 
confluent on 60-mm plates; 24 h after plating, transfection was carried 
out using 2 μg of pL3 plasmid using Lipofectamine 3000 (Invitrogen). 
Untrasfected HCT 116 -/- p53 cells were used as basal control. 
2.3.2 MTT assay 
HCT 116-/- p53 cells were seeded onto 96-well plates (2 × 
104cells/well) and after the treatments with NPs, their viability was 
evaluated, after 72 and 96 h, as mitochondrial activity using the MTT 
assay. Briefly, the medium was removed and cells incubated with 100 
μl MTT (0.5 mg/ml) for 1 h. After that, the solution was removed, 
formazan solubilized in 100 μl DMSO and the absorbance measured at 
575 nm using a microplate reader (Labsystems Multiskan, MS).  
 
2.3.3 Fluorescence microscopy 
HCT 116-/- p53 cells were plated on coverslips at a density of 2 × 
104cells per well in 6-well plates. At the end of the treatment (48, 72 
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and 96 h) with NPs, cells were washed three times with PBS and were 
fixed with 4% paraformaldehyde for 5 min. After washing, coverslips 
were mounted with PBS 1X-Glicerol (1:1) and stained with 4,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, CA, USA) to 
visualize the nuclei. Images have been acquired by using the Zeiss Cell 
Observer system composed by a motorized inverted microscope 
(Axiovert 200M) and a digital camera (Axiocam H/R). The 
fluorescence was measured with a Zeiss acquisition software 
(Axiovision 4.8.1). 
2.3.4 Western Blotting 
Whole protein extracts were prepared by lysing cells in 50 mM Tris–
HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1 
mM EDTA, 1% Igepal, 1× protease inhibitor (Roche Applied Science, 
Italy) and phosphatase inhibitor cocktail (Calbiochem, Italy). Protein 
concentration was determined by the Bradford protein assay using 
bovine serum albuminas standard. Protein extracts (40 μg) were 
separated on 10% SDS-PAGE and transferred to a nitrocellulose 
membrane (Millipore) and then incubated with rabbit monoclonal 
antibody raised against GFP) (1:1000, Santa Cruz) and goat polyclonal 
antibody raised against β actin (1:2000, Santa Cruz), used as protein 
loading control. 
2.3.5 Statistical analysis 
Error bars represent mean ± SEM from n = 3 biological replicates. 
Statistical comparisons were made by one-way ANOVA followed by 
Bonferroni‘s test for multiple comparisons. P<0.05 was considered 
significant, P<0.001 was considered highly significant. P>0.05 was 
considered not statistically significant. 
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3 Results and discussion 
In order to find an increased cytotoxicity of a conventional drug 
5FU in association whit plasmid pL3, we developed biodegradable 
NPs endowed with facilitated entry in cells overexpressing CD44 
receptor. We first assessed: i) the ability of NPs to entrap 5FU in the 
PLGA core and pL3 in the PEI shell; ii) the stability of pL3 association 
in biologically-relevant media and iii) release of drug and pL3 from 
NPs. Next, we assessed cytotoxicity of 5FU-NPs in CD44(+) colon 
cancer cells and combined activity of 5FU/pL3-NPs.  
 
3.1 Preparation and characterization of NPs 
Preparation of NPs is a multistep process comprising i) the 
preparation of a PLGA core template; ii) the absorption of a cationic 
PEI layer; iii) the absorption of a anionic layer of HA. Briefly, 5FU- 
NPs were prepared by nanoprecipitation of an organic mix composed 
by a PLGA acetone solution and a 5FU ethanol solution in ratio 5:1 v/v 
in a Pluronic F68 water solution. After NP collection, a positive layer 
of PEI was adsorbed through electrostatic interactions by incubating 
NPs with a PEI water solution followed by centrifugation and 
redispersion in water. In the following step, cationic NPs were 
decorated with a HA layer giving PLGA NPs with a double PI/HA 
coating.  
The ability of PLGA core to entrap 5FU was investigated in the 
range 2-15% theoretical loading. NPs presents a slight increase of size, 
a negative zeta potential which confirms the absorption of anionic 
layer of HA and show a crescent actual loading up to a theoretical 
amount of 15% w/w. (Table.1). 
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Table 1. Properties of 5FU-NPs with 5FU theoretical loading from 2% w/w to 
15 % w/w. SD were calculated on five different batches. 
 
5FU theoretical 
loading 
(% w/w) 
Hydrodynamic 
diameter 
(nm ± SD) 
Zeta 
potential 
(mV) 
P.I. Actual loading 
(mg/100 mg)a 
2 150 ± 10 -22 0.10 0.15 ± 0.1 
5 160 ± 2 -18 0.18 0.63 ± 0.1 
10 170 ± 7 -23 0.15 0.9 ± 0.4 
15 185 -20 0.11 0.6± 0.1 
a Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of 
NPs. 
 
PEI is a one of the most potent polymer for gene delivery and was 
first described by Behr et al. [19]. However it is toxic to cells because 
the high charge density of polyplexes contributes to membrane 
disruption[20]. Otherwise, dcNPs with PEI developed here exert no 
toxicity on different cell lines up to 1 mg/mL [16].  
For  pL3-NPs different amounts of plasmid in water were incubated 
with NPs (0.5mg/mL). All NPs show good loading of pL3 and the 
amount of plasmid did not influence the hydrodynamic diameter up to 
a concentration of 10.4 g/mL where a macroscopic aggregation was 
found. Adorption of pL3 onto PEI-coated NPs is due to the formation a 
complex between the anionic charge of the phosphates along the DNA 
backbone and the cationic charge displayed by PEI. The formation of 
complex is spontaneous and entropically driven [21]. Zeta potential 
after pL3 adsorption was still positive since the adsorption of plasmid 
did not neutralize all the cationic charges onto the surface thus 
allowing the further adsorption of HA.  
As expected, the amount of adsorbed pL3 onto final HA-coated 
NPs was related to the amount of plasmid initially added (Table 2).   
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Table 2. Characterization of pL3-loaded NPs. SD were calculated on five 
different batches. 
 
pL3 
(μg/mL NPs) 
Hydrodynamic 
diameter 
(nm ± SD) 
Zeta potential 
(mV) 
P.I. Actual loading 
(mg/100mg)a 
2.6 166 +35 0.1 0.15 ± 0.1 
5.2 158 +33 0.18 0.36 ± 0.1 
10.4 260 +25 0.15 1.2 ± 0.7 
a Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of 
NPs 
 
Final NPs were below 200 nm with a negative zeta potential. NPs 
could be freeze dried and redispersed in water or DMEM with FBS 
10% giving stable colloidal dispersion with a limited increase of size 
and without any macroscopic aggregation over time (data not shown).  
In table 3, properties of combined NPs prepared at constant loading 
of pL3and at increasing loading of 5FU core are also shown. As it can 
be seen, our strategy allows to tune the reciprocal amount of the 
delivered species with only simple adjustments of the experimental 
conditions. 
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Table 3.Properties of combined NPs. 
a Actual loading is expressed as the amount (mg) of drug encapsulated per 100 mg of 
NPs. 
 
To evaluate the effective association of plasmid to NPs, a gel 
retardation assay was performed. We used two theoretical 
concentrations of plasmid (2.6 and 5.2 µg/mL) and compared cationic 
NPs (Fig. 1 E,G) to both HA-coated NPs (D,F) and free 
plasmid(B,C).The results show that the run of pL3 loaded in NPs are 
retarded thus confirming the formation of a strong complex. From the 
comparison with PEI-coated NPs, it is evident that the adsorption of 
HA does not alter the stability of complex. All formulation show that 
plasmid was effectively associated to the NPs. 
  
5FU 
Th. Load. 
(% w/w) 
pL3 
Th. Load. 
(μg/mL) 
Size 
(nm ± SD) 
Zeta 
Potential 
(mV) 
P.I. pL3   
Ac. Load. 
(mg/100 mg) 
5FU  Ac. 
Load. 
(mg/100 mg) 
2 2.6 160 ± 5 -26 0.10 0.15±0.1 0.2±0.05 
5 2.6 165 ± 10 -25 0.13 0.15±0.1 0.4±0.02 
10 2.6 181 ± 8 -22 0.20 0.15±0.1 0.88±0.1 
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Intracellular degradation of HA is predominantly mediated by 
Hyal-1 and occurs after incorporation of HA by CD44. Although Hyal-
1 is active only in the intracellular compartment, a certain amount of 
the enzyme can be secreted to extracellular space. Hyal-2 is the 
enzyme involved in the extracellular degradation of HA and is 
overexpressed in several tumors [22]. To mimic more closely NP 
behavior in the presence of hyaluronidasess, quantitative release of 
glucuronic acid from NPs was assessed. Since the method can detect 
also HA oligomers, a control sample without hyaluronidases 1 was 
run. As observed in Fig. 2 a higher production of glucuronic acid is 
observed, which confirms the degradation of hyaluronic acid from 
NPs.  
 
 
 
Fig. 1. Gel retardation assay. A)10 µl of NPs 0.5 mg/mL. B) 2.6 
µg/mL and C) 5.2 µg /ml free plasmid; PEI-coated NPs loaded with 
plasmid D) 2.6 µg/mL and E) 5.2 µg /mL; NPs loaded with plasmid F) 
2.6 µg/mL and G) 5.2 µg /mL. 
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Release profile of 5FU from NPs was evaluated by dialysis using 
DMEM FBS+ as dispersing medium and PBS at pH 7.4 and 37°C as 
external medium (sink conditions were realized). 5FU release was 
monitored for 72 h and compared with that of free DTX (Fig. 3 A). A 
sustained release of 5FU from dc-NPs as compared with free 5FU was 
found. Free 5FU was completely released at 72 h while only a 40% of 
5FU was released from NPs. This result is in agreement with previous 
studies [23]. 
The pL3 amount released was assessed indirectly from the pellet in 
a separate experiment. The results (Fig. 3 B) suggest that within the 
first 3 h the release was around 50% while it was around 80% after 24 
h. The results are in agreement with Su et al. who showed a similar 
behavior for PLGA/PEI-NPs [24].  
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Fig. 2. Degradation of hyaluronic acid by hyaluronidases as 
followed by the amount of glucuronic acid released. 
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Fig. 3. Release of 5FU (A) and pL3 (B) from NPs at 72 h. 
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3.2 In vitro activity of 5FU-NPs in HCT 116 p53-/- cells 
We have previously demonstrated that NPs represent a very 
promising system for the targeted delivery of drug in CD44 positive 
cancer cells taking advantage of the shell and core properties [17]. In 
fact, we have already tested the ability of this NPs to improve the 
cytotoxic activity of DTX in different cancer cells. Here, HCT116 p53 -/-
cells were treated with a wide range of 5FU-NPs concentrations (0.05-
100 μM) and evaluated in vitro cytotoxicity after 72 and 96 h exposure 
by using MTT assay as compared to that of  free 5FU. As shown in 
Fig. 4, a significant decrease in the IC50was observed in cells treated 
with 5FU-NPsat both 72h and 96h (IC505 and1 μM,respectively) as 
compared to cells treated with free 5FU (IC5010 and 5 
μM,respectively). These results suggest that NPs enhanced 
antiproliferative activity of 5FU in CD44 positive colon cancer cells.  
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Fig. 4. In vitro cytotoxicity of free 5FU and 5FU NPs toward HCT 116 -/- p53 cells. The cells 
were exposed to increasing concentrations of free 5FU and 5FU NPs for 72 h (A) and 96 h (B). 
After incubation, cell viability was evaluated using the MTT assay. The cell viability from 
untreated cells was set to 100%. Results are presented as percentage (mean ± SEM) (n = 3) of 
the control cells.  
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Studies are in progress to elucidate the effect of different amount of 
plasmid on 5FU cytotoxicity and possibly translate the results to 
mouse models of colon tumors. 
 
4 Conclusions 
In this paper we have demonstrated that hyaluronan-coated NPs are 
a robust system to deliver plasmid in cancer cells and demonstrate 
superior activity to lipofectamine. Furthermore, plasmid can be 
combined to conventional chemotherapeutics to potentiate their 
cytotoxicity. We validated this approach on 5FU co-delivered with a 
plasmid to pL3 protein in colon cancer cells thus paving the way to 
testing different nucleic acid/chemotherapeutic combinations and 
traslation of the NPs in an in vivo setting. 
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General conclusions 
 
The experimental work illustrated in this thesis was aimed to design 
novel double coated NPs for cancer therapy. We explain how to build 
NPs with a functional double coating through a layer-by-layer strategy, 
entrapping a chemotherapeutic in the core together with a photosensitizer 
and a plasmid in the shell. NPs present good entrapment efficacy and an 
excellent stability in different complexmedia. 
 Double-coated NPs with Hyaluronan on the top demonstrate specificity 
toward CD44+ cancer cells which results in increased cytotoxicity of 
chemotherapeutics alone or in combination as compared to free drugs. It 
is demonstrated that dcNPs are a versatile platform to deliver drug 
combinations in cancer cells which can be considered for further testing 
in mice models of tumor. 
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Abstract 
Here, we develop Pluronic P123/F127 mixed micelles for the 
intravenous delivery of the anticancer drug sorafenib (SRB) or its 
combination with Verteporfin (VP), a photosensitizer for photodynamic 
therapy which should complement well cytoxicity profile of the 
chemotherapeutic. SRB loading inside the core of micelles was governed 
by drug: Pluronic weight ratio while in the case of SRB/VP combination 
a mutual interference between the two drugs occurred and only specific 
ratios could ensure maximum loading efficiency. Co-entrapment of SRB 
did not alter photophysical properties of VP, confirming that SRB does 
not participate in any bimolecular process with the photosensitizer. 
Fluorescence Resonance Energy Transfer (FRET) measurement of 
micelles in serum protein-containing cell culture medium demonstrated 
the excellent stability of the system in physiologically-relevant 
conditions. These results were in line with the results of the release study 
showing a release rate of both drugs in the presence of proteins slower 
than in phosphate buffer. SRB release was sustained while VP remained 
substantially entrapped in micelle core. Cytotoxicity studies in MDA-
MB231 cells revealed that at 24 h SRB-loaded micelles were more active 
than free SRB only at very low SRB concentrations while at 24 + 24 h 
prolonged cytotoxic effect of SRB-loaded micelles was observed very 
likely mediated by the block in the S phase of the cell cycle. The 
combination of SRB with VP under light exposure was less cytotoxic 
than both the free combination and VP-loaded micelles + SRB-loaded 
micelles combination. This behaviour was clearly explained in term of 
micelle uptake and intracellular localization. Beside the clear advantage 
of delivering SRB in Pluronic micelles, our results provide a clear 
example that each photo-chemotherapeutic combination needs detailed 
investigations on their particular interaction and no generalization on 
enhanced cytotoxic effects should be derived a priori.  
  
│Annex-I 
 
-178- 
 
  
                                                                                              Annex-I│ 
 
-179- 
1. Introduction 
Nanotechnologies promise to refine cancer treatments trying to 
overcome several issues associated to conventional chemotherapy by 
improving treatment efficacy, decreasing systemic side effects and 
overcoming multi drug resistance. In the wide scenario of nanoplatforms 
available for anticancer drug delivery, polymeric micelles based on 
biocompatible polymers have been attracting interest due to great 
versatility, small size, ease of functionalization and potential to transport 
a multidrug-cargo for combination therapies.1-3 Representatives of such 
materials are Pluronic® copolymers that are surfactants molecules 
containing two hydrophilic poly(ethylene oxide) (PEO) and one 
hydrophobic poly(propylene oxide) (PPO) regions arranged in a PEO-
PPO-PEO triblock structure. In water Pluronic self-assemble in core-
shell nano-sized micelles and entrap poorly water-soluble drugs 
increasing their apparent solubility. Furthermore, drug-loaded Pluronic 
micelles can passively target tumor by the enhanced permeability and 
retention (EPR) effect after intravenous injection. Pluronic unimers have 
also shown ability to hypersensitize multiple drug resistant cells by 
inhibiting glycoprotein P mediated drug efflux.4;5 Pluronic mixed 
micelles made of more than one type of Pluronic manifest properties 
superior to those made of the individual components. In fact, the correct 
selection of Pluronic type and unimer ratio induces a synergistic 
aggregation thus producing micelles with improved characteristics in 
term of colloidal stability and drug loading efficiency.6 For example, in a 
very recent paper we demonstrated that Pluronic P123/F127 mixed 
micelles enhanced the solubility and photodynamic activity of very 
hydrophobic benzoporphyrin derivatives.7Sorafenib (SRB) is a drug 
approved for the treatment of advanced inoperable hepatocellular and 
advanced renal cancers after oral administration (Nexavar®).8;9 Its 
possible use for systemic treatment of liver fibrosis10 and hepatocellular 
carcinoma11-13 has been recently highlighted. SRB is an inhibitor of 
different Raf serine/threonine kinases isoforms mediating cell 
proliferation and blocks upstream receptor tyrosine kinases, which play 
an important role in angiogenesis.14 Angiogenesis and tumor 
revascularization due to VEGF expression is a major problem associated 
with photodynamic therapy (PDT) application in cancer.15 Indeed, PDT 
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is a therapeutic procedure that uses a light-activated photosensitizer (PS) 
to produce reactive oxygen species, especially singlet oxygen (1O2), 
which trigger the destruction of tumor cells, damage to tumor 
vasculature and a severe inflammatory action.16;17 Co-administration of 
PDT agents with antiangiogenic chemotherapeutics could be a promising 
strategy to potentiate photodynamic treatments. Verteporfin (VP) is a 
FDA clinically approved agent for PDT of age-related macular 
degeneration (Visudyne®) and is currently in phaseI/II clinical trials to 
treat locally advanced pancreatic cancer.18 It was found that VP induced 
angiogenesis in the chicken chorioallantoic membrane model could be 
inhibited by SRB, giving prolonged vascular occlusion in the treated 
areas due to a synergistic effect.19Since the entrapment of multiple 
therapeutic agents in a single nanocarrier allows a precise and controlled 
delivery of the optimal drug-ratio in the same area of the body, enormous 
clinical advantages can be brought about.3;20;21Currently, this novel ‗two-
in-one‘ approach is under clinical and preclinical investigation against 
several cancer types.22;23 Furthermore, delivery in a nanocarrier can also 
alleviate poor water solubility, a drawback shared by several 
chemotherapeutics and PS. Although very promising in principle, there 
have been very few attempts in developing Pluronic micelles for the co-
delivery of PS and other anticancer molecules.24;25 In this contribution 
we aim to explore the potential of Pluronic P123/F127 mixed micelles as 
a suitable intravenous nanocarrier to deliver SRB while maintaining its 
activity and mechanism of action. Besides, we also focus on the 
combined delivery of SRB and VP, investigating how it can affect single 
drug cytotoxicity. To this end, Pluronic P123/F127 micelles were loaded 
with SRB alone or in combination with VP. Drug loading efficiency and 
release rate, spectroscopic and photodynamic properties of the micelles 
as well as stability in complex media were assessed. Finally, cytotoxicity 
of SRB and its combination with VP and trafficking of micelles in MDA 
MB-231 breast carcinoma cells were investigated. 
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2. Material and methods 
2.1 Materials 
SRB free base (MW = 464.8 g mol-1) was purchased from LC 
Laboratories, Division of PKC Pharmaceuticals, Inc., Woburn, MA 
(U.S.A.). VP (benzoporphyrin derivative monoacid ring A, MW = 718.8 
g mol-1) was kindly supplied by Prof D. Dolphin (University of British 
Columbia, Vancouver, Canada). Pluronic P123 (EO20–PO65–EO20, MW 
= 5750 g mol-1), Pluronic F127 (EO100–PO65–EO100, MW = 12600 g mol
-
1), trehalose, polysorbate 80 and Nile Red were purchased from Sigma-
Aldrich. Ethanol, dichloromethane, diethyl ether, acetone and 
acetonitrile were purchased from Carlo Erba Reagents. All the other 
chemicals were of analytical reagent grade and used without previous 
purification. 
 
2.2 Preparation of drug-loaded micelles 
Unloaded, SRB, and SRB/VP-loaded Pluronic P123/F127 micelles 
were prepared by the thin-film hydration method.26 Briefly, 10 mg of 
Pluronic P123/F127 mixture (proportion 2:1 w/w, which correspond to 
3.33 mg of F127 and 6.67 mg of P123) were dissolved in 1 mL of 
ethanol in a round-bottom flask. For drug-loaded micelles, different 
amounts of SRB (100-200 µg) and VP (4- 10 µg) were dissolved in 1 mL 
ethanol and added to the Pluronic solution. Then, the solvent was 
evaporated by rotary evaporation at 50 °C for about 20 minutes. Residual 
solvent in the film was removed under vacuum overnight. After that, the 
dried film was hydrated with 1 mL of filtered distilled water under 
sonication for 5 minutes to obtain a limpid solution and filtered through 
0.22 µm filters (RC Chemtek, Italy) to remove the unloded drug or 
possible large cylindrical aggregates formed by P123. When necessary, 
the resulting solution was lyophilized for 24 h in the presence of 
trehalose (2:1 mass ratio with the copolymer). 
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2.3 Micelle characterization 
Hydrodynamic diameter (DH), polydispersity index (PI) and zeta 
potential of micelles were determined using a Zetasizer Nano ZS 
(Malvern Instruments Ltd, UK). The freeze-dried formulations were 
dispersed in Milli-Q water and measurements were performed at 37.0 °C 
on 90° angle. Results are reported as mean of three separated 
measurements on three different micelle batches ±SD. 
 
2.4 SRB and VP entrapment efficiency 
SRB and VP encapsulation efficiency was evaluated by dissolving a 
known amount of freeze-dried micelles (10 mg) in 1 mL of ethanol. 
Before the analysis, the sample was filtered through a 0.22 μm filter 
(RC, Chemtek, Italy). Results are reported as mean of three separated 
measurements of three different samples ±SD. 
SRB was analyzed by HPLC on a Shimadzu apparatus equipped with a 
LC-10ADvp pump, a SPD-10Avp UV–Vis detector and a C-R6 
integrator. The analysis was performed on a Sphereclone ODS-2 5 μm, 
C18 column (250×4.6 mm, 80 Å) (Phenomenex, USA). The mobile 
phase was a 35:65 (v/v) mixture of water and acetonitrile pumped at a 
flow rate of 1 mL/min. The water phase contained triethylamine (2% 
v/v) and was adjusted to pH 5.4 with phosphoric acid. The UV detector 
was set at 265 nm. A calibration curve for SRB in ethanol was 
constructed in the concentration range 0.002-0.2 mg/mL. To exclude a 
possible interference of VP on SRB quantitative analysis, an amount of 
VP-loaded micelles was dissolved in ethanol and analyzed in the same 
conditions reported above. 
VP quantification was carried out by spectrophotometry on a Shimadzu 
UV-1800. The concentration of VP was calculated by means of a 
standard calibration curve derived for ethanol solutions of VP at known 
concentrations (20.0–0.1 ug/mL). Potential interference of SRB on 
absorption was preliminarily assessed spiking a VP solution in ethanol 
with different amounts of SRB. 
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2.5 Absorption, emission and transient spectroscopy 
UV/Vis absorption and fluorescence spectra were recorded with a 
Jasco V-560 spectrophotometer and Fluorolog-2 (Model, F-111) 
spectrofluorimeter, respectively. All measurements were performed in a 
thermostated quartz cell (1 cm path length, 3 mL capacity).Steady-state 
emission of 1O2 was recorded in D2O solutions with a Fluorolog-2 Mod- 
111 spectrometer, equipped with a InGaAs detector maintained at –196 
°C, by illuminating orthogonally the sample at 405 nm with a 
continuous-wave laser. Laser flash photolysis. All of the samples were 
excited with the second harmonic of Nd–YAG Continuum Surelite II–10 
laser (532 nm, 6 ns FWHM), using quartz cells with a path length of 1.0 
cm. The excited solutions were analyzed with a Luzchem Research 
mLFP–111 apparatus with an orthogonal pump/probe configuration. The 
probe source was a ceramic xenon lamp coupled to quartz fiber-optic 
cables. The laser pulse and the mLFP–111 system were synchronized by 
a Tektronix TDS 3032 digitizer, operating in pre-trigger mode. The 
signals from a compact Hamamatsu photomultiplier were initially 
captured by the digitizer and then transferred to a personal computer, 
controlled by Luzchem Research software operating in the National 
Instruments LabView 5.1 environment. The solutions were 
deoxygenated by bubbling with a vigorous and constant flux of pure 
argon (previously saturated with solvent). In all of these experiments, the 
solutions were renewed after each laser shot (in a flow cell of 1 cm 
optical path), to prevent probable auto-oxidation processes. The sample 
temperature was 295 ± 2 K. The energy of the laser pulse was measured 
at each shot with a SPHD25 Scientech pyroelectric meter. 
 
2.6 Micelle behaviour in cell culture medium 
Micelle stability in the medium employed for cell studies (DMEM 
enriched with 10% FBS) was evaluated. Briefly, 20 mg of micelles were 
added to 2 mL of cell culture medium and incubated at 37.0 ºC for 72 h. 
At selected time intervals, size and zeta potential were evaluated. Micelle 
stability was also evaluated by FRET technique by co-encapsulating two 
different fluorescence probes into micelle core.27 The hydrophobic dye 
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Nile Red (NR) was chosen as the fluorescent donor and VP as acceptor 
molecule. VP/NR micelles were prepared as described above for 
SRB/VP micelles (Preparation of drug-loaded micelles section). The 
concentration of NR in the micelles was 0.8 μg mL-1 and VP equal 4.0 
μg mL-1 which gives a VP:NR ratio of 5:1 by weight. The ratio between 
the maximum intensity of emission bands for VP and NR was monitored 
as function of time. Decrease of this ratio and/or micelle size increase 
was considered indicative of micelle aggregation or disassembly in cell 
culture medium. DMEM medium without FBS was also evaluated as a 
control experiment. Results are reported as mean of three separate 
measurements (n=3) ±SD.  
For release studies in PBS or in cell culture medium, the formulation 
(10 mg of Pluronic; [SRB] = 100 μg mL-1 and [VP] = 10.0 μg mL-1) was 
dispersed in 1 mL of DMEM with 10% FBS and placed in a dialysis bag 
(MWCO=3500 Da, Spectra/Por®). The sample was plunged in 5 mL of 
PBS containing 5% v/v of polysorbate 80 (sink condition) and kept at 37 
ºC up to 72 h. At selected time intervals, 1 mL of release medium was 
withdraw and replaced with an equal volume of fresh medium. SRB and 
VP quantitative analyses were carried out as described above. As 
control, release profile of free drugs diluted in PBS or DMEM with 10% 
FBS medium are reported for comparison. Results are expressed as 
release % over time (n=3) ±SD. 
 
2.7 In vitro experiments 
2.7.1 Cell culture 
Human breast cancer cell line MDA-MB231 was purchased from 
American Type Tissue Culture Collection (ATCC, Rockville, 
Maryland). The cells were grown in DMEM with GlutamaxTM 
supplemented with 10% FBS, 100 U/ml streptomycin and 100 µg/ml 
penicillin G (Life Technologies, Milan, Italy), and maintained at 37 °C 
in a humidified atmosphere containing 5% CO2. 
2.7.2 Dark and photo toxicity (PDT) in vitro 
The cytotoxicity in the dark of MDA-MB231 cells incubated with 
VP, SRB as well as their combination (free or loaded in Pluronic 
F127/P123 Micelles) was measured with the MTS assay after 24 h of 
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incubation (24 h) as well as after additional 24 h of cell growth in drug-
free medium (24 + 24 h). Cells (6 x 103) were seeded in 96-well plates 
(24 h of growth) and then incubated with the drug formulations for 24 or 
24 + 24 h. Lyophilized NP formulations containing 10 mg of micelles 
(loaded with 10 µg of VP and/or 100 µg of SRB) were solubilized in 2 
ml DMEM and then further diluted in medium added with 10% FBS. For 
the MTS assay the medium was replaced with 100 µl of serum-free 
medium and 20 µl of CellTiter 96® Reagent (Promega Co., Madison, 
USA) and the wells were incubated for 1 h at 37 °C. The absorbance at 
492 nm was measured with a Multiskan Go (Thermo Fischer Scientific, 
Waltham, USA) plate reader and the viability of treated cells was 
expressed as percentage of the absorbance of control cells that was taken 
as 100% viability. For the in vitro PDT experiments, cells were seeded 
as described above. After 24 h of incubation with the different drug 
formulations, the cells were washed once with PBS with Ca2+ and Mg2+, 
and irradiated in PBS with 0.75 J cm-2 of red light (600-700 nm, fluence 
rate 25 mW cm-2) from a Waldmann PDT 1200 lamp (Waldmann 
Medizintechnik, Germany). Immediately after irradiation the cells were 
brought back to the incubator after replacement of PBS with fresh 
medium. Cell viability was measured with the MTS test after additional 
24 h. 
2.7.3 Cellular uptake studies 
Cells (5 x 104) were grown in 24-well plates for 24 h and incubated 
for 24 h with increasing concentrations of free VP, VP-loaded micelles 
or VP/SRB-loaded micelles diluted in cell medium added with 10% 
FBS. After incubation, the cells were washed twice with VerseneTM, 
detached from the plates with trypsin, which was neutralized by the 
addition of FBS. Cells were centrifuged and re-suspended in VerseneTM 
before measuring VP fluorescence by a BD FACSCantoTM II (Becton 
Dickinson, San Jose, USA) flow cytometer. The blue laser at 488 nm 
was used as the excitation source and wavelengths of 670-735 nm 
(PerCP channel) were selected for the detection of VP fluorescence. 105 
events/sample were acquired and analyzed with the FACSDiva software. 
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2.7.4 Cell cycle analysis 
Cells (106) were seeded in 100 mm culture dishes and incubated with 
10 µM SRB free or loaded in Pluronic F127/P123 micelles for 24 or 24 + 
24 h. Treated and control cells were harvested, fixed in 70% cold ethanol 
and stored overnight at 4 °C. Before analysis, cells were washed in 
distilled water, centrifuged and resuspended in 1 mL PBS containing 50 
μg/mL propidium iodide (Sigma-Aldrich) and 100 μg/mL RNAse, for 
DNA staining. Samples were incubated for 1 h at 37 °C and then 
analyzed by flow cytometry. Data from 2 × 104 cells/sample were 
acquired with the FACSDiva software and analyzed with the ModFit LT 
3.0 software (BD Biosciences) to determine alterations in cell cycle 
distribution. 
2.7.5 Confocal microscopy 
The intracellular localization of VP, free or loaded in pluronic 
F127/P123 micelles, was determined by confocal microscopy. Cells (8 x 
104), seeded in special tissue culture dishes for fluorescence microscopy 
(μ-Dish 35mm, high, Ibidi GmbH, Planneg, Germany), were allowed to 
growth for 24 h and then incubated for 24 h with 2 µM Rho or 1 µM VP. 
Fifteen min before the end of the incubation, the cells were stained with 
MitoTracker® green FM (100 nM) or ER TrackerTM Green (1 µM) used 
as markers for mitochondria and endoplasmic reticulum, respectively. 
Cells were then washed twice with HBSS and analyzed with a Leica SP5 
confocal laser-scanning microscope (Leica Microsystems Srl, Milan, 
Italy); the images were elaborated with the ImageJ software. 
2.7.6 Statistical analysis 
The Primer software for biostatistics (McGraw-Hill, Columbus, USA) 
was used for statistical analysis of the data. The data are expressed as 
means ±SD for at least 3 independent experiments. The difference 
between groups was evaluated with the Student‘s t-test or with 
Bonferroni‘s test and was considered significant for p<0.05. 
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3. Results and Discussions 
3.1 Properties of drug-loaded micelles 
A preliminary study was devoted to evaluate the optimal conditions 
to obtain micelles with good encapsulation efficiencies of SRB alone and 
in combination with VP. In a previous work we demonstrated that the 
thin film method followed by freeze-drying (with trehalose as 
cryoprotectant) allows preparation of Pluronic P123/F127 mixed 
micelles loaded with VP.7 Results of this previous study demonstrated 
that, the optimal ratio between P123 and F127 was at 2:1 (w/w). This 
ratio was maintained in micelles explored here. Table 1 summarizes the 
physicochemical characteristics and drug-loading parameters of Pluronic 
P123/F127 micelles loaded with SRB (and SRB/VP combination).DH of 
empty and drug-loaded micelles demonstrated that Pluronic P123/F127 
form micelles with a size ranging between 25–43 nm and satisfactory PI. 
SRB entrapment was very efficient up to 2% drug/polymer by weight 
without any change in term of size and PI. Loading a combination of 
SRB and VP was feasible and mainly controlled by the initial amount of 
SRB employed, which is the most abundant drug in formulations. 
Considering that both drugs have low water solubility, it can be 
reasonably hypothesized that when entrapped together a mutual 
interference in micelle core may occur. As generally observed for 
polymeric micelles, drug-Pluronic ratio was found as a critical parameter 
to control encapsulation efficiency.28 In fact, the lipophilic drugs 
accommodate inside the PPO core of Pluronic P123/F127 mixed 
micelles and, once these domains are saturated, a decrease in 
encapsulation efficiency is experienced.29 The size increase after 
entrapment of drug combination can be ascribed to an increase of PPO 
core size probably due to the presence of entangled drugs. Nevertheless, 
the micelle size was still small enough for tumor-specific accumulation 
via the EPR effect.4 Thus, optimal encapsulation efficiencies were found 
at 100 µg mL-1 for SRB and 4.0 µg mL-1 for VP. Under this condition, 
both loading values can be considered satisfactory for a therapeutically 
relevant system. All formulations presented slight negative zeta potential 
values as generally found for PEGylated nanocarriers made of uncharged 
polymers. 
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Table 1. Composition and properties of Pluronic P123/F127 2:1 w/w mixed 
micelles (total of 10 mg, where 6.67 mg of P23 and 3.33 mg of F127) Results 
reported as mean of three separated measurements on three different batches 
(n=9) ± SD. 
 
a Actual loading is expressed as the amount (µg) of drug encapsulated per 10 mg of 
Pluronic P123/F127. b Entrapment Efficiency = Ratio between experimental and 
theoretical loading ×100. c DH = Hydrodynamic Diameter. 
d P.I. = Polydispersity index.  
 
Thin film rehydration methodology provided a fluffy lyophilized 
product, readily reconstituted in water within 20–30 s of manual shaking 
as already demonstrated in our previous work.7 Storage stability of the 
lyophilized formulations (Fig. 1) demonstrated small decrease of drug 
content with a slight size increase (about 5-6 nm) after reconstitution of 
the product stored for 6 months. The high recovery yield observed 
highlighted that neither drug nor micelle precipitation occurred during 
the preparation. 
 
SRB 
(µg) 
VP 
(µg) 
SRB loadinga 
(EE %)b 
VP loadinga 
(EE%)b 
Mean 
DH
c(nm) 
P.I.d Zeta 
Potential 
(mV) 
-- -- -- -- 25.3 ± 1.8 0.16 --4.37 ± 0.96 
-- 
4.0 
-- 0.038± 0.002 
(95.3 ±1.7) 
26.3 ± 1.8 0.18 -6.69± 0.78 
-- 
6.0 
-- 0.053 ± 0.004 
(89.2 ±2.4) 
30.6 ± 2.7 0.22 -5.27 ± 1.92 
-- 
10.0 
-- 0.076 ± 0.009 
(76.1± 3.9) 
36.8 ± 5.1 0.37 -3.13 ± 1.88 
100 -- 95.0 ± 0.1 
(95.0 ± 1.2) 
-- 24.0 ± 1.9 0.13 -3.55 ± 0.65 
200 -- 
187.0 ± 0.5 
(93.5 ± 4.0) 
-- 26.5 ± 3.2 0.22 -4.12 ± 1.01 
100 4.0 
93.1 ± 1.5 
(93.1 ± 1.92) 
3.8 ±0.7 
(95.0 ±2.4) 
29.4 ± 3.8 0.18 -3.63 ± 0.69 
200 4.0 
149.0 ± 12 
(74.8 ± 2.1) 
3.6 ±0.3 
(89.8 ±1.5) 
34.0 ± 4.9 0.27 -5.06 ± 1.40 
100 6.0 
88.2 ± 10 
(88.2 ± 1.1) 
5.0 ±0.2 
(83.3 ±1.7) 
32.7 ± 3.1 0.25 -2.76 ± 1.44 
200 6.0 
131 ± 07 
(65.3 ± 3.1) 
3.3 ±0.6 
(54.9 ±2.7) 
40.1 ± 3.5 0.343 -6.08 ± 2.10 
100 10.0 
88.2 ± 0.1 
(88.2 ± 2.3) 
7.8 ±0.9 
(78.2 ±1.5) 
43.0 ± 5.5 0.281 -3.88 ± 0.64 
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3.2 Spectroscopic and photodynamic properties 
Fig. 2 shows the absorption and emission spectra of VP free and 
loaded in the micelles under various experimental conditions. VP is 
poorly soluble in water media where it is mostly present as aggregated 
and non-fluorescent form (a and e in Fig. 2). In contrast, Pluronic 
P123/F127 mixed micelles are able to entrap VP in the monomeric form, 
as confirmed by the sharpening of VP absorption bands and the intense 
fluorescence emission (b and f in Fig. 2), similarly to VP in methanol 
where it is present as monomer (d and h in Fig. 2). Co-entrapment of 
SRB and VP did not influence the absorption and emission behavior of 
this latter (c and g in Fig. 2). In fact, only negligible changes were noted 
in the absorption region beyond 330 nm, being the SRB absorption 
dominating below this region. Besides, also the fluorescence emission 
was not affected, being the fluorescence quantum yield ca 0.06, basically 
the same value observed in methanol (F = 0.051
30) 
In order to gain insights into the efficiency of population of the triplet 
state we measured the laser intensity dependence of the transient 
.  
Fig.1. Stability to storage of lyophilized micelles. 
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absorbance under different experimental conditions. Fig. 3B shows the 
top ΔA of the triplet absorption observed for VP incorporated in the 
micelles in the absence and in the presence of SRB and, for comparison, 
for VP in methanol. The behavior observed is typical of a one-photon 
process, such as the generation of the lowest excited triplet state. In this 
case, the initial part of each set of data points is proportional to the 
product T T-T, where T and T-T are the quantum yield of the triplet 
state and its molar absorption coefficient, respectively. 
By taking into account that all solutions are almost optically matched 
at the excitation wavelength (only slight differences in the absorption at 
532 nm are observed in the whole range of ratios explored) and that large 
changes in the T-T are fairly unlikely, being substantially unchanged the 
band profiles, the very similar set of points obtained suggests that the 
efficiency of population of the triplet state of VP in the Pluronic micelles 
is not affected by the presence of SRB and is very close to that observed 
in methanol solution. 
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Energy transfer from the triplet of VP to molecular oxygen results in 
the concomitant photogeneration of 1O2. Near-infrared luminescence is 
the most suitable technique to unequivocally demonstrate the generation 
1O2. This species, in fact, exhibits a typical phosphorescence signal with 
maximum at 1270 nm.34 Fig. 4 shows the diagnostic phosphorescence 
 
 
Fig. 2. Absorption spectra of VP in different media. (A) VP in water (a), methanol 
(d) and in Pluronic P123/F127 mixed micelles (10 mg) dispersed in water solution in 
the absence (b) and in the presence of SRB (100 µg mL-1) (c). (B) Fluorescence 
emission spectra (exc = 580 nm) of VP in water (e), methanol (h) and in Pluronic 
micelles dispersed in water solution in the absence (f) and in the presence of SRB 
(g).VP and SRB concentrations were 4.0 and 100 µg mL-1, respectively. 
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spectrum for the Pluronic micelles loaded with VP alone and in the 
presence of SRB in D2O solutions, this solvent being used to take 
advantage of the larger radiative constant and longer lifetime with 
respect to H2O.  
 
Since all solutions are optically matched at the excitation wavelength, 
the very similar area of the spectra obtained for micelles containing 
either VP or VP co-encapsulated with SRB, lead us to conclude that the 
1O2 quantum yield of the PS is basically independent of the presence of 
 
 
Fig.3.Triplet state features of VP in different conditions. (A) Transient absorption 
spectra observed 0.8 µs (), 3.8 µs () and 8.7 µs () after 532 nm laser 
excitation (E532 ~ 10 mJ/ pulse) of Ar-saturated, aqueous solution of Pluronic 
micelles co-loaded with VP and SRB. The inset shows the decay trace monitored 
at 480 nm (a) and 400 nm (b) and the related first-order fittings. (B) Laser 
intensity dependence of the DA at 480 nm taken 0.1 µs after the laser pulse for VP 
in methanol() and in Pluronic micelles dispersed in water solution in the 
absence () and in the presence () of SRB. VP and SRB concentrations were 
4.0 and 100 µg mL-1, respectively. 
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the chemotherapeutic, according to what observed for the precursor 
excited triplet state (see above). 
 
3.3 Micelle behavior in cell culture medium 
Interaction of micelles with proteins is regarded as a critical factor 
since it has been demonstrated that micelles can aggregate/dissociate in 
complex media altering the interpretation of biological results.35 
Therefore, the behavior of Pluronic P123/F127 micelles in DMEM 
enriched with 10% v/v of FBS was assessed by DLS and fluorescence 
measurements. However, monitoring only one fluorescent probe in the 
medium can lead to a false positive result because, even if the micelle is 
disrupted, the fluorescent tag could bind to FBS proteins resulting in no 
significant change of fluorescence properties, as demonstrated for VP.36 
FRET represents an efficient tool to track NPs stability in biological 
relevant media.27;37 For FRET evaluation it was necessary to co-
encapsulate into the micelle core two fluorescent probes, an energy 
donor and an energy acceptor, with appropriate spectroscopic 
 
Fig.4.Singlet oxygen luminescence detected in D2O solutions of 
Pluronic micelles loaded with VRB in the absence () and in the 
presence () of SRB.exc = 405 nm.  
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characteristics. The acceptor molecule in this work was VP. As donor, 
we choose the hydrophobic dye NR since its emission spectrum well 
overlaps with VP absorption spectrum, one of the indispensable 
requisites for FRET to be observed. (Fig.5) NR presents a strong 
association constant with Pluronic P123/F127 micelles and is located 
inside Pluronic hydrophobic core. DLS measurements showed no 
significant change in size and zeta potential after co-encapsulation of VP 
and NR under the present conditions (data not shown). 
  
 
Fig.5. Normalizes absorption spectrum of Verteporfin and emission spectrum of 
nile red co-loaded in micelles 
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0.15, Fig. 6A). Similar results were observed when the dyes are 
solubilized directly in cell culture medium without micelles. This design 
allows to monitor micelle stability in different conditions.27No 
significant difference in FRET signal and size were observed for up to 
72 h for Pluronic P123/F127 mixed micelles incubated in cell culture 
medium (Fig. 6B), suggesting that the steric hindrance conferred by the 
PEO corona offers efficient protection against protein adsorption on 
micelle surface and following disassembly.38Release profile of dual-drug 
loaded Pluronic P123/F127 mixed micelles dispersed in PBS at pH 7.4 
and 37.0 °C were evaluated by dialysis method (Fig.7). Polysorbate 80 in 
the external medium ensured both sink conditions and prevention of drug 
aggregation. SRB/VP-loaded micelles displayed lower rate of release as 
compared to free SRB and VP (Fig.7A) . The incomplete release of free 
VP was likely due to due to extensive aggregation in water which 
hindered transport through the dialysis membrane. Since the amount of 
drug free to diffuse through cell membranes cannot be derived directly 
from release studies in PBS,39 the release behavior was followed after 
micelle dispersion in DMEM enriched with FBS 10% v/v (Fig. 7B). SRB 
presented a sustained released pattern while VP remained substantially 
entrapped in the micelle core. Similarly to PBS, SRB/VP-loaded 
micelles displayed lower rate of release as compared to free SRB and 
VP. Furthermore, release in DMEM with FBS occurred at slower rates 
than in PBS (Fig. 7,8 and 9). Once assumed that micelles are stable in 
DMEM as demonstrated by FRET, the interaction of SRB and VP with 
FBS proteins, especially albumin, 36is likely contributing to a decreased 
release rate. This hypothesis is supported by the fact that also therelease 
rate of free drug in DMEM is slower as compared to PBS. Thus, the 
fraction of drugs released from micelles can interact with medium 
proteins contributing to albumin-mediated transport inside cells.40 
Release profile from SRB/VP-loaded micelles in all the media was 
faster than that from micelles loaded with single drug (Fig. 8 and 9). This 
result together with the slight increase of micelle size when both drugs 
are co-loaded is indicative of the looser packing of hydrophobic PPO 
chains, which can leads to a faster release rate. 
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Fig. 7. Release profile of SRB and VP as free or loaded in SRB/VP Pluronic P123/F127 
micelles dispersed in (A) PBS or (B) DMEM with FBS 10%. The external medium used 
for dialysis was PBS buffer with polysorbate 80 (5% v/v) at pH 7.4; T = 37 °C. SRB and 
VP concentrations were 100 and 10.0 μg mL-1, respectively. Data are reported as mean of 
three independent experiments (n=3) ±SD. 
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Fig.8.Release profile of free and micelle-loaded SRB (A) and VP (B)in PBS pH 7.4 
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Fig.9.Release profile of free and micelle-loaded SRB (A) and VP (B)in DMEM enriched with FBS 10% 
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3.4 Cytotoxicity of SRB 
The concentration-dependent cytotoxicity of SRB loaded in Pluronic 
P123/F127 micelles was measured in MDA-MB231 cells after 24 h of 
exposure and compared to that of the free drug. Cell death measured 
with the MTS assay immediately after the drug exposure was 
significantly higher for free SRB incubated at 15 o 20 µM with respect to 
SRB micelles, which in contrast demonstrated higher efficacy only at 
very low drug concentration (ie 1 µM ) (Fig. 10A). However, the 
cytotoxicity of SRB delivered in Pluronic micelles was significantly 
higher with respect to free SRB 24 h after drug exposure (24 + 24 h) 
with an IC50 of 7.7 and 14.8 µM for SRB micelles and free SRB, 
respectively. The data suggest that after the removal of free SRB the 
cells resume to proliferate, at least in the lower range of concentrations 
used in these experiments, while SRB in micelles exerted a delayed but 
stronger and prolonged cytotoxic effect that might be associated to slow 
but sustained release of the drug from micelles. Accordingly, free SRB 
did not perturb to a great extent the progression through the various 
phases of the cell cycle nor caused the appearance of a hypo-diploid cell 
population indicative of apoptosis (Fig. 10B and C). On the contrary, 
SRB in Pluronic P123/F127 mixed micelles caused an accumulation of 
the cells in the S phase already at 24 h, with a further increase at 24 + 24 
h (Fig. 10C) and the appearance of hypo-diploid events in the flow 
cytometry histograms relative to cell DNA content (Fig.10B). In any 
case, the induction of an apoptotic response was not ascribable to the 
presence of the delivery system, since empty Pluronic P123/F127 mixed 
micelles did not induce cytotoxicity or cell cycle alterations in the same 
concentration range of SRB micelles (data not shown). Similarly to our 
results with MDA-MB231 cells, the induction of apoptosis was reported 
also for in BGC-823 gastric cancer cells after incubation with SRB 
loaded in salicylic acid-chitosan/heparin coated Pluronic NPs.41 
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3.5 Cytotoxicity of the combination SRB plus VP-mediated 
PDT 
Based on the results reported above, showing a benefit by delivering 
SRB in Pluronic micelles, and those reported previously by our group7 
on the delivery with the same micelles of the photosensitizer VP, we 
investigated on the possibility of further improving the cytotoxic effect 
on MDA-MB231 cells by treating them with the combination of SRB 
and PDT with VP.  
Fig.11 shows that the reduction of viability of cells treated with PDT 
(irradiated with 0.75 J cm-2 of red light) after 24 h-incubation with the 
combination of free SRB + free VP was very similar to that measured 
after cell incubation and irradiation with free VP only. The absence of 
 
Fig. 10. Cytotoxicity of SRB-loaded Pluronic P123/F127 mixed micelles vs. free SRB. (A) Cell 
viability measured with the MTS assay in MDA-MB231 cells incubated with increasing 
concentrations of SRB free or loaded in micelles for 24 or 24 + 24 h. Data are mean ±SD of at least 
three independent experiments carried out in triplicate. * p< 0.05, ** p<0.001 SRB-micelle vs. free 
SRB 24 h; ## p< 0.001 SRB-micelle vs free SRB 24 + 24 h (t test). (B) Representative cell cycle 
histograms showing the appearance of a hypo-diploid populations (gray arrows) in the samples 
treated with SRB-micelles. C) Summary table of cell cycle analysis.  
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any increased cytotoxicity of the combination with respect to free VP 
alone is very likely explained by the negligible cytotoxicity of free SRB 
at 24 + 24 h (Fig.10) i.e. the same time point at which the viability of 
PDT-treated cells was measured. 
 
The experiments carried with the combination in the dark confirmed 
that free SRB was poorly cytotoxic at concentrations lower than 10 µM 
(Fig. 12). These latter experiments also confirmed that VP alone is 
devoid of any toxicity in the absence of light independently from 
delivery modality. Contrary to our expectation, the combination of SRB 
and VP formulated in separate micelles was less photo-to toxic than the 
combination of the free drugs. This is very likely caused by the reduced 
photo-toxicity of VP-loaded micelles in comparison to free VP. In any 
case, the treatment with the combination of VP Pluronic-mediated PDT 
and SRB-loaded micelles was slightly more efficient in reducing cell 
viability than the single treatments. This positive interaction appeared 
however disturbed by the encapsulation of the two drugs in the same 
 
Fig. 11. Photo-toxicity in MDA-MB231 cells exposed to the photosensitizer alone 
(VP) or to the drug combination (VP + SRB) delivered or not by Pluronic P123/F137 
micelles (24 h) and irradiated with 0.75 J cm-2 of red light. Cell viability was 
measured with MTS assay 24 h post-irradiation. Data are mean ±SD of at least three 
independent experiments carried out in triplicate. Bonferroni test (p<0.05); SRB/VP-
micelle significantly different from * free VP, free SRB + free VP, ^ VP-micelle + 
SRB-micelle, VP-micelle. 
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micelle for their co-delivery to MDA-MB231 cells. In fact the reduction 
of viability in cells treated with VP/SRB-loaded Pluronic micelles was 
less than that caused by VP-micelles plus SRB-micelles added 
separately.  
 
  
 
 
Fig. 12. Cytotoxicity of MDA-MB231 cells incubated in the dark with VP 
alone or drug combination (VP + SRB) delivery or not whit micelles at 24 h 
(A) and 24 + 24 h (B). 
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One possible explanation of the reduced efficacy of the combination 
of co-loaded VP/SRB is the increased size of micelles associated with 
drug co-encapsulation, as shown by the DLS measurements of Table 1 
that might have reduced the efficiency of cell internalization and drug 
bioavailability. 
 
3.6 Uptake and cellular localization of BPDMA in MDA-
MB231 cells 
The hypothesis of a reduced cellular uptake of drugs encapsulated in 
micelles as compared to the free forms was confirmed for VP. The red 
fluorescence of VP was exploited to easily investigate both the cellular 
uptake by flow cytometry and cellular localization by confocal 
microscopy.  
 
Fig.13. Uptake and intracellular localization of VP formulations. (A) Flow 
cytometry measurements of VP uptake after 24 h of cell incubation with 
increasing concentrations of free VP, VP-micelles or VP/SRB-micelles. 
Confocal microscopy images of MDA-MB231 cells incubated with free (B) or 
VP-loaded micelles (C) (red fluorescence) for 24 h and stained with the 
endoplasmic reticulum probe ER Tracker green (green fluorescence). Clear co-
localization between the probe and VP fluorescence is visible exclusively in B. 
Scale bar = 50 µm. 
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We found that the uptake of free VP in MDA-MB231 cells incubated 
for 24 h increased linearly at least up to 1.5 µM (Fig. 13A). On the 
contrary, the uptake of VP loaded in Pluronic micelles reached a plateau 
at approx. 0.5 µM. Of interest is the fact that co-loaded VP/SRB micelles 
showed a decreased uptake at the plateau with respect to VP-loaded 
micelles. 
Note that, the reduced cellular uptake of the micelles cannot be 
trivially ascribed to a lower fluorescence of the VP when encapsulated in 
the carrier. In fact, we demonstrated that the fluorescence quantum yield 
of this fluorophore is not affected by its compartmentalization in the 
Pluronic micelles and is also independent by the presence of SRB. Thus, 
reduced uptake of VP when loaded in micelles parallels the poor 
internalization of PEO-coated nanocarriers.42The observations on the 
decreasing uptake of VP well correlate with the decreasing of cell 
photosensitisation efficiency that is higher for free VP with respect to 
VP-loaded micelles (Fig. 11). For VP/SRB-loaded micelles we can 
safely assume that, based on the uptake experiments, the contribution of 
PDT to the overall effect of the combined treatment is less than in the 
combination VP-loaded micelles + SRB-loaded micelles with a 
consequent decreased cell mortality. The fluorescence microscopy 
analyses (Fig. 13B,C) confirmed the lower uptake of VP-loaded micelles 
with respect to free VP and showed cytoplasmatic localisation of both 
formulations, with exclusive accumulation of free VP in the endoplasmic 
reticulum. 
Moreover, together with the reduced uptake, the different intracellular 
localization of the two formulations can be responsible of the reduced 
photo-toxic profile measured for VP-loaded micelles at least in MDA-
MB 231 cells. In our previous work we reported a mitocondrial 
localization of both free and micelle VP in HeLa cells and significantly 
increased photo-toxicity of VP with the delivery by Pluronic P123/F137 
micelles at least for PS concentrations lower than 0.1 µM.7 It must 
however be considered that, the latter results were obtained in HeLa cells 
incubated with VP for 4 h only before performing PDT. Therefore, to 
exclude any timing effects that might negatively affect cell 
photosensitation and/or drug combination sequence, we performed 
experiments in which MDA-MB231 cells were incubated for 4 h with 
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VP, irradiated with 0.75 J cm-2 of red light and incubated for further 24 h 
with SRB (Fig.14).  
The changing of incubation time and schedule of delivery of the 
treatments, however, did not improve the cytotoxic effects of the 
combination VP-PDT and SRB, did not show any synergism or additive 
effects for the drugs delivered free nor in Pluronic P123/F127 mixed 
micelles. 
  
 
Fig.14.Cytotoxicity of MDA-MB231 cells incubated in the dark at 4 h 
and with o.75 J cm 2 of red light 
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4. Conclusions 
The present study demonstrates that Pluronic P123/F127 mixed 
micelles do not suffer neither disassembling nor size changes in 
biological media and are very suited to entrap effectively the poorly 
water soluble SRB, VP and their combination. While cytotoxicity of 
SRB delivered by Pluronic micelles is significantly higher than that 
observed for the free drug, the effect is the opposite for VP. Furthermore, 
micelles co-delivering the two active components do not improve the 
anticancer performances. These findings cannot be attributable to 
reduced photodynamic properties of VP when encapsulated in the 
micelles, being its capability to photogenerate 1O2 basically the same to 
that observed in organic solvent and in the micelles co-encapsulating 
SRB. One possible explanation of the reduced efficacy of the 
combination VP/SRB is the different cell uptake and localization of the 
micelles, which result in a reduced efficiency of cell internalization and 
drug bioavailability. In view of previous study reporting enhanced 
cytotoxic effects on systems based on photo-chemotherapeutic 
combination, the present contribution provides a clear example that no 
generalizations are possible at this regard and then each system must be 
investigated in detail. Co-encapsulation of a PDT agent and a 
chemotherapeutic in a single nanodelivery system cannot be proposed as 
a general strategy to observe amplified cell mortality effects, even under 
the complete preservation of the photodynamic properties of the PS in 
the co-presence of the chemotherapeutic agent, which, in any case, 
remain always a key pre-requisite to be fulfilled. 
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ANNEX-II 
In vitro/in vivo investigation of the potential of 
Pluronic mixed micelles for pulmonary drug 
delivery
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1 Introduction 
Pulmonary delivery systems are in the limelight for local release of 
active agents in severe lung diseases, including cancer, asthma, cystic 
fibrosis and chronic lung infections[1,2]. In fact, direct delivery of the 
drug to the site of action is feasible by this way, thus improving 
therapeutic potential while reducing drug-related systemic side effects. 
However, a number of obstacles must be considered before the 
administered drugs reaches the site of action [3]. For example, 
mucociliary clearance can eliminate drugs and foreign particles from the 
airways reducing residence time and the drug amount reaching the target. 
In addition, undesirable interactions of the formulation with lung lining 
fluids, airway macrophages and lung epithelial cells may be detrimental 
for drug therapeutic efficacy [4]. 
To overcome these drawbacks, controlled and targeted delivery of 
drugs to the lungs by means of biodegradable polymeric nanoparticles 
(NPs) is under investigation. Indeed, NPs may, at least in principle, assist 
the drug getting through extracellular and cellular barriers 
[5]Additionally, NP composition and surface properties can be 
adequately manipulated to reduce mucoadhesive tendency or to improve 
NP targeting ability [5]. Nevertheless, nanocarriers cannot be 
administered as such since they suffer from the disadvantage of being 
exhaled from the respiratory tract. To reach smaller airways (bronchus 
and bronchioles), inhalable NPs must be appropriately engineered in 
order to meet optimal aerodynamic properties [6]. 
 Although a huge number of studies have been recently focused 
on the development of polymer NPs for lung delivery [5], only few 
works have exploited the potential of polymeric micelles as drug 
delivery systems for local therapies of lung diseases [7]. One 
representative of such nanocarriers are poloxamer, or Pluronic ®, 
micelles, having the ability to load and to stabilize a great variety of 
drugs [8]. The very small size (<100 nm) and the hydrophilic surface 
properties (i.e., polyethylene oxide shell) of Pluronic micelles make 
them very intriguing to facilitate drug diffusion through human airway 
mucus [9]. In addition, Pluronic micelles can be modified at unimer 
terminus to bind functional molecules in order to gain surface decorated 
micelles with improved targeting properties. Finally, recent studies 
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demonstrated that Pluronic micelles are safe and may efficiently promote 
drug release in different lung cells both in vitro and in vivo [10,11]. 
Despite their great potential, Pluronic has been mainly used as 
excipient or helper polymer in drug delivery systems for inhalation 
[12,13]. To our knowledge just two papers developed nanostructured 
self-assembled Pluronic micelles as vehicle for drug release to the lung 
through spray-dried microparticles technology [7,14].  
Thus, the objective of this work is to test pluronic micelles as a 
platform for pulmonary drug delivery. To this purpose, multimodal 
Pluronic mixed micelles (PMM) in form of aqueous liquid suspension 
and solid nano-embedded microparticles (NEM) were developed and 
tested. PMM stability in different pulmonary-relevant media, their 
interaction with mucin and penetration through artificial mucus were 
evaluated. PMM-based NEM engineered for inhalation were produced 
by spray-drying using lactose as carrier and evaluated in term of 
stability, flow and aerosolization properties. Finally, PMM 
biodistribution after administration in mice was assessed. 
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2 Materials and Methods 
Pluronic s® P123 (EO20–PO65–EO20, MW = 5750 g mol
-1) and F127 
(EO100–PO65–EO100, MW = 12600 g mol
-1) were purchased from Sigma-
Aldrich and the solutions were prepared by weighting materials 
previously desiccated under vacuum for 24 h. European Pharmacopoeia 
7th Ed. (Ph.Eur.) grade lactose was used (NEW.FA.DEM., Italy). 
Calcium chloride dihydrate, magnesium chloride, potassium chloride, 
potassium phosphate dibasic, sodium acetate, sodium bicarbonate, 
sodium chloride, sodium citrate dihydrate, sodium phosphate dibasic, 
sodium sulfate,nile red, gelatin from bovin skin type B, 
diethylenetriaminepentaacetic acid (DTPA), RPMI amino acid solution, 
type II mucine from porcin stomach, Egg Yolk Emulsion were purchased 
from Sigma Aldrich (Italy). Verteporfin was kindly supplied by 
Professor D. Dolphin (University of British Columbia, Vancouver, 
Canada).  
 
2.1 Synthesis of biotin-conjugated and rhodamine-conjugated 
Pluronics 
The synthetic procedure was similar for both Pluronics. For biotin-
conjugated Pluronic, F127 (5.0 g, 0.40 mmol) was dissolved in 75 mL of 
dichloromethane followed by the addition of biotin (0.12 g, 0.48 mmol). 
For Rhodamine-conjugated Pluronic, P123 (3.0 g, 0.40 mmol) was 
dissolved in 75 mL of dichloromethane followed by the addition of 
rhodamine B (0.44 g, 0.48 mmol). After that, DMAP (0.004 g, 0.03 
mmol) was added to each reaction flask and the solution cooled to 0°C. 
DCC (0.08 g, 0.40 mmol) was added dropwise via a dropping funnel 
over 30 min, and the reactions were carried out for 48 h at room 
temperature under agitation. The reaction mixtures were then extracted 
with a NaHCO3 water solution (10% v/v). After this step, the organic 
phases were frozen overnight and the insoluble substances were removed 
by filtration. The organic solutions were then precipitated twice in cold 
diethyl ether. The functionalized polymers were filtered and dried 
overnight under vacuum.  
Biotin-F127 reaction yield = 82%. 1H-NMR (300 MHz, DMSO-d6, 
TMS), δ (ppm): 1.000-1.485 (s, -CH3 b), 1.493 (m, H5, 2H), 2.200 (m, 
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H3, 2H), 2.821 (m,H5, 2H), 3.105 (m, H4, 2H), 3.260-3.619 (m, -O-CH2-
CH2- a), 4.138 (m, H6‘, 1H), 4.300 (m, H6, 1H), 6.363 (s, HN2, 1H) e 
6.437 (s, HN1, 1H). 
Rhodamine-P123 reaction yield = 68%. 1H-NMR (300 MHz, DMSO-
d6, TMS), δ (ppm): 1.000-1.126 (s, -CH3 b), 1.209 (t, N-CH3, 12H), 
3.260-3.549 (m, -O-CH2-CH2- a), 3.641 (d, N-CH2, 8H), 6.980 (m, H2-
H7-H4-H5, 4H), 7.094 (d, H8-H1, 2H), 7.473 (dd, H6‘, 1H), 7.842 (m, H4‘-
H5‘, 2H), 8.320 (dd, H3‘, 1H). 
 
2.2 PMM preparation 
PMM were prepared by the thin-film hydration method [15]. Briefly, 
100 mg of the Pluronic P123/F127 mixture (2:1 w/w ratio) were 
dissolved in 10 mL of ethanol in a round-bottom flask. Then, the solvent 
was evaporated by rotary evaporation at 50 °C for about 20 minutes. 
Residual solvent in the film was removed under vacuum overnight. 
Thereafter, the dried film was hydrated with 10 mL of filtered distilled 
water and the material was sonicated for 5 minutes to obtain a limpid 
solution. This solution was filtered through 0.22 µm filters (RC 
Chemtek, Italy) to remove possible large cylindrical aggregates formed 
by P123. When indicated, the resulting solution was lyophilized for 24 h. 
For Biotin-decorated PMM (Bio-PMM), biotin-conjugated F127 was 
added at 20% of total F127 weight. For Rhodamine B-tagged PMM 
(Rho-PMM or Bio/Rho-PMM) rhodaminated-P123 was added in order 
to give rhodamine B concentrations of 5.0 µM. For Bio/Rho-PMM 
micelles at 10 mg mL-1, for example, 2.66 mg of F127 and 0.66 mg of 
biotin-conjugated F127, 6.60 mg of P123 and 0.066 mg of rhodamine B-
conjugated P123 (a stock solution in ethanol of all the components) were 
used. 
Hydrodynamic diameter (DH), polydispersity index (PI) and zeta 
potential (ζ) of micelles were determined using a Zetasizer Nano ZS 
(Malvern Instruments Ltd, UK). On the freeze-dried formulations 
dispersed in water. Results are reported as mean of three measurements 
on three different micelle batches (n=9) ±SD. 
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2.3 Micelle stability in pulmonary-relevant media 
Micelle stability in saline solution, mucin aqueous solution, artificial 
mucus and simulated interstitial lung fluids (SILF) was evaluated. For 
mucin aqueous solution, mucin powder was dispersed in water (0.08% 
w/v) and stirred overnight. Then, the dispersion was centrifuged at 6000 
rcf for 20 min to collect the mucin-containing supernatant. Artificial 
mucus was prepared adding 250 μL of sterile egg yolk emulsion, 250 mg 
of mucin, 0.295 mg DTPA, 250 mg NaCl, 110 mg KCl, 1 ml of RPMI to 
50 mL of water. SILF was prepared following the preparation 
instructions dictated by [16]. Briefly, 1 L of SILF contains 0.095 g of 
magnesium chloride, 6.019 g of sodium chloride, 0.298 g of potassium 
chloride, 0.126 g of sodium phosphate dibasic, 0.063 g of sodium 
sulfate, 0.368 g calcium chloride dihydrate, 0.574 g of sodium acetate, 
2.604 g of sodium bicarbonate, and 0.097 g of sodium citrate dehydrate. 
Stability was assessed by fluorescence resonance energy transfer (FRET) 
technique by co-encapsulating Nile Red (NR) and Verteporfin (VP) into 
micelles (FRET-PMM). The concentrations of NR and VP in FRET-
PMM were 0.8 µg and 4.0 µg mL-1, respectively. For the analyses, 20 mg 
of lyophilized FRET-PMM were added to 2 mL of each medium and 
incubated at 37.0 ºC for 72 h. At selected time intervals, the ratio 
between the maximum intensity of emission bands for Verteporfin and 
NR size and micelle size were monitored. A decrease of this ratio and/or 
micelle size increase was considered indicative of micelle aggregation or 
disassembly. The fluorescence measurements were made on a Shimadzu 
RF-1501 spectrofluorometer using a 1.00 cm path-length quartz cuvette. 
Results are reported as mean of three separate measurements (n=3) ±SD. 
 
2.4 In vitro assessment of micelle interactions with mucus 
2.4.1 Mucoadhesive tendency 
Mucoadhesive tendency of PMM was assessed by turbidimetric 
measurement of their interaction with mucin [16]. Equal volumes of 
mucin and PMM dispersions (20 mg/mL) were mixed by vortexing for 1 
min. The turbidity of the mixtures was measured at time 0 and after 
incubation at 37 °C (30–60 min). The ABS at 650 nm was recorded by 
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electronic spectrophotometry on a Shimadzu UV-1800 
spectrophotometer. Reference ABS of mucin and PMM dispersions was 
also evaluated. Experiments were run in triplicate. Results are expressed 
as ABS at 650 nm±SD over time. 
The ζ potential of PMM dispersions in mucin was also measured. The 
mucin dispersion was first diluted in water (1:4 v/v) and analyzed. 
Afterwards, a drop of micelle dispersion was added to mucin and the ζ 
potential of the samples recorded.  
2.4.2 Penetration of fluorescent micelles through artificial mucus 
The penetration of fluorescent Rho-PMM through artificial mucus 
was followed in an artificial mucus model as previously reported [17]. 
Briefly, 50 ml of artificial mucus solution was prepared as described 
above. A 10% (w/v) gelatin solution was prepared in hot water. One 
milliliter of gelatin solution was placed in each well of a 24-well plate, 
hardened at room temperature and stored at 4 °C until use. One milliliter 
of artificial mucus was placed on the hardened gelatin gel. Then, 500 μl 
of a Rho-PMM water dispersion fluorescent-tagged micelles (10 mg/ml) 
were placed on the artificial mucus layer and maintained at room 
temperature for 24 h. At regular time intervals, artificial mucus was 
withdrawn from 3 plates, gelatin washed with water (2 ml×6) and 
subsequently melted at 60 °C. Mean while, micelle dispersions in mucus 
were centrifuged at 6000 rcf and 4 °C for 20 min. The amount of 
micelles permeated in the gelatin layer was evaluated by 
spectrofluorimetry (EX= 480 nm, EM= 520 nm). Results are reported as 
percentage of Rhodamine penetrated through artificial mucus (amount of 
Rhodamine in gelatin plates/total amount of Rhodamine in micelles 
×100) ±SD. 
 
2.5 Production and characterization of NEM 
NEM were produced by co-spray drying PMM and lactose as inert 
carrier. Briefly, PMM were dispersed in a 100 mL of lactose aqueous 
solution (2% w/v) in order to achieve Pluronic /lactose ratio 1:1, 1:10 
and 1:20 in weight. Dispersions were processed in a Mini Spray Dryer 
Büchi 190 (Flawil, Switzerland) equipped with a high-performance 
cyclone for the recovery of small powder amounts. PMM and Bio-PMM 
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dispersions in lactose were individually spray-dried with the following 
process parameters: feed rate 4 ml/min; aspirator setting 20; spray-flow 
400 Nl/h; inlet temperature 150 °C (resulting outlet temperature = 95 
°C). A 0.5 mm nozzle was used throughout the experiments. Powders 
were collected and stored in a glass dryer under vacuum at room 
temperature until use. 
The mean geometric diameter and size distribution of NEM were 
determined by laser light scattering (Coulter LS 100Q, USA) on a NEM 
suspension in chloroform/span 80 (2% w/w) solution. Size is expressed 
as volume mean diameter ±S.D. of values collected from three different 
batches (n = 6). Powder tapped density (ρ) and flowability (Carr's Index) 
were evaluated according to European Pharmacopoeia 7th Edition 
(Ph.Eur.) The theoretical mass mean aerodynamic diameter (MMADt) of 
particles was estimated as previously reported [18]. 
 
2.6 In vitro aerosolization properties of NEM 
The aerosolization properties of NEM were tested in vitro after 
delivery from Turbospin® (PH&T Pharma, Milano, Italy), a breath-
activated, reusable DPI working with single unit gelatin capsule 
containing the dry powder, as previously reported [18].  
Mean geometric diameter and size distribution of NEM were 
determined by laser light scattering (Coulter LS 100Q, USA) on NEM 
suspensions in chloroform containing sorbitan monooleate (2% w/v) as 
dispersing agent. Size is expressed as volume mean diameter ± SD of 
values collected from three batches.  
Powder tapped density () and flowability (Carr‘s Index) were 
assessed according to European Pharmacopoeia (Ph.Eur. 8 Ed) by a 
tapped density tester (Mod. IG/4, Giuliani, Italy).  
The theoretical mass mean aerodynamic diameter (MMADt) of 
particles was estimated on the basis of the definition (1): 
 MMADt = d (/0X)
1/2 (1) 
where d is the mean geometric diameter, 0is a reference density of 1 
g/ml and X is the dynamic shape factor, which is 1 for a sphere. An 
approximate bulk measure of  is provided by tapped density 
measurements. 
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The aerosolization properties of powders were tested in vitro after 
delivery from Turbospin®(PH&T Pharma, Milano, Italy), a breath-
activated reusable DPI, ina Next Generation ImpactorTM(NGI) (Copley 
Scientific, UK) according to European Pharmacopeia (Ph.Eur. 8 Ed). 
The NGI was coupled with a DFM critical flow controller (Copley 
Scientific, Nottingham,UK), which was connected to an HCP5 vacuum 
pump (Erweka, USA).The airflow rate was measured and adjusted prior 
to each experiment to a constant value of 60 L min-1.  
The powder amount deposited on the seven NGI collection cups was 
quantitatively collected by dissolution in 2 mL of water. The amount 
deposited in the induction port and remaining inside the nebulizer 
chamber was also determined by washing with an appropriate amount of 
water. To quantify powder deposition, Rho-PMM were used to produce 
NEM and rhodamine-B absorption evaluated by spectrofluorometry as 
reported in 2.5.2. 
The emitted dose (ED) was calculated by accurately weighing the 
capsule before and after Turbospin® actuation. The fine particle fraction 
(FPF), the experimental mass median aerodynamic diameter (MMADexp) 
and the geometric standard deviation (GSD) were calculated according 
to Ph.Eur. deriving a plot of cumulative mass of powder detained at each 
stage (expressed as percent of total mass recovered in the impactor) 
versus cut-off diameter of the respective stage. The FPF was calculated 
by interpolation from the plot as the percentage of powder emitted from 
the inhaler with an aerodynamic diameter less than 5μm. The MMADexp 
of the particles was determined from the same graph as the particle size 
at which the line crosses the 50% mark and the GSD was defined as 
GSD = (Size X / Size Y)1/2 
where size X was the particle size at which the line crosses the 84% 
mark and size Y the size at which it crosses the 16% mark. 
 
2.7 In vivo biodistribution of PMM 
2.7.1 Animals 
Male Wistar rats (200-220 g; Charles River, Lecco, Italy) were used. 
All the experimental procedures were performed following the specific 
guidelines of the Italian and the European Council law for animal care 
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and were approved by the Animal Ethics Committee of the University of 
Naples ―Federico II‖ (Italy).  
 
2.7.2 Treatments 
Rats were anesthetized using ketamine (80-100mg/kg, i.p.) and 
xilazine (10mg/kg, i.p.) and the depth of anesthesia was continuously 
controlled. Rats were divided into different groups and treated with 
saline (100 µL, SHAM group), 10 mg mL-1 Rho-PMM dispersion in 
saline (100 µl, corresponding to 66 µg mL-1 of Rhodamine B-Pluronic 
P123 conjugate) or an aqueous solution containing an equivalent amount 
of free rhodamine B (100µl, 52 µg mL-1). The formulations were intra-
tracheally administered by using a Microsprayer® (Model 1A-1B, 
PennCentury, USA). 
 At 5 min, 1 h, 3 h and 24 h 5 after treatment and under anesthesia, 
the carotid artery was cannulated for blood collection and, after 
euthanization, bronchoalveolar lavage (BAL) and lungs were obtained. 
Briefly, the trachea was cannulated with a polyethylene tube (1 mm 
inner diameter) to perform BAL as previously reported [19]. Lungs were 
washed (three times) by flashing sterile ice cold PBS. The BAL was 
centrifuged to separate cells (BALC) from fluid (BALF), while blood 
was withdrawn in a glass tube and left for 24 h at 4°C to obtain serum. 
BALC and lungs were homogenized in PBS containing Triton 0.1% 
 
2.7.3 Quantitative determination of PMM amount in BALF, lung and 
serum 
Fluorescence emission of rhodamine B in biological samples deriving 
from treated animals was evaluated and compared to that of SHAM 
group. To this purpose, BALF (500 µL), BALC (200 µL) and lung 
homogenate samples were freeze dried, while fresh serum was 
processed. 
For BALF and BALC analysis, freeze-dried samples were dispersed 
in 200 µL of ethanol and centrifuged at 5.000 rpm for 5 min. After 
centrifugation, 100 µL of supernatant were analyzed.  
For lung tissue analysis, 10 mg of freeze dried powder were treated 
with 300 µL of ethanol and samples centrifuged at 13.000 rpm for 5 min. 
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After centrifugation, 100 µL of supernatant were collected for 
quantitative analysis.  
For serum analysis, fresh samples (200 µL) were treated with the 
same volume of a 1:1 water/acetonitrile mixture for protein precipitation. 
The samples were then centrifuged at 13.000 rpm for 5 min and 100 µL 
of supernatant were analyzed. 
To evaluate recovery, known amounts of Rho-PMM or free 
Rhodamine B were added to biological samples deriving from SHAM 
animals before freeze-drying and analysis.  
In each case, the fluorescence of the sample was measured in 96 
multi-wells on an ENVISION apparatus at Ex/Em 480/520 nm. A 
calibration curve was obtained by plotting fluorescence intensity versus 
the concentration of fluorescently-tagged Pluronic P123 solutions in 
ethanol. The linearity of the response was verified in the Pluronic 
P123concentration range of (equivalent to 0.2-0.0002 μg mL-1 of 
rhodamine B free) (r2 ≥ 0.99).  
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3 Results and discussion 
The technological development of drug-based respiratory therapies in 
humans runs into the need of specifically tailored inhalable formulations 
able: i) to protect the encapsulated drug from in vitro/in vivo 
degradation; ii) to promote drug transport through mucus barriers and iii) 
to facilitate drug uptake by lung cells, the target of action. To this end, 
we choose PMM as nano-vehicle for the delivery of hydrophobic drugs 
to the lungs, since they are easy to formulate, have a low cost of 
production and promising features for pulmonary delivery [20]. In water, 
Pluronic P123/F127 mixed micelles (PMM) self-assemble as core-shell 
nanostructures. The micelle core promotes the solubilization of very 
hydrophobic drugs with high encapsulation efficiency as previously 
demonstrated [11] while the shell contributes to high stability and 
biocompatibility both in vitro and in vivo [20]. 
 
3.1 PMM stability in pulmonary-relevant media 
PMM based on Pluronic P123/F127 mixtures 2:1 by wt formed 
nanostructures with size of 22 nm (PDI = 0.12) and zeta potential of -3.6 
mV [11]. PMM are stable upon dilution up to 1:100 and do not 
disassemble in protein-rich media (Annex I and Pellosi et al., 2016, in 
press). 
Indeed, stability of a new formulation in complex media is regarded 
as a critical factor since it has been demonstrated that micelles can 
aggregate/dissociate in different conditions, with a consequent poor 
therapeutic outcome [21]. Conceiving PMM for lung delivery of active 
species, the behavior of PMM in pulmonary relevant media was assessed 
by size and FRET measurements as previous described (Annex I and 
Pellosi et al., 2016, in press). 
To this purpose, PMM co-encapsulating the two fluorophores nile red 
(NR) and verteporfin (FRET-PMM) were prepared at the 2:1 P123/F127 
ratio by wt. As pulmonary relevant media we choose saline, mucin, 
artificial mucus and SILF. As shown in Fig. 1 PMM size increased of 
about 6 nm in SILF and 10 nm (from 23.0 nm in water – control 
experiment) in artificial mucus probably due the high ionic strength of 
these solutions. Results for Bio-PMM were comparable to those obtained 
for PMM.  
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The ABS values of reference mucin and PMM dispersions did not 
significantly differ (ranging from 0.01 to 0.02). Only a slight increase in 
turbidimetry was observed for PMM-mucin dispersions during time up 
to an absorption value as low as 0.09, which could not be considered 
indicative of PMM/mucin interactions. This hypothesis was supported by 
ζpotential values of PMM, which were not significantly different in the 
presence or not of mucin (Fig. 2B), confirming the poor mucoadhesive 
tendency of PMM. Of note, biotinylation did not result in a different 
PMM behavior in mucin (data not shown). 
To go in depth into PMM tendency to interact with airway mucus, 
Rho-PMM underwent diffusion studies in a previously-developed in 
vitro model consisting of a layer of artificial airway mucus applied on 
solidified gelatin [17][12].Ascan be seen in Fig. 3, a high percent of 
Rho-PMM was found in gelatin after 24 h. Visual inspection (Fig. 3A) 
associated with quantitative data of permeation (Fig. 3 B) demonstrated a 
rapid and continuous penetration of the developed PMM through the 
mucus layer allowing a homogeneous dispersion of the formulation in 
the gelatin layer after 24 h. Again, biotinylation did not alter PMM 
penetration profile in artificial mucus model (data not shown). 
In line with results of mucoadhesion tests, the facilitated transport of 
PMM through the artificial mucus model suggests poor PMM/mucin 
interactions and a consequent ability of PMM to penetrate inside mucus. 
Indeed, several literature data indicate that mucoinert NPs modified at 
surface with poly(ethylene glycol) may deeply penetrate a variety of 
human lung mucus secretions independently upon their viscosity. In 
particular, Pluronic F127-coated poly(lactide-co-glycolide) NPs rapidly 
penetrated fresh undiluted human mucus, with only a 10-fold reduced 
speed in mucus compared to their theoretical speeds in water. This effect 
is likely due to a reduction of hydrophobic and/or electrostatic 
interactions with mucus components. 
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3.3 Developing dry powders for pulmonary delivery of PMM 
NP aqueous liquid dispersions can be delivered through commercially 
available nebulizers to generate an aerosol with a 1-5 µm droplet size to 
achieve the desirable distribution in lungs [5].However, low delivery 
time efficiency and low formulation stability in water solutions are 
challenges for the practical applications of NP-based liquid formulation. 
To overcome these limitations, formulations can be engineered through 
the incorporation in an inert micron-scale dry powder. These particles, 
also termed as nano-embedded microparticles (NEMs), may be prepared 
by spray-drying with adequate technological properties to reach deep 
lung and to locally release NPs after the dissolution of inert carrier 
[12][22]. Thus, we developed NEM by co-spray drying of PMM and an 
inert sugar, lactose, with proved biocompatibility in pulmonary delivery 
and also with good properties for NEM production[23]. Both lactose and 
 
Fig. 3. In vitro assessment of Rho-PMM interaction with artificial airway mucus 
(AM). A) Visual inspection of penetration through an AM layer at different 
times ( ---- artificial mucus layer, — gelatin layer). B) kinetic profile of 
rhodamine B permeation inside gelatin (total percent of rhodamine B permeated 
after 24 h = 21.3%). 
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Pluronics are soluble/dispersable in water media allowing the 
preparation of NEM without the use of organic solvents. 
With the aim to optimize the production process, three aqueous 
dispersions, at different PMM/lactose ratios by weight (1:1, 1:10 and 
1:20) were individually spray-dried. Rho-PMM were selected for 
formulation studies to permit the fully characterization of the system. 
The 1:1 Rho-PMM/lactose formulation produced a sticky dry powder 
unsuitable for inhalation purposes likely due the high concentration of 
the gel-type Pluronic P123 in the spray-dried mixture. Nevertheless, 
good powders with high recovery yields (78.0 and 81.9%, respectively) 
were achieved at the lower PMM/lactose ratios of 1:10 and 1:20.  
Nanostructure integrity is a very important pre-requisite for NEM 
therapeutic application since NP disruption implies the loss of the 
encapsulated drug and a potential reduced therapeutic outcome [5]. In 
order to verify if the structure of PMM was not disrupted during spray-
drying process. FRET-PMM were prepared and spray-dried with lactose 
at the selected PMM/lactose ratios. After production, the resulting dry 
powders were suspended in water to dissolve lactose without disrupting 
the PMM structure - if present - for size and FRET studies. Of note, both 
formulations presented very similar hydrodynamic diameters and FRET 
signal compared to the solutions pre-spray drying (data not shown), 
which clearly demonstrated that Pluronic s are assembled as PMM even 
after processing at high temperatures.  
Micron-sized dry powders were achieved in both cases, with mean 
geometric volume diameters ranging between 7.2 and 8.1 µm. In 
addition, tapped density and Carr‘s index values along with the 
estimation of MMADt confirmed the good flow properties of the 
developed formulations likely suitable for lung deposition (Table 1). 
Indeed, a crucial factor to consider when developing inhalable dry 
powders relies on their aerosolization properties. In vitro aerosol 
performance of spray-dried formulation was assessed according to 
Pharmacopoeia test through NGI. The seven NGI stages produce cutoff 
diameters in the range 8.06-0.34 µm, with cup 3 to CMO (4.66-0.34 µm) 
representing deep lung airways. Results presented in Table 1 
demonstrated that both formulations have good aerosolization properties, 
with approximately 95% of the capsule content being emitted during 
aerosolization, very high FPF and a suitable MMADexp. 
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Table 1. Flow and aerosolization properties of NEM based on Rho-PMM and 
lactose (value ±SD calculated on 3 different batches; n=6). 
 Rho-PMM/lactose 
1:10 (w/w) 
Rho-PMM/lactose 
1:20 (w/w) 
Volume mean diameter
a
 
(μm ±SD) 
8.08 ±1.85 7.24 ±2.70 
Tapped density
b
 
(g/mL ±SD) 
0.25±0.05 0.13±0.04 
MMAD
t
c
 
(μm ±SD) 
4.04 ±0.80 2.58 ±0.58 
Carr’s index
b
 15.3 ± 0.8 16.8 ±1.9 
Emitted dose  
(% ±SD) 
93.5 ±2.0 96.8 ±2.9 
Fine particle fraction 
(% ±SD) 
58.8 ±3.5 62.0 ±4.0 
MMAD
exp
c 
(μm ±GSD
d
) 
4.9 ±0.7 4.4 ±1.3 
 
a Mean geometric diameter as determined by laser light diffraction analysis. 
b Tapped density and flowability index (Carr‘s index) were estimated according to 
Ph.Eur. VII ed. 
cTheoretical (MMADt) and experimental (MMADexp) Mass Mean Aerodynamic 
Diameter. 
d Geometrical standard deviation. 
 
In each case, the aerodynamic assessment of fine particles upon 
delivery from DPI confirmed that the developed formulation have a great 
potential for lung deposition of PMM, and consequently their drug 
cargo, in deep lungs. 
Once again, functionalization of Pluronic micelles did not influence 
significantly the results (data not show).  
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3.4 PMM biodistribution after pulmonary delivery in rats 
Since flow and aerosolization properties of PMM/lactose 1:10 and 
1:20 formulations were very similar, we decided to work in the 
formulation condition ―1:10‖ because higher contents of PMM means a 
higher content of the drug and, subsequently, a higher dose. 
To allow a proof of principle of the potential the developed PMM for 
in vivo drug delivery to the lung, biodistribution studies were performed 
upon intra-tracheal aerosolization of a micelle dispersion in saline. The 
amount of Rho-PMM in BALF, BALC and lung tissue during time was 
evaluated and results reported as fluorescence intensity (FI).  
To fully understand the behavior of the PMM after intra-tracheal 
administration, the distribution in BALF, serum and lung at time 0 of the 
Rho-PMM dispersion was compared to that of a solution containing an 
equivalent amount of free rhodamine B. Results showed that the amount 
of free Rho B in BALF was much lower than that of micelles 
presumably due to its fast distribution in lung tissue and serum (Fig. 
4A).Kinetics of micelle persistence in the BALF (Fig. 4B) showed that 
Rho-PMM are still present in the rat lung after 24 h and are able to reach 
dry lung tissue (Fig. 4C). Furthermore, no significant amount of PMM 
was found in BALC at each time interval (data not shown). 
Annex-II│ 
-235- 
 
 
 
 
 
Fig. 4.Fluorescence in lung homogenate, BALF and serum after intratracheal 
administration of Rho-
(A). Amount of Rho-PMM in BALF (B) and dry lung (C) along time. For sample 
treatment see materials and methods. Data are mean ± SD of values calculated on 
5 animals. 
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